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Monoclonal antibodies (mAbs) have received considerable attention over the past 
three decades for the treatment of many diseases. With the significant titer improvement in 
cell culture processes, the mAb capture step using protein A chromatography has become 
one of the major downstream bottlenecks due to limited resin capacity and high production 
cost. As such, affinity precipitation has been increasingly explored as a promising 
alternative to purify mAbs and other therapeutic proteins. Despite recent advances in new 
affinity precipitants, challenges still remain in achieving high capture efficiency and 
complete removal of the precipitants. Supramolecular polymers formed by self-assembly 
of peptides and peptide derivatives are attractive biomaterials due to their inherent 
biodegradability and biocompatibility and have been widely explored for use in 
regenerative medicine, drug delivery, and disease diagnostics. Importantly, the selective 
presentation of various bioactive epitopes on a supramolecular substrate enables specific 
biology interfacing and molecular recognition. Furthermore, the multilevel reversible 
transitions within a supramolecular system make it uniquely suited for use as effective 
affinity agents for mAb precipitation and purification. 
The aim of this dissertation is to develop peptide-based supramolecular polymers 
as affinity agents for efficient capture and purification of mAbs. First of all, Z33, a protein 
A-derived peptide with two α-helical strands, was selected from literature as the mAb 
binding ligand due to its high binding affinity and short sequence. I discovered that the 
alkylation strategy plays an important role in preserving the α-helical conformation of the 
peptides within its supramolecular assemblies. Second, I designed and constructed self-
assembling immuno-amphiphiles (IAs) via the direct conjugation of the Z33 peptide to 
 iii 
linear hydrocarbons. The resulting IAs can effectively associate under physiological 
conditions into immunofibers (IFs) while preserving their native α-helical conformation 
and mAb binding affinity. However, the mAb precipitation efficiency was found to be very 
modest, which was attributed to the steric hindrance among tightly packed ligands that 
prevents their efficient interactions with mAbs. 
Third, to reduce the steric hindrance among Z33 ligands, I developed co-assembled 
IFs formed by a Z33-containing amphiphile with a rationally designed filler molecule to 
modulate the distribution of Z33 on IF surfaces. Under optimized conditions, IFs can 
specifically precipitate mAbs with a yield greater than 99%. I also demonstrated the 
feasibility of capturing and recovering mAbs from clarified cell culture harvest. 
Importantly, the added IFs can be easily removed via membrane separation, without 
introducing new contaminants. However, this system was limited by the high ammonium 
sulfate concentration necessary to trigger mAb precipitation. Lastly, to minimize the usage 
of salt, a series of IF building blocks with OEG (or PEG) linkers was designed to optimize 
the presentation of Z33 on IF surfaces. Results reveal that the mAb-IF interactions could 
be significantly improved as the linker length increases; however, too long a linker has an 
adverse impact on the function of the resultant IFs. I demonstrated that the desired IF 
system was able to precipitate mAbs without the help of additional salt and promising 
yields were obtained, especially when using a sequential precipitation strategy. 
These findings shed important light on the engineering of supramolecular polymers 
for specific molecular recognition and capture. I envision that the peptide-based 
supramolecular IF system can be potentially scaled up, serving as an efficient alternative 
for the purification of mAbs and other proteins of interest. 
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self-assembly	 of	 various	 peptide	 motifs.	 (B)	 Possible	 non-covalent	 interactions	 among	 peptide-based	
building	 blocks,	 including	 hydrophobic	 collapse,	 van	 der	Waals	 interactions,	 hydrogen	 bonding,	 π–π	
stacking,	and	electrostatic	interactions.	Adapted	with	permission	from	ref.	181	(©	2016	The	Authors.)
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Figure	 1-5.	 (A)	 Molecular	 structure	 of	 a	 representative	 PA	 with	 four	 rationally	 designed	 chemical	
entities.	 (B)	Molecular	graphics	 illustration	of	an	 IKVAV-containing	PA	molecule	and	 its	 self-assembly	
into	nanofibers.	(C)	Scanning	electron	micrograph	of	the	IKVAV	nanofiber	network	formed	by	adding	cell	
media	 (DMEM)	 to	 the	 PA	 aqueous	 solution.	 (D)	 The	 encapsulation	 and	 release	 of	 biologics	 using	









Figure	2-2.	 Representative	 TEM	micrographs	 of	 filamentous	 assemblies	 formed	 by	 the	 four	 designed	
immuno-amphiphiles	 in	 aqueous	 solution,	 pH	 7.4.	 TEM	 images	 of	 (A)	 Helix1-C16	 and	 (C)	 C16-Helix2	
reveal	filament	morphology	with	diameters	of	9.6±1.3	nm	and	12.4	±	1.7	nm,	respectively.	TEM	images	of	
(B)	Helix1-2C8	and	(D)	2C8-Helix2	also	relatively	shorter	filaments	with	diameters	of	11.0±1.4	nm	and	
9.7±1.3	 nm,	 respectively.	 Inserts	 (A-D)	 are	 higher	 resolution	 images	 illustrating	 the	 representative	
features.	All	the	samples	were	prepared	in	water	at	a	concentration	of	1	mM	at	pH	7.4,	aged	overnight	

























































Figure	 2-20.	 RP-HPLC	 (A)	 and	 MALDI-TOF	 MS	 (B)	 characterization	 of	 Helix1-C12.	 The	 RP-HPLC	
spectrum	confirms	the	purity	of	the	product	(>99%).	The	expected	mass	is	2292.2.	The	peak	at	2293.3	
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spectrum	confirms	the	purity	of	the	product	(>99%).	The	expected	mass	is	2321.2.	The	peak	at	2322.2	
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Figure	 2-24.	 RP-HPLC	 (A)	 and	 MALDI-TOF	 MS	 (B)	 characterization	 of	 Helix1-2C8.	 The	 RP-HPLC	
spectrum	confirms	the	purity	of	the	product	(>99%).	The	expected	mass	is	2489.3.	The	peak	at	2490.2	
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Figure	 2-25.	 RP-HPLC	 (A)	 and	 MALDI-TOF	 MS	 (B)	 characterization	 of	 2C8-Helix2.	 The	 RP-HPLC	
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blue-shift	 of	 the	 emission	 maximum,	 where	 the	 transition	 indicates	 the	 dye	 partitioning	 into	 the	
hydrophobic	compartment	of	assembled	nanostructures.	All	spectra	shown	here	are	normalized	by	the	
emission	maximum.	......................................................................................................................................................................	118	
Figure	 4-7.	 Representative	 TEM	 images	 of	 supramolecular	 copolymers	 formed	 by	 filler	 and	 ligand	
molecules	at	(A)	5:1,	(B)	25:1,	and	(C)	50:1	molar	ratios	with	a	diameter	of	14.1	±	0.8	nm,	8.4	±	0.9	nm,	
and	7.5	±	0.9	nm,	respectively.	Filament	diameters	are	represented	as	mean	±	SD	(n	=	30).	(D)	CD	spectra	
of	 co-assembled	 IFs	 at	 different	 spacer:ligand	 molar	 ratios.	 The	 spectra	 were	 normalized	 by	 the	
concentration	of	the	ligand	molecules,	showing	a	transition	of	the	apparent	conformation	from	α-helix	to	
β-sheet	 with	 the	 increase	 of	 the	 spacer:ligand	 molar	 ratio.	 (E)	 Representative	 TEM	 image	 of	 50:1	
IFs+mAb1.	Representative	cryo-TEM	images	of	 (F)	50:1	 IFs+mAb1,	 (G)	50:1	 IFs,	and	(H)	mAb1	 in	PBS	
showed	 the	binding	between	mAb1	and	 IFs.	All	TEM	 sample	was	 stained	with	2	wt	%	uranyl	 acetate	
aqueous	solution	to	improve	imaging	quality.	Scale	bars	are	100	nm.	.................................................................	120	
Figure	4-8.	Key	experimental	parameters	 in	the	selective	capture	of	mAbs	and	Fc-fusion	proteins.	 (A)	
Precipitation	 yields	 of	mAb1	and	Fc-fusion	protein	at	 different	molar	 ratios	 of	 filler:ligand	with	 fixed	
ligand	 concentration.	 (B)	 Schematic	 illustration	of	 the	 effect	 of	 ligand	density	 in	 IFs	when	 the	 ligand	













with	 10:1	 ligand:protein	 molar	 ratio	 at	 different	 salt	 conditions.	 All	 experiments	 were	 performed	 in	
triplicate	and	the	data	is	shown	as	mean	±	standard	deviation.	..............................................................................	126	
Figure	4-12.	Selectivity	of	co-assembled	IFs	in	precipitating	immunoglobulin	G	(IgG).	(A)	Photographs	





was	 not	 observed	 in	 vi)	 and	 vii),	 showing	 high	 specificity	 of	 mAb	 precipitation	 by	 IFs.	 Fluorescence	
measurements	of	supernatant	in	sample	i)-vii)	on	the	(C)	green	and	(D)	red	channels.	Fluorescence	of	IgG	






molecules	 in	 three	 resuspension	buffers	 at	 pH	3.7,	 pH	7.4,	 and	pH	10.1,	 respectively.	 The	precipitated	
samples	were	50:1	 IFs	and	mAb1	at	10:1	 ligand:protein	molar	ratio	with	1	M	ammonium	sulfate.	 (D)	
Precipitation	and	overall	yields	of	mAb1,	filler,	and	ligand	molecules	after	the	incubation	of	pure	mAb1	
with	50:1	IFs	and	1	M	ammonium	sulfate.	(E)	Schematic	illustration	of	the	process	of	purifying	mAbs	from	
CB	using	IFs.	 (F)	mAb	precipitation	yields,	overall	yields,	and	percentage	retention	of	 filler	and	 ligand	
molecules	 after	 the	 whole	 purification	 process	 for	 mAb1	 CB	 and	 mAb2	 CB.	 All	 experiments	 were	
performed	in	triplicate	and	the	data	is	shown	as	mean	±	standard	deviation.	..................................................	130	
















monitored	 by	 a	 Fluorolog	 fluorometer	 (Jobin	 Yvon,	 Edison,	 NJ)	 after	 incubation	 with	 a	 series	 of	
concentrations	of	ligand	molecules.	Plotting	the	ratio	of	intensity	at	635	nm	(emission	maximum	of	Nile	
red	 in	 a	 hydrophobic	 environment)	 to	 that	 at	 660	nm	 (emission	maximum	of	Nile	 red	 in	 an	aqueous	
environment)	 against	 the	 tested	 concentration	 indicates	 the	 transition	 that	 occurs	 when	 the	
concentration	exceeds	 the	CMC.	The	CMC	value	 for	 each	 ligand	molecule	was	 then	determined	by	 the	
intersection	of	the	two	fitting	lines.	.......................................................................................................................................	147	
Figure	5-6.	Characterization	of	filler	and	ligand	molecules.	Representative	TEM	images	of	self-assembled	


















(2.5	 mM	 filler,	 250	 μM	 O16)	 at	 different	 salt	 concentrations.	 (D)	 Proposed	 mechanism	 of	 mAb-IF	
agglomeration	as	the	ligand	concentration	increases	for	a	fixed	mAb	concentration.	mAbs	at	States	3,	
















1.1 Background and Motivation 
mAbs have received considerable attention in the past two decades for the treatment 
of diseases in oncology, hematology, dermatology, rheumatology, etc.1-2 The mAb market 
has rapidly increased in the past five years with market sales exceeding $98 billion in 2017 
and predicted sales of $137-200 billion by 2022.2 The rapidly growing mAb market and 
the competition from biosimilars have placed an increasing burden on industrial mAb 
manufacturing.2-4 Downstream processing is considered one of the most challenging 
phases of industrial manufacturing of therapeutic proteins, accounting for a large portion 
of the total production costs. Meanwhile, increasing pressure on downstream processing is 
due to the significant growth of upstream titers.5-6 More than tenfold increase in titers has 
been seen over the past 30 years with an average of 3 g/L, while several new products are 
reported to reach more than 10 g/L.5, 7-8 In contrast, improvement of downstream 
processing lags substantially behind the increase in titers, and downstream costs increase 
dramatically as the capacity increases.7 Currently, protein A affinity chromatography 
dominates the mAb capture step but suffers from limited production capacities and high 
media cost.9 Optimization of the mAb capture step or exploration of potential alternatives 
to chromatography is essential to improve process efficiency and reduce production costs.6, 
10-12 
Affinity precipitation has been increasingly explored as a promising alternative that 
features high affinity capture as well as reversible soluble-insoluble transitions.13-14 The 
precipitation can be triggered either by the ligand-mAb interactions or external stimuli such 
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as temperature, pH, ionic strength, and concentration.15 To some extent, affinity 
precipitation can surpass chromatography limitations involved with column size and ligand 
immobilization;16 however, it demands high mAb capture selectivity and the complete 
removal of precipitants. Therefore, rational design of affinity precipitants is key for this 
technology, which requires at least one segment to specifically capture mAbs and the 
feature to make the whole system responsively and reversibly soluble. Several biomaterials 
such as elastin-like polypeptide (ELP) based materials,17-19 smart polymers,20 and affinity 
peptides21 have been investigated as affinity precipitants for mAb capture and purification. 
However, concerns remain in capture efficiency and difficulty in removing these 
biomaterials. 
Supramolecular peptide assemblies have been widely explored in the past three 
decades for applications in drug delivery,22-30 regenerative medicine,31-35 and disease 
diagnostics.36-38 As molecular building units, peptides are particularly attractive for 
creating supramolecular materials for biomedical applications due to their inherent 
biodegradability and biocompatibility, and most importantly, their ability to incorporate a 
variety of bioactive epitopes for specific biology interfacing.39-43 Of all the peptide-based 
assemblies explored thus far, peptide amphiphile nanofibers44 and protein analogous 
micelles45 are the most studied as bioactive materials for diverse biomedical applications. 
In both cases, the underlying molecular design involves covalent linkage of one or more 
hydrocarbons/lipids onto either the N or C terminus of a short peptide to generate self-
assembling peptide amphiphiles (PAs). In a typical peptide-based supramolecular system, 
reversible transitions can occur at multiple length scales,46 including the intramolecular 
chain adjustment to adopt various conformations,47 the intermolecular interactions to 
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assemble into discrete polymeric nanostructures,40, 48-49 and the inter-particle interactions 
to percolate into a 3D network (gelation) or to cause macroscopic phase separation 
(coacervation or precipitation).50-52  
In this work, I took advantage of the inherent reversible transitions in 
supramolecular systems to develop peptide-based supramolecular polymers as effective 
affinity precipitants for selective capture and purification of mAbs. My approach was to 
incorporate a mAb-binding peptide ligand with high affinity into the molecular building 
units of the supramolecular system. The design principles of constructing the building units 
while preserving the conformation of the peptide ligand were first investigated. The 
supramolecular system created using self-assembly or co-assembly strategy has been 
thoroughly studied for mAb capture and purification. I believe these results shed important 
light on the use of supramolecular systems for non-chromatographic purification of mAbs 
and other protein therapeutics. 
1.2 Downstream Processing Strategies for Purification of Monoclonal 
Antibodiesa 
1.2.1 Overview 
Nowadays, downstream processing of therapeutic proteins is facing great 
challenges created by the rapid increase of the market size and upstream titers, starving for 
significant improvements or innovations in current downstream unit operations. The 
emergence of advanced biomaterials has contributed to addressing the downstream 
                                                
 
a Reprinted with permission from Li, Y.; Stern, D.; Lock, L.L.; Mills, J.; Ou, S.-H.; Morrow, M.; Xu, X.; 
Ghose, S.; Li, Z.J.; Cui, H. Emerging biomaterials for downstream manufacturing of therapeutic proteins, 
Acta Biomaterialia, 2019, 95, 73-90. Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. 
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bottleneck by introducing high-performance and cost-effective downstream technologies.7, 
10, 53 Typically, downstream mAb processing involves a sequence of different 
chromatographic separations, virus inactivation and filtration, and membrane-based 
separations.7 After clarifying cell culture harvest, protein A or other affinity-based 
chromatography is used to capture the target mAb product, followed by a virus inactivation 
step.7, 54 Then combinations of polishing chromatography steps, including but not limited 
to ion exchange chromatography (IEX) and hydrophobic interaction chromatography 
(HIC), are allowed to further reduce impurity levels by utilizing the differences in physical 
properties such as charge, hydrophobicity, and molecule size.7, 11 Finally, a virus filtration 
step and an ultrafiltration/diafiltration step are performed to ensure viral clearance and to 
exchange the product into the formulation buffer, respectively.10, 54 Despite the high media 
cost and limited loading capacity, affinity chromatography remains the most widely used 
capture method for large-scale purification.53 Proteins of interest can be separated from 
impurities through reversible interactions between the target protein and affinity ligands 
immobilized on chromatography media. For example, protein A chromatography has been 
widely used in the purification of mAbs and Fc-fusion proteins.9 Over the past decades, 
numerous affinity ligands have been developed to improve the binding capacity, capture 
efficiency, and ligand stability.55 Furthermore, affinity tags that are genetically grafted onto 
target proteins have also gained widespread attention, as these pre-defined affinity pairs 
are independent of each particular target protein.56-57 Advances have also been made in 
developing more efficient chromatography media such as natural or synthetic polymers to 
achieve higher column performance.11 To overcome limitations of chromatographic 
procedures for high cost and demanding operations, continuous efforts have also been 
5 
made to develop non-chromatographic methods including membrane separations,58
magnetic separations,59 and precipitation/phase separations.60-61 These are promising 
alternatives to chromatography-based approaches, with advantages including cost-
effectiveness and operational simplicity in some applications. Among these non-
chromatographic methods, polymer/peptide-based biomaterials have been intensively 
utilized in the design and construction of membranes, magnetic nanoparticles, and 
precipitants with high capture efficiency and high selectivity. This section provides an 
overview of the recent advances in the development and optimization of biomaterials for 
applications in downstream processing of therapeutic proteins (Figure 1-1). Discussions 
will be focused on chromatography and membrane separation. Approaches currently used 
in industry and in development will be discussed. 
 
Figure 1-1. Schemes of representative methods discussed in this review for purification of 
therapeutic proteins. Reprinted with permission from ref. 12, Copyright © 2019 Acta 
Materialia Inc. Published by Elsevier Ltd. 
1.2.2 Affinity Chromatography 
Affinity chromatography is the predominant unit operation for large-scale 
bioprocessing and purification of therapeutic proteins.55 Despite its high binding specificity 
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to the target protein, affinity chromatography is currently still the downstream productivity 
bottleneck due to its relatively low resin binding capacity, limited column size amenable 
to biomanufacturing, and high resin cost.62 Affinity ligands that are immobilized on the 
chromatography media can recognize and bind to specific proteins through molecular 
interactions such as hydrophobic and electrostatic interactions, hydrogen bonding, and van 
der Waals forces.55 Important features of an affinity ligand include its high affinity and 
specificity to the target, stability in various solution conditions, ease of immobilization, 
and target-binding retention following attachment to the matrix.63 A myriad of affinity 
ligands can be used for protein purification depending on the biophysical properties of the 
target protein. Table 1-1 shows some of the vast array of affinity ligands that have gained 
interest over the last several years for applications in the purification of therapeutic proteins. 
The majority of ligands currently being used in affinity chromatography are 
biospecific ligands. They are ligands of biological origin that are derived from natural 
sources and can bind to specific targets such as bacterial immunoglobulin-binding proteins, 
antibodies, lectins, and nucleic acids.55 The most frequently used biospecific ligands for 
mAb and Fc-fusion protein purification processes are protein A, protein G, and protein L, 
which are all derived from bacterial cell walls.55 Many species of antibodies can bind to 
these ligands, yet, their affinities vary depending on the antibody subclass.64-65 However, 
the harsh environment during elution and other conditions at extreme pH and exposure to 
organic solvents or detergents can denature coupled biospecific molecules, often resulting 
in ligand leaching.63 The stability and binding capacity of recombinant protein A affinity 
resins are constantly being improved. For example, Toyopearl AF-rProtein A-650F, a 
recombinant protein A affinity resin derived from an immunoglobulin G (IgG)-binding 
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domain, has been optimized to withstand alkaline solutions during cleaning and 
sanitization procedures and displays higher binding capacities, up to 50-70 mg/mL, 
yielding eluted antibodies of about 99% purity.66 Additional resins with high binding 
capacities and high alkaline stabilities are found in GE Healthcare’s MabSelect family, 
including MabSelect Sure, Sure LX, Sure pcc, and PrismA.67-69 Within this family of 
resins, MabSelect Sure pcc and MabSelect PrismA have the highest binding capacities for 
mAbs and bispecific antibodies, ranging from 58-74 mg/mL. These MabSelect resins are 
derived from the B domain of protein A, giving them a high binding affinity for various 
mAbs and Fc-fusion proteins, such as immunoglobulins.67-69  
Table 1-1. Commonly used affinity ligands for protein purification in affinity 
chromatography. 
Ligand/Family Affinity Target Scaffold/Origin References 
Recombinant protein A 
derived from an IgG-
binding domain 
 
IgG, IgM, and Fab fragments Fc-region (B domain) and 
Fab-region (D&E) domains 
of protein A 
70 
MabSelect Sure, Sure 
LX, Sure pcc, PrismA 
 
Fc-region of IgG B domain of protein A 67-69 
Camelid VHH IgA, IgG, various blood factors, 




Anti-EGFR Affibody EGFR receptor Z domain, modified from B 
domain of Staphylococcal 
protein A (SpA) 
73 
    
Anti-TNF-α Affibody 
 
TNF-α receptor Z domain, modified from B 
domain of SpA 
73 
Anti-idiotypic Affibody Human epidermal growth factor 
receptor 2 affibody molecule 
Z domain, modified from B 






















Ugi and Triazine de 
novo ligands 
 
Glycoproteins, EPO, IgG (Fc and 
Fab fragments) 
protein L (A&C domain), 
protein G Streptococcal 
protein G (SpG-III domain) 
77-80 
Short peptide ligands 
(HWRGWV, HYFKFD, 
and HFRRHL) 










Fc region of IgG Fc-binding domain of 
protein A 
83 
Cibacron Blue F3GA Several enzymes and proteins 
(non-specific) 







Variety of small molecules, 
proteins, membrane-bound 
receptors, cell surface epitopes 
Nucleotide sequences 
selected from combinatorial 
libraries (i.e. SELEX) 
85-88 
 
Since most biospecific ligands are derived from bacteria, there is a risk of 
contamination by viruses, DNA, and pyrogens; thus, further purification is essential, which 
increases the manufacturing and bioprocessing costs. Compared to biospecific ligands, 
pseudo-biospecific ligands, are more robust, economically feasible, structurally simple, 
less toxic, and very stable with resistance to punitive sterilization environments. However, 
pseudo-biospecific ligands are not as selective as biological ligands, and require substantial 
optimization for each protein to achieve high selectivity, thus limiting their acceptability 
as a superior purification technique in industry.63 There are many types of synthetic ligands 
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that can be chemically modified including biomimetic peptoidal, peptidic, and dye-based 
ligands. Biomimetic peptoidal ligands utilize the physicochemical properties of amino acid 
residues to interact and bind with the target protein. For example, protein A mimetic 
peptoidal ligand is commonly used for mAb purification because of its specificity towards 
the Fc fragment of immunoglobulins. Rational design and synthesis of synthetic ligands 
like biomimetic triazine and Ugi ligands, known as de novo ligands, have already led to 
successful purification of several proteins at the bench scale.77-80 Additionally, DNA 
aptamer affinity ligands have also been developed to selectively purify human plasma-
related proteins from various origins.85 
Affinity tags have also gained widespread attention in the purification of 
therapeutic proteins. They are comprised of exogenous amino acid sequences with a high 
affinity for certain biological or chemical ligands. Affinity tags are normally fused to the 
N-terminus or C-terminus of a target protein, which allows the protein to be selectively 
captured and purified using a tag-specific resin via affinity chromatography or other 
methods.89 Affinity tags are advantageous to utilize in the downstream processing of 
protein therapeutics for several reasons. In many instances, the target protein exists as a 
version with an affinity tag from prior research stages. Furthermore, the high yields of 
affinity purification make the use of affinity tags economically favorable. Affinity tags can 
be both beneficial and harmful for the target protein, and are typically removed through the 
addition of proteolytic enzymes or more recently, through self-cleaving modules that have 
been developed over the past several years.90-91 
Table 1-2 shows a multitude of relevant affinity tags commonly used in affinity 
chromatography for protein purification. His-tags are one of the most prevalent affinity 
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tags used in purification strategies due to their abundance in many different proteins. 
Additionally, His-tags do not require a specific protein folding conformation to function 
and have been used to purify soluble membrane proteins stabilized by detergents or lipids, 
thus demonstrating their robustness.90, 92-93 Purification of His-tagged proteins is 
accomplished by using chelated metal ions as affinity ligands that are complexed with an 
immobilized chelating agent. The target protein is separated through interactions between 
the imidazole side chain of histidine and the affinity ligands and is purified using 
immobilized metal affinity chromatography.94 Another very common epitope tag used for 
affinity protein purification is the FLAG tag, which consists of a short, hydrophilic 
octapeptide (DYKDDDDK).95 The FLAG tag contains an intrinsic enterokinase cleavage 
site at the C-terminus, allowing it to be easily removed from the target protein. Affinity 
tags present a viable alternative to affinity ligands for enhancing the purification of 
therapeutic proteins. Over the next several decades, we can expect that the number of 
affinity tags will continue to rise as newer tags continue to be developed to improve 
purification strategies for a vast array of therapeutics. 
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Table 1-2. Commonly used affinity tags for protein purification in affinity 
chromatography. 
Tag Fusion/Recognition Partner Function/Purpose References 
His-tag Metal chelate Purification under native and denaturing 
conditions 
90, 92-93 
GST GST-fusion protein Enhances purification and stability with 










12 CA5 mAb Mostly used as a detection tool for 
recombinant proteins through 
immunoblotting assays 
95, 99 
Heme tag Various peptide motifs High affinity for specific amino acid 
sequences found in various proteins (e.g. 
Az-Hm14 and MBP-Hm16) utilizing 
coordination chemistry 
100 
S1v1 Various peptide motifs Multifunctional tag that is a substitute 
for the His-tag; simultaneously enhances 
expression, thermostability, and 





Strep-Tactin protein Matrix modified with streptavidin for 




Amylose (maltose analog) Single step purification via cross-linked 
amylose affinity resin; mild conditions 
for elution of target fusion protein; 




Depends on the affinity tag 
intein is fused with (eg. 
chitin binding domain) 
Intein can be fused to many different 
affinity tags to induce self-cleavage and 
avoid the risk of nonspecific cleavage of 






1.2.3 Non-Affinity Chromatography 
Non-affinity chromatography is commonly used during the polishing steps in the 
downstream processing of therapeutic proteins. In a typical platform operation for mAb 
purification, one or two polishing steps follow a protein A affinity capture step to remove 
residual host cell protein (HCP), DNA, viruses and other product-related impurities.106 
Unlike affinity chromatography, which relies on the likeness or specificity of an antibody 
binding to a stationary phase, non-affinity chromatography utilizes charge, hydrophobicity, 
or molecule size for purification.106-107 The most frequently used non-affinity 
chromatographic modes are ion exchange chromatography (IEX), either anion exchange 
or cation exchange, and hydrophobic interaction chromatography (HIC). Other methods 
include mixed-mode chromatography (charge and hydrophobicity based separation), size-
exclusion chromatography and reverse-phase chromatography. Current IEX resins utilize 
a cross-linked matrix commonly made of agarose, silica, polymethacrylate, poly(styrene-
divinylbenzene) with a functional ligand, such as a sulfonate group (cation exchanger) or 
a quaternary amine (anion exchanger), to facilitate binding. HIC resins exploit similar 
support matrices but have hydrophobic ligands such as ethyl, propyl, or benzyl/aromatic 
groups to enable adsorption. In most cases, non-affinity chromatography is crucial for 
obtaining high purity in biopharmaceuticals manufacturing.  
IEX has served as an essential tool for the separation of biomolecules for decades 
and remains a frontrunner in impurity-removal steps and charge heterogeneity 
evaluation.108 This modality utilizes a charged (negative or positive) stationary phase with 
immobilized ligands and binds therapeutic proteins under specific solution conditions, 
particularly pH. With increasing pH, the overall charge of the protein changes from net 
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positive to net negative, with the transition occurring at the isoelectric point (pI), the point 
of zero net charge.109 Ion exchangers typically operate in one of two modes: (1) bind-and-
elute mode where proteins bind to a resin and impurities are forced out, or (2) flow-through 
where impurities bind to the resin and the desired protein is allowed to flow through the 
column. 
HIC is exceptional at removing product-related impurities and is an essential tool 
in downstream mAb purification.110 HIC works by adsorbing the non-polar sidechains of 
proteins to hydrophobic ligands on a stationary phase typically in the presence of high salt 
concentrations and allowing more polar molecules or impurities to pass through. 
Hydrophilic interaction chromatography (HILIC) works in the opposite manner and 
utilizes a polar stationary phase with a non-polar mobile phase.111 Hydrophobic charge-
induction chromatography (HCIC) operates similarly but requires no addition of salt to the 
mobile phase. Desorption is based on electrostatic charge repulsion and is achieved by 
lowering the pH of the mobile phase.112 These modalities are effective at removing 
molecular weight variants (aggregates and fragments) and process related impurities, and 
are often utilized as polishing steps in the purification of therapeutic proteins.113 Much like 
IEX, HIC, HILIC, and HCIC are typically operated in a column format and can suffer from 
diffusion limitations and fouling. Methods such as grafted resins with novel ligands and 
bio-based monoliths have been developed to improve the efficiency and robustness of these 
modalities.114-115 
Mixed-mode chromatography (MMC) is a new purification method that utilizes 
more than one form of interaction between the stationary and mobile phases. Mixed-mode 
resins typically have ligands with multiple functional groups to facilitate hydrophobic 
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interactions, electrostatic interactions, and even hydrogen bonding.116 MMC resins usually 
combine ion exchange and hydrophobic interactions to achieve high selectivity and 
sensitivity.117 Over the past decade MMC has shown great performance in the separation 
of mAbs and therapeutic proteins.54, 118 Some MMC resin types utilize a multimodal ligand 
with a carboxylic group and an aromatic group to facilitate electrostatic and hydrophobic 
interactions, respectively. Other commercially available MMC materials contain 
hydrocarbyl amines or sulphur atoms to enable interactions. A significant benefit to MMC 
is that protein binding can occur without any feedstock dilution or addition of lyotropic 
salts.119 While relatively little ground-breaking work has been done in recent years to 
incorporate biomaterials into MMC resins for protein purification, this technology is 
promising in its use as a platform chromatography method.  
1.2.4 Membrane Separation 
Membrane separation is one of the key systems utilized in therapeutic protein 
purification and downstream processes, such as depth filtration, ultrafiltration, virus 
filtration, and sterile filtration. Depth filters are commonly used in downstream processes 
during the cell culture product harvest and post viral-inactivation step to remove biomass 
particulates, precipitates, HCP, DNA, and potentially high molecular weight species in 
some instances.120-121 Typically, a depth filter is composed of filter aid, binder, and 
cellulose fiber. The filter’s effective protein absorption capacity was evaluated by Khanal 
et al. to gain optimal usage.58 As conventional depth filters contain naturally-derived 
diatomaceous earth and potentially beta-glucan leachable material that could affect process 
variability and endotoxin assays, all-synthetic depth filtration media (e.g., Millistak+® HC 
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Pro X0SP) has emerged as the alternative to address these challenges and has shown to 
improve HCP clearance.122  
Sorting molecular components through optimized and engineered barriers could 
enhance efficiency and selectivity between the feed and permeate streams.123 To achieve 
highly concentrated mAbs intended for a subcutaneous injection, ultrafiltration is the main 
unit operation on the manufacturing scale. For example, Pall Omega® T-series and 
Millipore Pellicon® series offer ultrafiltration membranes with different screen channel 
types, ultra-low protein binding membrane, and different sizes depending on the required 
scale. However, there are existing challenges associated with this process, such as 
increased risk of aggregate formation or membrane fouling affecting selectivity and 
permeability at high protein concentrations.124-125 Furthermore, physical properties can 
alter filtration flux and high viscosities can limit operating pressures.126-127 Various 
research groups have developed new biomaterials or membrane modifications to enhance 
the performance of the ultrafiltration unit operation.128 Membrane surface modifications 
such as chemical grafting and physical coating post polymer matrix formation provide 
options for presenting the membrane surface with various functional groups based on 
specific applications. On the other hand, bulk blending is another approach for membrane 
modification by which the functional modifiers of interest are added into the membrane 
casting solution.  
Separation of similarly sized proteins has been a challenge due to limited 
fabrication techniques and biomaterials. In the work reported by Qiu et al., an amphiphilic 
block co-polymer (PS-b-P4VP) was introduced to self-assemble into a thin layer of densely 
packed, highly ordered cylindrical channels with uniform pore sizes of ~34 nm and lengths 
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of ~100 nm (Figure 1-2 A-C).129 By customizing the membrane properties with 
quaternization, the membrane was able to separate similarly sized proteins based on their 
respective pIs. Additionally, the authors found that other parameters such as molecular 
shape, mobility, and the hydrophilic-to-hydrophobic ratio of amino acids could also affect 
the protein transport behavior through the nanopores.129  
 
Figure 1-2. (A) Schematic illustration of similarly sized protein separations through 
tunable nanoporous block copolymer membrane. (B) Regular order of the membrane's 
surface as shown by SEM. (C) Cross-section SEM image showing the thin top layer and 
the sponge-like bottom layer. (A) (B) (C) were reprinted with permission from ref. 129, 
Copyright © 2013, American Chemical Society. SEM images of (D) 100 nm PS latex beads 
and (E) SIV particles following filtration on Cladophora cellulose membrane. Reprinted 
with permission from ref. 130, Copyright © 2014, John Wiley and Sons. 
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Viral filtration is an expensive operation and generally produced by a synthetic 
polymer for the biotechnology industry to remove adventitious virus particles from the 
therapeutic drug product. Metreveli et al. described a natural, unmodified nanofibrous 
polymer-based membrane, utilizing size-exclusion principles, that was able to remove 
nano-sized virus/particles by ≥ 6.3 log reduction value, which is comparable to industrial 
filters (Figure 1-2 D and E).130 The nanocellulose filter paper had an average pore size of 
19 nm and was shown to efficiently filter beads ranging from 30 nm to 500 nm.130 With 
the filter’s ease of large-scale manufacturing, it showed potential for applications in the 
industrial sector.  
Membranes with nanochannels that feature charged groups can be applied to the 
purification of biomolecules by allowing the passage of uncharged or oppositely charged 
solutes, but opposing the passage of co-ions.131 Sadeghi et al. have developed membranes 
that feature a packed array of self-assembled micelles with carboxylate functional 
surfaces.131 The interstices (1-3 nm minimum) serve as charged nanochannels that allow 
the passage of solutes. The membranes have been shown to effectively retain negatively 
charged molecules and allow positively charged and neutral molecules to pass through. In 
filtration experiments, anionic and neutral compounds were separated with water fluxes 
comparable to existing commercial membranes.131 These membranes are also 
manufactured using easier and more scalable methods than other comparable approaches. 
The self-assembled micelle membranes can be used for processes that involve the 
separation of charged particles, such as IEX in the processing of therapeutic proteins. 
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1.3 Recent Advances in the Precipitation of Monoclonal Antibodiesb 
1.3.1 Overview 
Protein precipitation has long been developed for protein purification and 
concentration in both laboratory protein isolation and downstream processing.132 
Ammonium sulfate precipitation is often performed before the chromatography steps to 
concentrate target proteins and remove impurities based on solubility differences in 
proteins. However, relying on bulky and expensive centrifuge systems and relatively low 
selectivity limit its applications in large-scale purification.11 Nevertheless, methods based 
on solid-liquid phase separation mechanisms, e.g., crystallization and precipitation, have 
seen a renaissance in protein purification to achieve high throughput and reduced costs.13 
To overcome the obstacles of current precipitation methods, continuous efforts have been 
made to develop more advanced precipitants using biomaterials to reduce or avoid the use 
of column chromatography. Meanwhile, the improvement of membrane filtration 
techniques will facilitate the wide implementation of the precipitation methods for protein 
purification. 
1.3.2 Non-Affinity Precipitation 
1.3.2.1 PEG-Induced Precipitation 
Polymers such as polyethylene glycol (PEG) can be used as non-specific 
precipitants. PEG precipitation has received broad interest in the field of mAb purification 
because of its simple operation in mild conditions, fast precipitation kinetics, and low cost. 
                                                
 
b Reprinted with permission from Li, Y.; Stern, D.; Lock, L.L.; Mills, J.; Ou, S.-H.; Morrow, M.; Xu, X.; 
Ghose, S.; Li, Z.J.; Cui, H. Emerging biomaterials for downstream manufacturing of therapeutic proteins, 




It was originally found that the logarithm of protein solubility follows a linear relationship 
with the concentration of PEG and higher molecular weight PEGs show higher 
precipitation efficiency due to excluded volume effects.133 Linear PEG4000-6000 of high 
concentrations were traditionally employed and followed by the exploration of branched 
PEG to reduce viscosity caused by the large linear PEG chains, although protein 
precipitation yield can be compromised using branched PEG.134 Recent studies revealed 
that the efficiency of PEG precipitant could be further characterized by the hydrodynamic 
radius of PEG, rh,PEG, which takes into account the effects of PEG branching and 
environmental conditions.134-135 Conditions such as PEG and protein concentration, pH, 
ionic strength, and time should be optimized to achieve the best precipitation efficiency. 
However, PEG is insufficient at removing product-related high molecular weight 
impurities.136 Low selectivity remains the major limitation of this technique. In recent 
years, the combination of PEG with other precipitation methods has been investigated to 
improve selectivity and achieve higher yields. For example, Oelmeier et al. reported the 
employment of centrifugal partitioning chromatography (CPC) in combination with PEG 
precipitation for mAb purification. PEG-driven precipitation was performed in the CPC 
output stream and results showed that the reduction of HCP was improved from 88 % to 
99 % after PEG precipitation while recovering 93% of the target protein after re-
solubilization.137 To address the limitation of PEG precipitation in removing process-
/product-related impurities such as DNA and mAb aggregates respectively, the 
combination of different precipitants, including PEG, caprylic acid, CaCl2, and cold 
ethanol, were intensively investigated.136, 138 In a subsequent study, continuous PEG 
precipitation of different recombinant antibodies was developed with similar performance 
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to that for batch operation.139 Recently, the integration of PEG precipitation and cation 
exchange chromatography was demonstrated a feasible alternative to protein A 
chromatography.140 Despite the wide application of PEG-induced precipitation, concerns 
still remain about solubility predictions of target proteins in high protein concentrations, 
the removal of impurity precipitates and PEGs, and assay interference. Careful 
investigations and additional validation of results are recommended for the development 
of PEG-based precipitation conditions.141-142 
1.3.2.2 Polyelectrolytes-Induced Precipitation 
 Depending on the pH of the environment, therapeutic proteins or impurities can 
exhibit charged groups and be precipitated by oppositely charged polyelectrolytes due to 
electrostatic interactions.143 Extensive efforts have been made to study the mechanism and 
influencing factors of precipitating protein-polyelectrolyte complexes.144-145 Proteins carry 
positive or negative charges when the solution pH is below or above their pIs, respectively. 
It provides the opportunity for charge-based precipitation of target proteins or impurities 
by controlling solution pH condition. Typically, anionic polyelectrolytes including 
polyvinylsulfonic acid, polyacrylic acid, and polystyrenesulfonic acid are used to 
precipitate mAbs of basic pIs.146 Conversely, cationic polyelectrolytes such as polyamines 
can be used to remove negatively charged impurities such as HCP and DNA.147 The 
reversible nature of ionization eases the re-solubilization of the precipitated complex by 
tuning the solution pH or ionic strength.  
Sieberz et al. investigated the impact and interactions of various parameters on the 
separation of a mAb from a model impurity, BSA, using anionic polyelectrolytes. A Design 
of Experiments (DOE) strategy was utilized to show that all parameters should be 
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optimized simultaneously to account for any significant parameter interactions.148 In a later 
study, influencing factors for the precipitation of BSA with cationic polyelectrolytes were 
investigated and two statistical models were established using DOE.149 Recently, 
poly(glutamic acid) (polyE) was utilized to precipitate IgGs in high-concentration 
solutions. The formation of reversible liquid droplets of the IgG-polyE complex 
demonstrated an indispensable role in improving precipitation and redissolution yields to 
nearly 100%.150 Future studies in polyelectrolytes-induced precipitations require 
fundamental understanding of more complicated systems involving the prediction of 3D 
structures of proteins, local charge distributions, and multi-type interactions including 
hydrophobic interactions, hydrogen bonding, etc.145 
1.3.2.3 Self-Precipitation with Fusion Tags 
As mentioned previously, fusion tags (mostly peptides and proteins) have been 
widely used to purify target proteins through tag-specific affinity chromatography. As 
increasing attention has been focused on the development of column-free purification 
methods, a variety of aggregating tags have been explored to induce the self-precipitation 
of fusion proteins.61 Subsequent removal of aggregating tags can be achieved by 
incorporating a cleavage site or a cleavage tag in favor of chemical cleavage, protease 
cleavage, or self-cleavage.89 Mechanisms of how these tags induce the aggregation of 
proteins can be interpreted by the responsive solubility, high hydrophobicity, and self-
assembling behavior of the aggregating tags.  
Elastin-like polypeptide (ELP), a representative fusion tag composed of repeating 
peptides Val-Pro-Gly-Xaa-Gly, where Xaa is any amino acid except for proline, is well-
known for its thermally reversible phase transition behavior which has attracted 
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considerable attention in protein purification, drug delivery, and tissue engineering.151 
ELPs in aqueous solutions abruptly aggregate when temperature is raised above the 
transition temperature (Tt). The pellet can be further redissolved at a temperature below Tt. 
Meyer and Chilkoti demonstrated for the first time that recombinant proteins can be 
purified by fusion with thermally-responsive ELP.151 A large number of subsequent 
studies have been reported to optimize properties of ELP-fusion proteins such as molecular 
weight, Tt, and ELP cleavage to achieve better purification performance for various 
proteins.152 A self-cleaving ELP tag was designed by Wood and coworkers to purify RNA 
polymerase and several recombinant proteins with reasonable yield and purity (Figure 1-3 
A).153-154 The tagged target protein could be precipitated with a mild temperature shift and 
resuspended in a cleaving buffer to remove the ELP tag. A subsequent precipitation step 
was conducted to separate the cleaved tag from the target protein. A recent study built upon 
this concept and established a high-throughput platform using 24-well plate cultures 
followed by purification in 96-well plates.155 It was demonstrated that this high-throughput 
format showed high well-to-well reproducibility without compromising purity or 
robustness.155 
Apart from the thermally responsive ELP, many tags were constructed with high 
hydrophobicity to promote the aggregation of the target protein. These include proteins 
such as Npro, Ketosteroid isomerase, 4AaCter and short self-assembling peptides like 
ELK16 and 18A.61 For example, recombinant cystatin C was expressed as an insoluble 
fusion protein with a peptide-tag, 4AaCter, for simple and efficient purification steps. 
Recently, Xu et al. reported recombinant production of influenza hemagglutinin and HIV-
1 GP120 antigenic peptides using a cleavable self-aggregating tag comprised of a short 
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self-assembling amphipathic peptide ELK16 (LELELKLKLELELKLK) and an intein 
molecule. The target proteins were first expressed as insoluble aggregates and released by 
intein self-cleavage into the soluble fraction with high yield and reasonable purity.156 In 
general, using these aggregating tags is a simpler purification method and requires minimal 
production or processing costs. However, the yield and purity of purified proteins are 
inferior to that achieved by traditional chromatography methods. Further exploration of 
more efficient designs of cleavable fusion tags to address co-aggregation of impurities, 
partial premature cleavage, and incomplete removal of the fusion tags are necessary for 
more applicable purification systems.  
 
Figure 1-3. (A) Schematic of ELP-tagged split intein purification method. Reprinted from 
ref. 154. (B) Affinity precipitation of mAbs from cell culture with Z-ELP-E2 nanocages. 
(1) Mix nanocage stock with clarified culture. (2) Spontaneous aggregation through 
multivalent crosslinking. (3) Wash pellet by suspending in target wash buffer pH>5. (4) 
Elute by suspending pellet in buffer pH<4. (5) Add salt for selective precipitation of 
nanocage and collect purified mAb in supernatant. (6) Regenerate nanocage to recycle for 




1.3.3 Affinity Precipitation 
Affinity precipitation colligates the advantages of both specific capture of affinity 
ligands/tags and reversible precipitation. It seems contradictory to possess both 
characteristics simultaneously since affinity binding requires thermodynamic stability 
while precipitation represents a phase separation behavior. In fact, the precipitation of the 
affinity precipitant and protein complex are often triggered either by environmental stimuli 
such as temperature, pH, ionic strength, and concentration after the formation of the 
complex or by the internal changes in the complex such as crosslinking or aggregation 
upon the ligand-protein interactions. For the precipitation triggered by external stimuli, the 
design of affinity precipitants requires one segment to specifically capture target proteins 
and the other segment to be responsive and reversibly soluble. To render the crosslinking 
of target protein, a design of one precipitant molecule with multiple ligands is necessary in 
the case of capturing proteins with more than one binding site. In spite of the strict criteria 
of affinity precipitants, several types of biomaterials including ELP-based materials, smart 
polymers, and affinity peptides have been investigated for affinity precipitation. 
1.3.3.1 ELP-Mediated Precipitation   
As mentioned above, ELP has been employed as a fusion tag for thermally 
reversible precipitation. A major drawback of this method is the limited availability of the 
genes coding for fusion construction especially in the case of novel proteins. An alternative 
method is the creation of an external ELP fused with a binding ligand to capture the target 
protein and undergo inverse transition cycling. Affinity partners could also be engineered 




Chen and coworkers pioneered the design of a series of ELP-ligand precipitants for 
mAb affinity precipitation processing.60, 158-160 The ELP-ligand-protein complex was 
precipitated at an elevated temperature and/or specific salt concentration at neutral pH. 
After redissolving the complex, an elution buffer at a lower pH was added to release the 
target protein. Subsequently, the free ELP-ligands were removed by a second round of 
thermally triggered precipitation. In addition to the ease of purification and the high 
efficiency, the avoidance of tag cleavage and favorable reusability property make it a 
promising method for protein purification.158 
 Recently, ELP fused Z-domain, a shorter synthetic domain derived from the B-
domain of protein A, was designed to bypass the lower expression levels previously 
observed with protein G-fused ELP.159 High-throughput screening was employed to 
determine appropriate conditions for the precipitation and elution of mAbs using ELP-Z.19, 
60 Greater than 99% mAb precipitation yields were obtained at ELP-Z:mAb molar ratio of 
4:1 with 0.25 M Na2SO4 for pure mAbs as well as the mAb harvest mixtures.60 More than 
90% overall yields were achieved in elution buffers with pH up to 4.2.60 However, the 
potential denaturation of antibodies at an elevated phase transition temperature and high 
salt concentration especially in low pH conditions, remain the major concerns for the ELP-
Z precipitants. Therefore, exploring new substrates to present antibody-binding ligands at 
physiological temperature with low/no salt condition is crucial.  
 Recent progress in creating an ELP-Z functionalized E2 protein nanocage 
significantly lowered the temperature and salt concentrations due to increased scaffold 
dimensions and IgG triggered scaffold crosslinking (Figure 1-3 B).18, 160 High-yield 
isothermal purification of IgG without adding salt was achieved in a simple and non-
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destructive manner. Similar to ELP-Z, several other binding ligands such as Z33 and lectin 
were fused with ELP as the affinity precipitants for purification of human antibodies and 
glycoproteins.161-162 With more affinity ligands or affinity pairs being identified, ELP-
mediated precipitation has substantial potential for the large-scale downstream processing 
of therapeutic proteins.  
1.3.3.2 Peptide-Based Materials and Smart Polymers 
In addition to ELP, several peptide-based materials and smart polymers with 
affinity ligands have been used in affinity precipitation for protein purification. Peptide-
based trivalent haptens were designed with the ability to form cyclic complexes with 
trastuzumab and rituximab.21 It was demonstrated that the purified antibodies had native 
levels of binding to the cells.21 Unlike ELP-based systems, additional precipitation was not 
required to remove the trivalent haptens. After the dissociation of the trivalent haptens from 
the target antibody in specific buffers, membrane filtration can be used to remove the 
trivalent haptens.21 This is due to the significant size difference between the trivalent 
haptens and target proteins.21  
Smart polymers including thermo-responsive polymers, pH-responsive polymers, 
and reversibly cross-linked polymer networks are often combined with affinity ligands to 
create effective precipitants.20, 163-164 In recent work, a pH-responsive copolymer 
Eudragit® S-100 was linked to protein A ligand for precipitation and elution of IgG at pH 
5 and pH 2.5, respectively.20 It was demonstrated that 89% of IgG was recovered from a 
protein mixture with a purity greater than 95%. However, special considerations for pH-
sensitive protein-ligand interactions are necessary when designing the pH-responsive 
polymers. Ideally, the critical pH for protein precipitation and elution should be 
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independent. With the abundant monomer types and easily modulated structures, polymer-
based materials show enormous potentials in constructing affinity precipitants. 
In this section, I discussed the recent advances in affinity or non-affinity 
precipitation of therapeutic proteins. Affinity precipitation is more favorable than non-
affinity precipitation due to its high selectivity, however, more efficient methods to remove 
precipitants or fusion tags need to be developed and validated. Based on existing studies 
and prior work, several criteria must be satisfied for a successful and efficient precipitant 
design. First, the precipitant should not compromise the functionality of the target protein 
and it should be easily removed from the protein solution. Second, high selectivity and 
high efficiency are needed for either the precipitation of target proteins or impurities. Third, 
the precipitation behavior should occur in a well-predicted and well-controlled manner. 
Fourth, the precipitant could be easily manufactured at a large scale and economically. 
Finally, the precipitant can be conveniently recycled without causing the loss of protein 
activity. These criteria should be considered for future improvement and development of 
precipitants for therapeutic protein purification. 
1.4 Peptide-Based Supramolecular Polymers 
1.4.1 The Self-Assembly of Peptide-Based Supramolecular Polymers 
At the molecular scale, self-assembly is a spontaneous and reversible process when 
molecular components form ordered structures via non-covalent interactions, presenting a 
fascinating bottom-up approach to construct complex and hierarchical nanostructures. 
Supramolecular polymers, formed by self-assembly of monomeric units, represent 
attractive materials for various biomedical applications including drug delivery, 
regenerative medicine, and biosensing. Amphiphiles, consisting of both hydrophilic and 
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hydrophobic moieties, are the most common self-assembly building blocks that have been 
widely explored to mimic biological systems. When dispersed in solvents, amphiphiles 
such as surfactants, lipids, and amphiphilic block copolymers are able to self-assemble into 
various supramolecular nanostructures, e.g. micelles, nanofibers, nanotubes, vesicles, etc. 
As a result of minimizing system free energy to assume a spontaneous interfacial curvature, 
the solvophilic moieties of the amphiphile preferentially interact with the solvent while the 
solvophobic moieties tend to pack internally. The final morphology is determined by the 
balance of multiple non-covalent interactions including hydrophobic attraction, ionic 
repulsion, the system entropy, van der Waals interaction, as well as some directional 
interactions such as hydrogen bonding or π–π stacking. Critical micelle concentration 
(CMC) is an important characteristic for amphiphiles, above which amphiphilic monomers 
start to self-assemble into ordered structures. Besides, the self-assembly process can be 
readily tuned by many environmental factors such as pH, ionic strength, temperature, 
solvents, and co-assembling molecules.  
Among the recently developed supramolecular polymers, peptide-based assemblies, 
formed by self-assembly of synthetic or naturally occurring peptides and their derivatives, 
are notably fascinating because of their biocompatibility, biodegradability, and low 
toxicity.165-167 In particular, one-dimensional (1D) nanostructures (nanofibers, nanotubes, 
nanowires, nanobelts, etc.) formed by β-sheet-forming peptides via directional, 
intermolecular hydrogen bonding, have been intensively investigated for use as scaffolding 
materials in regenerative medicine31, 41, 44, 168-170 and also as therapeutic and diagnostic 
carriers in drug delivery171-178 and molecular imaging.179-180 With the hierarchically 
organized structures, peptide-based materials are suitable as building blocks for self-
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assembly (Figure 1-4 A). The diversity of amino acids provides a broad basis for non-
covalent interactions including hydrogen bonding (polar amino acids like glutamine), π–π 
stacking (aromatic amino acids like phenylalanine), hydrophobic collapse (non-polar 
amino acids like valine), and electrostatic interactions (acidic and basic amino acids like 
glutamic acid and lysine) (Figure 1-4 B).167 Moreover, the well-established solid-phase 
peptide synthesis (SPPS) protocols further contribute to the efficient and easy synthesis of 
peptides by researchers who have not had rigorous chemistry trainings.  
 
Figure 1-4. Schematic representation of the self-assembly of peptide-based materials. (A) 
The reversible self-assembly of various peptide motifs. (B) Possible non-covalent 
interactions among peptide-based building blocks, including hydrophobic collapse, van der 
Waals interactions, hydrogen bonding, π–π stacking, and electrostatic interactions. 
Adapted with permission from ref. 181 (© 2016 The Authors.) 
 
 30 
1.4.2 Design Principles of Bioactive Peptide Amphiphile Nanofibers 
Of all the peptide-based assemblies explored thus far, peptide amphiphile (PA) 
nanofibers are the most studied as bioactive materials for diverse biomedical applications. 
The Stupp laboratory has molecularly developed and crafted a class of PAs by conjugating 
linear hydrocarbons onto a β-sheet-forming sequence that could self-assemble into 
supramolecular nanofibers under the physiological conditions with hydrocarbons packed 
in the core of the fibers and peptide segments exposed to the aqueous environment.31, 41, 44, 
182-185 The incorporation of this hydrophobic segment on either the N- or C- terminus of the 
intended peptide sequence not only enhances the self-assembly potential of the peptide 
amphiphile in an aqueous environment, but also enables the specific presentation of 
enhanced bioactive signals on the resultant assemblies.186-188 Given that molecular and 
cellular signaling are highly regulated events, a variety of bioactive epitopes, either 
naturally occurring peptides or de novo designed sequences, have been incorporated into 
the PA design to enhance their biologically active features for a target application,31, 41, 172, 
183, 186, 189-190 with the respective goal of promoting cell adhesion, proliferation and 
differentiation, or selectively recognizing particular cells or tissues for disease treatments. 
Since some of these epitopes must assume an appropriate secondary structure to interact 
with their molecular target(s), the challenge remains how to retain their bioactive 
conformation within their respective supramolecular assemblies.191-192 It has been shown 
by a number of research laboratories that the solvent property,193-195 the added hydrophobic 
segment,187, 196-199 and the thermal history197, 200 could all potentially affect the peptide’s 




Figure 1-5. (A) Molecular structure of a representative PA with four rationally designed 
chemical entities. (B) Molecular graphics illustration of an IKVAV-containing PA 
molecule and its self-assembly into nanofibers. (C) Scanning electron micrograph of the 
IKVAV nanofiber network formed by adding cell media (DMEM) to the PA aqueous 
solution. (D) The encapsulation and release of biologics using supramolecular PA 
nanofiber hydrogels. (A) (B) (C) were reprinted with permission from Science 
(http://www.sciencemag.org) ref.186 (© 2004 AAAS). (D) was reprinted with permission 
from ref. 181 (© 2016 The Authors.) 
A typical PA design consists of four structural regions (Figure 1-5 A). Region 1 
contains a hydrophobic tail, usually an alkyl chain or other hydrophobic components, to 
enhance the amphiphilicity for self-assembly and enable the presentation of bioactive 
epitopes on the nanofiber periphery in an aqueous environment. Region 2 is a short peptide 
sequence with high tendency of forming β-sheets via intermolecular hydrogen bonding to 
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direct the formation of 1D nanostructures. This sequence usually contains hydrophobic 
amino acids (V, A, I, L) and large aromatic residues (F, Y, W). Region 3 includes charged 
amino acids, such as D, E, K, to promote the solubility of the whole PA molecule and 
provide the responsive feature to pH or ionic strength for nanofiber growth or gelation. The 
last region usually represents the functional groups of the PA molecule for various 
biological purpose. Bioactive epitopes can be incorporated into this region and displayed 
on the nanofiber surfaces after self-assembly without changing the cylindrical geometry of 
the nanofibers. In the meanwhile, their conformation and functionality can be potentially 
maintained at the self-assembled state. In some cases, it may not be necessary to have all 
four regions in the molecular design. For example, Region 3 can be omitted if there are 
charged groups in Region 4. Figure 1-5 A-C show the design of an IKVAV-containing PA 
molecule and its self-assembly into nanofibers. The Stupp Lab has shown that the high-
density presentation of neurite-promoting laminin epitope IKVAV on peptide amphiphile 
nanofibers is critical for the selective differentiation of neural progenitor cells into neurons 
while discouraging the development of astrocytes.186 In another example, Webber et al. 
investigated bioactive PA nanofibers displaying the RGDS epitope on the surface for 
therapeutic delivery of bone-marrow mononuclear cells (BMNCs), implying an enhanced 
biological adhesion.41 In an effort to modulate immunogenicity of peptide assemblies, 
Collier and coworkers covalently linked the self-assembling peptide Q11 to an antigen 
OVA peptide and found that the resultant supramolecular OVA-Q11 nanofibers possess 
enhanced immunogenicity.174 This direct placement of bioactive peptide on either C- or N- 
terminus of a self-assembling peptide motif has become a popular strategy to create 
bioactive materials for a specific biomedical application.  
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Extensive investigations have also been focused on engineering self-assembled PA 
nanofibers into hydrogels under the physiological condition. Typical nanofibers formed by 
self-assembled PAs have diameters between 5 nm and 15 nm and lengths on the micro-
meter scale, and are able to further entangle to form a 3D network as a result of several 
types of non-covalent interactions among individual nanofibers. In general, the gelation of 
PA nanofibers could be aided by charged amino acid residues201 or mediated by metal 
ions202 and the network displays unique reversibility and bioresponsibility that most 
chemically cross-linked hydrogels do not possess. For example, the self-assembly process 
of charged peptides can be facilitated by tuning the pH or adding salts to reduce the 
electrostatic repulsions and promote aggregation. The PA hydrogels are able to encapsulate 
small hydrophobic drugs or large hydrophilic biologics in the inter- or intra-fiber areas and 
offer a stimuli-triggered and well-controlled release capability (Figure 1-5 D). For 
instance, tubular hydrogels formed by circumferentially aligned peptide amphiphile 
nanofibers were shown to encapsulate vascular cells and direct cellular organization.203 
Recently, C16-V2A2E2-NH2 PA hydrogels were used as a sonic hedgehog protein delivery 
system for the treatment of erectile dysfunction, suggesting the PA hydrogels have 
potentially broad applications as protein vehicles.204 Tirrell and coworkers designed pH-
responsive branched peptide amphiphile composed of histidine and serine amino acids 
conjugated to a palmitoyl tail.205 These PA solutions are able to switch from viscoelastic 
liquids to an injectable tissue scaffold above pH 6.5 as a result of the protonation of 
histidine. In another study, a PA hydrogel consisting of C16GSH was optimized to have 




1.4.3 Construction of Peptide-Based Supramolecular Polymers for Antibody 
Affinity Precipitation and Purification 
The demand for therapeutic proteins has rapidly grown over recent decades, 
creating a dramatic shift in the pharmaceutical industry from small molecule drugs to 
biological macromolecular therapeutics. Therapeutic proteins, mainly consisting of mAbs, 
Fc fusion proteins, recombinant enzymes, and antibody fragments, are the most rapidly 
growing field in biopharmaceutical industry.207-209 In general, therapeutic proteins possess 
superior properties over small molecule drugs, such as highly specific and diverse functions 
that are associated with structural complexity and delicacy and that cannot be easily 
mimicked by synthetic chemistry.210-211 The largest and fastest growing protein 
therapeutics in the USA are antibody-related drugs for the treatment of many diseases such 
as cancer, chronic inflammatory disease, cardiovascular, and infectious diseases.209 
Nowadays, downstream processing of therapeutic antibodies is facing great challenges 
created by the rapid increase of the market size and upstream titers, starving for significant 
improvements or innovations in current downstream unit operations for the implementation 
of more efficient and economical purification methods. 
Supramolecular PA assemblies show a great potential as antibody precipitants for 
antibody capture and purification. First, there have been a variety of peptide-related ligands 
identified with high mAb binding affinity. Protein A, a protein originally found in the cell 
wall of staphylococcus aureus, is the most frequently used ligand that specifically binds to 
the Fc-portion of IgG from most mammalian species, including human.212-213 It is 
composed of five homologous domains that fold into a three-helix bundle. The binding 
occurs at the neutral or mild basic pH and could be disrupted at acidic pH. However, the 
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large size and instability of protein A limit its industrial application, and as such a number 
of synthetic and minimized domains of protein A have been designed and studied.214-216 
The Z-domain of protein A is the first and most famous synthetic domain with 59 amino 
acid residues and a dissociation constant (Kd) of ~10 nM when bound to human IgG1.217-
219 To further minimize the Z-domain of protein A, several two-helix derivatives such as 
Z33 were designed without significantly changing the binding affinity.214 As the decrease 
of ligand length, the incorporation of affinity ligands into PAs becomes more facile. 
However, the way to present these antibody-binding ligands on a PA template is equally 
essential for ligand-protein interactions and requires elaborate investigations. 
Second, the most intriguing properties that favor the use of supramolecular peptide 
assemblies for antibody precipitation and purification are their dynamic and reversible 
features. In a typical supramolecular peptide assembly system, reversible transitions can 
occur at multiple length scales, including the intramolecular chain adjustment to adopt 
various conformations,47 the intermolecular interactions to assemble into discrete 
nanostructures,40, 49 and the inter-filament interactions to percolate into a 3D network 
(gelation) or to cause macroscopic phase separation.50-51 The transitions among different 
assembly states can be induced by changes in temperature, pH, ionic strength, 
concentration, or molecular interactions. Among these transitions, the reversible 
aggregation and macroscopic phase separation of the assemblies, either triggered by ionic 
strength or inter-filament crosslinking, could enable the reversible precipitation of captured 
antibodies. The transition between monomeric units and their assembled nanostructures 
could provide an effective means for their effective removal from the protein product pool 
through dissociation. Third, PAs are highly customizable to fine-tune their overall 
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nanostructure characteristics as a result of the diversity of amino acids. In particular, 
charged amino acids and hydrophobic chains can be modified to facilitate the transition 
between PA monomer, nanofibers, and macroscopic aggregations. 
To construct a peptide-based supramolecular polymer system for antibody capture 
and purification, the strategy is to use the customized PA as molecular building unit, 
creating antibody-targeting immunofibers (IFs) (Figure 1-6). Through non-covalent 
interactions, PA monomers spontaneously form IFs in aqueous condition with a high 
density of antibody-binding ligands presented on their surface, serving as the docking 
station for antibody binding. The precipitation and resuspension of the IFs and captured 
antibodies can be readily tuned by pH-, salt-, concentration-, or binding-dependent 
conditions. After the elution of antibody from IFs by adjusting the buffer pH, the 
dissociated PA monomers building units can be easily removed through membrane 
separation, maintaining purified antibody at relatively high concentration. 
 




1.5  Dissertation Overview 
This dissertation aims to develop a peptide-based supramolecular polymer system 
for efficient capture and purification of monoclonal antibodies, which could potentially 
address current limitations in chromatography. The incorporation of a high-affinity mAb-
binding ligand into the building units enables the strong mAb binding of the 
supramolecular system. Moreover, the dynamic property of the supramolecular assemblies 
enables the reversible mAb precipitation and efficient clearance of the capture agents. This 
dissertation covers several milestones that has been reached along the way to improving 
and optimizing the supramolecular polymer design. Chapter 2 investigates the design 
principles of incorporating α-helical peptide ligands into the supramolecular building units 
while preserving its conformation. Chapter 3 demonstrates the design and construction of 
a self-assembly system can specifically bind monoclonal human IgG1 (mAb1). Chapter 4 
develops a co-assembly system on the basis of the self-assembly system described in 
Chapter 3 for successful capture, precipitation, and recovery of mAbs. Chapter 5 explores 
more advanced designs of the co-assembly system by using oligo ethylene glycol (OEG) 
linkers to significantly improve the ligand-mAb interactions and achieve a better 
performance in mAb capture and precipitation. Lastly, Chapter 6 presents the conclusions 
as well as potential future work to further explore and improve this supramolecular polymer 
system. 
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Conformation Preservation of α-Helical 
Peptides within Supramolecular Filamentous 
Assembliesc 
2.1 Overview 
Hydrogen-bonded β-sheets are the most commonly explored building motifs for 
creating peptide-based filamentous nanostructures; however, most bioactive epitopes must 
assume an α-helix conformation to exert their functions. Incorporating α-helical sequences 
into β-sheet-forming peptides often involves the use of a flexible spacer to alleviate the 
steric impact of the intermolecular hydrogen bonding on the α-helical conformation. In this 
context, I report the findings on the alkylation-regulated conformation preservation of α-
helical peptides within their filamentous assemblies. I found that the chemical conjugation 
of two short linear hydrocarbons (octanoic acids, C8) can retain the α-helical conformation 
of two protein A-derived peptide sequences while effectively driving their assembly into 
filamentous nanostructures. In contrast, the use of a single palmitoyl tail (C16) of similar 
hydrophobicity would lead to formation of β-sheet assemblies. My studies further 
demonstrated that the length of the conjugated hydrocarbon also plays an important role in 
       
c Reprinted with permission from Li, Y.; Wang, Y.; Ou, S.-H.; Lock, L. L.; Xu, X.; Ghose, S.; Li, Z. J.; Cui, 
H. Conformation Preservation of Alpha-Helical Peptides within Supramolecular Filamentous Assemblies, 
Biomacromolecules, 2017, 18(11), 3611-3620. Copyright © 2017 American Chemical Society. 
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partially preserving the native α-helical conformation, with longer ones promoting β-sheet 
formation and short ones stabilizing α-helices to some extent. I believe that these findings 
offer important guiding principles for the alkylation of self-assembling peptides containing 
α-helical sequences.  
2.2  Introduction 
Peptide-based filamentous nanostructures have been exploited for use as 
scaffolding materials in regenerative medicine31, 41, 44, 168-170 and also as therapeutic and 
diagnostic carriers in drug delivery171-178 and molecular imaging.179-180 From the 
perspective of supramolecular materials design, these filamentous nanostructures are often 
constructed by self-assembly of low-molecular weight peptides or their rationally designed 
conjugates or derivatives that have high propensity to form intermolecular hydrogen 
bonding.45-46, 192, 220-222 Unlike traditional cylindrical micelles that are stabilized by a 
spontaneous curvature as a result of minimizing system free energy, the one-dimensionality 
for peptide-based assemblies primarily roots in the formation of directional hydrogel bonds 
among the chosen β-sheet-forming peptide sequences.223-224 Of all the peptidic assemblies 
explored thus far, peptide amphiphile nanofibers44 and protein analogous micelles45 are the 
most studied as bioactive materials for diverse biomedical applications. In both cases, the 
underlying molecular design involves covalent linkage of one or more hydrocarbons/lipids 
onto either the N or C terminus of a short peptide to generate self-assembling peptide 
amphiphiles (PAs). The incorporation of this hydrophobic segment not only enhances the 
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self-assembly potential of the peptide conjugate in an aqueous environment, but also 
enables the specific presentation of enhanced bioactive signals on the resultant 
assemblies.186-188 For example, the Stupp Lab has shown that the high-density presentation 
of neurite-promoting laminin epitope IKVAV on peptide amphiphile nanofibers is critical 
for the selective differentiation of neural progenitor cells into neurons while discouraging 
the development of astrocytes.186 
Given that molecular and cellular signaling are highly regulated events, a variety 
of bioactive epitopes, either naturally occurring peptides or de novo designed sequences, 
have been incorporated into the PA design to enhance their biologically active features for 
a target application,31, 41, 172, 183, 186, 189-190 with the respective goal of promoting cell 
adhesion, proliferation and differentiation, or selectively recognizing particular cells or 
tissues for disease treatments. Since some of these epitopes must assume an appropriate 
secondary structure—for the most part an α-helical conformation—to interact with their 
molecular target(s), the challenge then becomes how to retain their bioactive conformation 
within their respective supramolecular assemblies.191-192 It has been shown by a number of 
research laboratories that the solvent property,193-195 the added hydrophobic segment,187, 
196-199 and the thermal history197, 200 could all potentially affect the peptide’s secondary 
structures, and consequently, their assembled morphologies. For α-helical peptides in 
particular, the Tirrell lab has suggested that confinement and crowdedness within the 
micellar corona would favor the α-helical conformation, and reported formation of protein 
analogous micelles with significant α-helicity.172, 225-228 Recently, it was also found that the 
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linker chemistry190 and the contour length of the chosen peptide229 play a critical role in 
retaining the native peptide conformation within supramolecular nanostructures. Despite 
important progress, concerns still remain on the structural uncertainty of α-helical peptides 
upon forming their respective supramolecular assemblies.224, 230 
In this context, I report the findings on the alkylation-regulated conformation 
preservation of α-helical peptides within their filamentous assemblies. Although the β-
sheet-forming peptide sequences are essential for the formation of one-dimensional 
nanostructures and have been applied to many peptide-based self-assembling systems for 
diverse biomedical applications, this work focuses on the strategy of the preservation of 
the α-helix conformation in the self-assembling nanostructures for the peptide epitopes that 
must assume an α-helix conformation to exert their functions. I found that the chemical 
conjugation of two short linear hydrocarbons (octanoic acids, C8) can retain the α-helical 
conformation of the two protein A-derived peptide sequences while effectively driving 
their assembly into filamentous nanostructures. In contrast, the use of a single palmitoyl 
tail (C16) of similar hydrophobicity would lead to formation of β-sheets assemblies. As for 
single chain alkylation, I further discovered that the length of the conjugated hydrocarbon 
is crucial for tuning the peptide conformation, in addition to affecting the critical micelle 
concentration (CMC) and assembled morphologies. α-helical conformation was also 
observed in the lauric acid (C12) alkylated peptide sequence. Further, increasing the double 
alkyl chains to 12 carbons can also induce the formation of β-sheets, underscoring the effect 
of the overall hydrophobicity. Although it is well known that the alkylation can enhance 
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the conformation stability of α-helical peptides,187, 198 it is rare that such a subtle difference 
in the number and length of hydrocarbons could lead to dramatic changes in secondary 
structures from β-sheets to α-helices within filamentous assemblies. I believe these findings 
provide important insight into the design and construction of supramolecular filaments 
containing α-helical peptides. 
2.3  Experimental Procedures 
2.3.1  Materials and Molecular Synthesis  
All Fmoc amino acids and resins were purchased from Advanced Automated 
Peptide Protein Technologies (Louisville, KY), and Fmoc-Lys(Fmoc) were obtained from 
Novabiochem (San Diego, CA). All other reagents were obtained from VWR (Radnor, PA) 
and used as received without further purification. 
Peptide conjugates were synthesized using similar methods. All the peptide 
sequences were synthesized on the Focus XC automatic peptide synthesizer (AAPPTEC, 
Louisville, KY) using standard 9-fluorenylmethoxycarbonyl (Fmoc) solid phase synthesis 
protocols. Alkyl chains were then manually coupled at the N-terminus of the peptide or the 
side chain of lysine (K) to produce different peptide conjugates, and shaken overnight at 
room temperature. Fmoc deprotections were performed using a 20% 4-methylpiperidine in 
DMF solution for 10 minutes, repeated once. In all cases, reactions were tested using the 
ninhydrin test (Anaspec Inc., Fremont, CA) for free amines. Completed Peptide conjugates 
were cleaved from the solid support using a mixture of TFA/TIS/H2O in a ratio of 
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92.5:5:2.5 for 2.5 hours. Excess TFA was removed by rotary evaporation and cold diethyl 
ether was added to precipitate the crude peptide. By centrifugation method, precipitated 
peptide and diethyl ether were separated at 6000 rpm for 3 minutes. Peptides were washed 
2 more times with diethyl ether and the solution was removed by centrifugation.  
The peptide conjugates were purified by preparative RP-HPLC using a Varian 
Polymeric Column (PLRP-S, 100 Å, 10 µm, 150 × 25 mm) at 25 °C on a Varian ProStar 
Model 325 preparative HPLC (Agilent Technologies, Santa Clara, CA) equipped with a 
fraction collector. A water/acetonitrile gradient containing 0.1% v/v TFA was used as 
eluent at a flow rate of 20 mL/min. The absorbance peak was monitored at 220 nm for 
peptide segments. The crude materials were dissolved in 20 mL of 0.1% aqueous TFA, and 
each purification run was carried out with a 10 mL injection. Collected fractions were 
analyzed by MALDI-ToF (BrukerAutoflex III MALDI-ToF instrument, Billerica, MA) 
and those containing the desired product were lyophilized (FreeZone -105 °C 4.5 L freeze 
dryer, Labconco, Kansas City, MO) and stored at -30 °C.  
2.3.2  Self-Assembly and Transmission Electron Microscopy (TEM) Imaging 
Peptide conjugates of 1 mM concentration were pretreated with 
hexafluoroisopropanol (HFIP), a good solvent for the peptide conjugates, to eliminate any 
pre-existing nanostructures that could be possibly formed during the synthesis, purification 
and lyophilization process. HFIP were then removed via rotatory evaporation, followed by 
subsequent addition of deionized water to reach a final concentration of 1 mM. Sodium 
hydroxide was used to tune the pH of the solution to 7.4. After aged overnight at room 
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temperature, 10 µL of 10-fold diluted sample was spotted on a carbon film copper grid with 
400 square mesh (from EMS: Electron Microscopy Sciences) and the excess was removed 
with filter paper to leave a thin film of sample on the grid. After letting the sample dry for 
5 minutes, 10 µL of 2% uranyl acetate was added to the sample grid, and the excess was 
removed after 30 seconds. All samples were dried for at least 3 hours before TEM imaging. 
2.3.3  Critical Micelle Concentration (CMC) Measurement 
The CMC of the peptide conjugates was determined by incubating these molecules 
at various concentrations with a certain amount of Nile Red.231-232 The stock solution of 
Nile Red was initially prepared by dissolving the dye in acetone at 50 µM. 10 µL stock 
solution was loaded into several centrifuge tubes, where the solvent evaporates under room 
temperature to yield the dry mass of Nile Red. Various concentrations of the peptide 
solutions were prepared in deionized water, and then identical volume was added into the 
centrifuge tubes containing dry Nile Red and aged overnight. Fluorescent spectra of Nile 
Red were then monitored by a Fluorolog fluorometer (Jobin Yvon, Edison, NJ) with fixed 
excitation wavelength at 560 nm; emission spectra were monitored 580–720 nm. The CMC 
of peptide conjugates is determined by a blue-shift of the emission maximum, whereas this 
transition occurs as the incubated peptides exceed their CMC values.  
2.3.4  Circular Dichroism (CD) Spectroscopy 
The CD experiments of self-assembled samples were conducted on a Jasco J-710 
spectropolarimeter (JASCO, Easton, MD) using a 1 mm path length quartz UV-Vis 
absorption cell (ThermoFisher Scientific, Pittsburgh, PA) at 25°C. The samples were 
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instantly diluted from the 1 mM stock solution to 100 µM in deionized water at pH 7.4 
prior to the experiment. Using the average of three scans, the spectra were collected in the 
wavelength range of 190–280 nm. A background spectrum of the solvent was acquired and 
subtracted from the sample spectrum. The collected data was normalized with respect to 
the sample concentration. A curve was fit for each IA molecule using a linear combination 
of polylysine basis spectra to estimate the content of α-helix, β-sheet, and random coil 
peptide secondary structure.  
2.3.5  Thioflavin T (ThT) Assays 
A ThT stock solution was prepared in deionized water at 50 µM. 100 µM Peptide 
conjugates were vortexed and incubated with an identical volume of ThT stock solution 
for 1 h. The fluorescence intensity was then measured by a Fluorolog fluorometer (Jobin 
Yvon, Edison, NJ) with excitation at 440 nm (slit width 5 nm) and emission at 482 nm (slit 
width 10 nm). 
2.4  Results and Discussions 
2.4.1  Molecular Design  
The protein A-derived peptide, Z33 (FNMQQQRRFYEALHD-
PNLNEEQRNAKIKSIRDD) contains two α-helical strands as the core binding motifs for 
immunoglobulin G (IgG).214, 233 Considering the complexity and possible complication 
factors in working with this long sequence, I decided to investigate the impact of alkylation 
on each of the individual helical strand. Also given that proline is a known disrupter for α-
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helix, I decided to separate the two helices between the aspartic acid residue (D) and the 
proline residue (P) to obtain Helix1 (FNMQQQRRFYEALHD) and Helix2 
(PNLNEEQRNAKIKSIRDD). As such, two series of peptide amphiphiles, termed here 
immuno-amphiphile (IAs) due to the origin of Z33 peptide for immunoglobulin binding, 
were constructed using each helical sequence. The alkyl chains are conjugated onto the C-
terminus of the Helix1 but to the N-terminus of Helix2 (Figure 2-1 A). The reason I chose 
to conjugate alkyl tails on the different termini of the two helical peptides was to mimic 
the relative position between Helix1 and Helix2 shown in the Z33 peptide. Under aqueous 
conditions, Helix1- and Helix2-based IAs are expected to associate into supramolecular 
assemblies with the hydrophobic segment trapped in the core and the peptides facing 
towards the aqueous environment (Figure 2-1 B). All the molecules studied here were 
synthesized using solid-phase peptide synthesis methods, and then purified with RP-HPLC. 
The purity and expected molecular masses of the synthesized compounds were confirmed 
using analytical HPLC and mass spectrometry, respectively.  
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Figure 2-1. (A) Schematic illustration of the molecular design of Helix1- and Helix2-
based peptide amphiphiles via direct alkylation with C16 and 2C8, respectively. These 
peptide amphiphiles are termed immuno-amphiphiles because of the origin of the protein 
A-derived peptide Z33 for its specific binding ability to immunoglobulin antibodies. (B) 
Schematic illustration of the self-assembly of the designed IAs into one-dimensional 
nanostructures. 
2.4.2 Molecular Assembly 
All the synthesized peptide conjugates were first pretreated with Hexafluoro-2-
propanol (HFIP) to eliminate any pre-existing nanostructures that could be possibly formed 
during the synthesis, purification and lyophilization process. HFIP were then removed via
rotatory evaporation, followed by subsequent addition of deionized water to reach a final 
concentration of 1 mM. After aging overnight, TEM was utilized to visualize the assembled 
morphologies (Figure 2-2). Figure 2-2 A and C are representative TEM micrographs, 
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revealing that single-chain alkylated peptides, both Helix1-C16 and C16-Helix2, self-
assembled into filamentous structures with a diameter of 9.6 ± 1.3 nm and 12.4 ± 1.7 nm, 
respectively. Two or more of these filaments were occasionally observed to intertwine into 
bundled structures of larger diameters. The lengths of the observed filaments are very 
polydisperse but on tens of micrometer scale. For double-chain alkylation with octonoic 
acid (C8), filamentous assemblies were also found for both Helix1-2C8 and 2C8-Helix2 
under the same conditions (Figure 2-2 B and D). However, these filaments are relatively 
shorter, also appearing more polydisperse in length. In addition, variations in the diameter 
were observed, with smallest filaments possessing a diameter of 11.0±1.4 nm for Helix1-
2C8 filaments and of 9.7±1.3 nm for Helix2-2C8 filaments. It is very likely that those of 
larger diameters are hierarchical structures formed by intertwining and bundling of smaller 
ones (vide infra). 
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Figure 2-2. Representative TEM micrographs of filamentous assemblies formed by the 
four designed immuno-amphiphiles in aqueous solution, pH 7.4. TEM images of (A) 
Helix1-C16 and (C) C16-Helix2 reveal filament morphology with diameters of 9.6±1.3 nm 
and 12.4 ± 1.7 nm, respectively. TEM images of (B) Helix1-2C8 and (D) 2C8-Helix2 also 
relatively shorter filaments with diameters of 11.0±1.4 nm and 9.7±1.3 nm, respectively. 
Inserts (A-D) are higher resolution images illustrating the representative features. All the 
samples were prepared in water at a concentration of 1 mM at pH 7.4, aged overnight and 
diluted 10 fold right before TEM sample preparation. All TEM samples were stained with 
2 wt% uranyl acetate aqueous solution, a negative contrast agent, to improve imaging 
resolution. All scale bars: 200 nm. 
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Figure 2-3. Emission spectra of a reporter dye Nile Red upon incubating with (A) Helix1-
C16, (B) C16-Helix2, (C) Helix1-2C8, and (D) 2C8-Helix2 for determining the critical 
micelle concentrations (CMCs). All spectra shown here are normalized by the emission 
maximum. A blue-shift is expected when the IA concentrations exceed the CMC. The 
CMC range for each IA is boxed in the legend. 
To understand the assembly differences between single-chain and double-chain 
alkylated peptides, I conducted further experiments to evaluate their critical micelle
concentrations (CMCs) as well as secondary structures in supramolecular assemblies. The 
CMCs were measured using a Nile Red assay. Nile Red is a lipophilic dye that fluoresces 
depending on solvent polarity and local environment. When incubated with various 
concentrations of self-assembling IAs in aqueous solution, Nile Red prefers to partition 
into the hydrophobic domains if there exist any supramolecular assemblies. The CMC 
value can be determined when a blue-shift of the emission maximum started to occur. 
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Figure 2-3 A shows a plot of Nile Red fluorescence intensity versus emission wavelengths 
for a series of Helix1-C16 aqueous solutions of various concentrations. The maximum 
emission peaked at 660 nm at low peptide concentrations up to 0.5 µM. At 1 µM, this peak 
was blue-shifted to 635 nm, suggesting formation of micellar structures. Similarly, CMC 
values for C16-Helix2, Helix1-2C8, and 2C8-Helix2 can be observed as 0.5-1µM, 10-20
µM, and 5-10 µM from Figure 2-3 B-D, respectively. Although two C8 alkyl chains carry 
a similar number of carbon atoms to that of one single C16 alkyl chain, I found that double-
chain alkylated peptides exhibit consistently higher CMCs compared to the single-chain 
alkylated ones. This likely arises from the differences in packing order among the 
hydrophobic segments and also the secondary structure that the peptides assume. In 
addition, 2C8-Helix2 shows a stronger tendency for aggregation than Helix1-2C8, likely 
due to the fact that Helix2 contains residues of bearing opposite charges. 
2.4.3 Secondary Structure Measurements 
 
Figure 2-4. Normalized CD Spectra of 100 µM (A) Helix1, Helix1-C16, Helix1-2C8, and 
(B) Helix2, C16-Helix2, 2C8-Helix2 in water, pH 7.4. The spectra show that double-chain 
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alkylated peptides can effectively preserve their native helical conformation, whereas 
single-chain alkylation led to a transition from helical conformation to β-sheet-bonded 
assemblies. 
Next, circular dichroism (CD) spectroscopy was used to study the aqueous 
solutions of peptide assemblies to understand the molecular packing within their self-
assembled structures. As shown in Figure 2-4, the unconjugated, free peptides of Helix1 
and Helix2 display typical CD absorption of random coils, indicating a loss of the α-helical 
structures (Figure 2-5). This is not unexpected since it is well known that isolation from 
the parent Z33 sequence may disrupt the mutual dependence for stability between the two 
helices.214 Helix1-C16 and C16-Helix2 assemblies exhibit strong negative signals at 
around 218 nm and a positive signal between 190 nm-200 nm, suggesting the formation of 
β-sheet secondary structures. The β-sheet conformation plays an important role in 
promoting the formation of one-dimensional nanostructures.223, 234 In contrast, it was found 
that both Helix1-2C8 and 2C8-Helix2 assumed typical α-helix secondary structure within 
their respective filamentous assemblies, as evidenced by the two negative signals at around 
225 nm (n-π* transition) and 208 nm (π-π* transition). These CD spectra can be fit using 
a linear combination of polylysine basis spectra to evaluate the content of each secondary 
structures (Figure 2-6).172, 235 The analysis suggested that β-sheets are the major constituent 
of Helix1-C16 and C16-Helix2 conjugates, while double-chain alkylated peptides present 
higher contents of α-helix secondary structures.  
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Figure 2-5. Normalized CD Spectra of Helix1, Helix2, and Z33 at 100 µM in water, pH 
7.4. 
 
Figure 2-6. Analysis of CD spectra for Helix1- and Helix2-based IAs. The content of three 
main secondary structures in (A) Helix1-based and (B) Helix2-based molecules. The CD 
data were fit from 200 nm to 240 nm using a linear combination of polylysine basis spectra 
to determine approximate α-helix, β-sheet, and random coil peptide secondary structure. 
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Figure 2-7. Fluorescence of ThT dye with (A) Helix1 and Helix1-based and (B) Helix2
and Helix2-based immuno-amphiphiles at 100 µM in deionized water, pH 7.4. 
To further confirm the component of secondary structures in the self-assembled 
conjugates, I performed Thioflavin-T (ThT) assays to examine the existence of β-sheet 
secondary structures in both Helix1-based and Helix2-based conjugates. ThT is a 
fluorescent dye with large enhancement of its fluorescence upon binding to β-sheets.236-237
As shown in Figure 2-7 A, ThT emissions of pre-incubated Helix1 and Helix1-2C8 at 482 
nm maintain a similar or slightly higher level compared with that of the pure ThT solution, 
implying the lack of β-sheets in those solutions. In stark contrast, a dramatic increase in 
fluorescence was observed in the pre-incubated Helix1-C16 solution, further confirming 
the presence of β-sheet assemblies for this conjugate which is in consistency with the CD 
results. In Figure 2-7 B, the pre-incubated C16-Helix2 can largely increase the 
fluorescence of ThT. A minor increase was also observed in the 2C8-Helix2 solution, 
indicating that β-sheet conformation truly exist in the 2C8-Helix2. Combined with the CD 
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spectrum in Figure 2-4 B and CD analysis result Figure 2-6 B, I would deduce that the 
conformation of 2C8-Helix2 is a mixture of α-helix and β-sheet. 
One may argue that the observed CD signals may come from the unassembled 
monomers in solution, not from those within the assembled filaments. To exclude this 
possibility, CD spectra were collected from a series of diluted solutions of α-helix IA 
(represented by Helix1-2C8) (Figure 2-8 A) and β-sheet IA (represented by Helix1-C16) 
(Figure 2-8 B). The helical content increases as the increase of Helix1-2C8 concentration 
(Figure 2-8 A). Although at the lower concentrations under CMC there are slight helical 
signals, their contributions to the overall secondary structures at higher concentrations are 
very limited. Because the concentration for unassembled, monomeric Helix1-2C8 is 
constant and will not change above the CMC. This observation clearly suggests that it is 
the assembled structures not the unassembled monomers that dominate the CD absorption 
associated with the helical contents. In a similar way, the β-sheet CD signals for Helix1-
C16 solutions (Figure 2-8 B) became prominent and stable only when the IA concentration 
surpassed the CMC value, again revealing that peptide conjugates within the filamentous 
structures is the major contributor to the observed CD absorption. 
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Figure 2-8. Normalized CD Spectra of (A) Helix1-2C8 and (B) Helix1-C16 at various 
concentrations in water, pH 7.4. These studies suggest that peptide conjugates within their 
supramolecular assemblies primarily contribute to the observed CD absorption. Both 
conjugates appear to be unstructured random coils when concentrations are dropped below 
their respective CMCs.  
Considering the difference in contour length between β-sheets (3.4 Å per residue) 
and α-helices (1.5Å advancement per residue), I would expect dramatic diameter 
differences for the assembled filaments if these conjugates all assembled into the classic 
core-shell peptide amphiphile nanofibers. The TEM imaging studies revealed that the 
filaments formed by self-assembly of Helix1-2C8 and 2C8-Helix2 measure the diameters 
of ~11.0 nm and ~9.7 nm, respectively, matching well with the core-shell model of α-
helical conformation. It should be noted that filaments of larger diameters can be frequently 
observed, and can be attributed to further bundling and intertwining of the core-shell 
filaments. It is interesting, however, filaments of hydrogen-bonded β-sheets did not appear 
to be much larger, but rather their diameters fell into a similar range, with ~9.6 nm for 
Helix1-C16 and ~12.4 nm for C16-Helix2. I therefore speculate that these β-sheet rich 
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filaments bear more resemblance to amyloid fibrils rather than the typical core-shell 
cylindrical micelles. The diameter of the filaments depends not only on the conformation 
of the peptide but also the degree of stretching of the alkyl tails. There is a delicate 
correlation and balance among the shorter alkyl tail, steric hindrance, and represented 
conformation for assembly of 2C8 conjugated IAs. In this regard, it’s rather difficult to 
project the diameters of their filamentous assemblies. Bundles and twisted structures such 
as ribbon-like assemblies (Figure 2-2) can be observed in these assembly systems, likely 
due to the longer peptide sequences of Helix1 and Helix2 that dominates the assembly 
process.  
These results led to the conclusion that the molecular packing within the 
hydrophobic domains contributes significantly to the peptide conformation within the 
filament corona. Considering the packing geometry of α-helix and β-sheet, the center-to-
center distance among helices is typically around 12 Å depending on the side chain 
lengths,238-239 while β-strands are spaced by a hydrogen bond distance within the β-sheet, 
~4.7 Å.240-241 This difference in packing requirements eludes that a looser packing among 
the molecular units is important for the formation of α-helix over β-sheets. For conjugation 
with two shorter C8 tails, not only did the double chain afford more volume to relieve the 
crowdedness of packing, but also that the two C8 chains were not symmetrically 
conjugated onto the two helical peptides due to the use of lysine residue as the anchoring 
point (Figure 2-13 and Figure 2-14). In this way, the two C8 alkyl chains are placed 
asymmetrically at one terminus of the peptide and would likely introduce some steric 
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hindrance for molecular arrangement, resulting in relatively larger CMC and looser 
packing that favor the presentation of helical conformation. 
2.4.4  Effect of Alkyl Chain Length 
It is known that long alkyl chains can be packed in a highly ordered fashion within 
their supramolecular assemblies,242-243 thus likely forcing the peptide segments into closer 
proximity. As such, increasing the length of the two alkyl tails to C12 (lauric acid) may 
offset the effect of looser packing induced by the double chain alkylation. To validate this 
assumption, Helix1-2C12 and 2C12-Helix2 were synthesized and characterized (Figure 2-
15, 2-16, 2-25). They both exhibit lower CMCs and form immunofibers with wider 
diameters than 2C8 conjugates in aqueous solutions at neutral pH. It was found that Helix1-
2C12 retains the α-helix conformation, while 2C12-Helix2 shows β-sheet structures. This 
conformational difference could result from the sequence difference between Helix1 and 
Helix2. The recurrence of the β-sheet in the double chain alkylation suggests that the 
increase of the hydrophobicity in the double chain alkylated conjugates can potentially 
promote the formation of β-sheets, leading to the conclusion that the packing of the 
peptides is determined not only by the way of alkylation but also the overall hydrophobicity 
of the conjugated alkyl tails. When comparing 2C8 with C16 conjugates, the interfacial 
area per peptide chain in 2C8 conjugates is expected to be greater as a result of the 
increased steric hindrance, thus providing more room and flexibility for the formation of 
α-helix. However, by changing 2C8 tails to 2C12 tails, a tighter packing can be resulted 
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due to the potential of crystallization by longer alkyl chains, which may promote β-sheet 
conformation. 
 
Figure 2-9. Characterization of Helix1-2C12 and 2C12-Helix2. TEM images of (A) 
Helix1-2C12 and (B) 2C12-Helix2 display nanofibers morphology with diameters of 15.7 
± 1.4 nm, and 13.4 ± 0.9 nm, respectively. The samples were prepared in deionized water 
at pH 7.4. (C) Normalized CD Spectra of 100 µM Helix1-2C12 and 2C12-Helix2 in water, 
pH 7.4. Emission spectra of the reporter dye Nile Red when incubated with (D) Helix1-
2C12 and (E) 2C12-Helix2 for determining the CMC values.  
Given that the looser packing of double-chain alkylated peptides may account for 
stabilization of α-helix assemblies, I presume that shortening the length of single alkylated 
chains (low potential for crystallization) may likely reduce the packing order within the 
hydrophobic domains. In order to confirm this assumption, I chose two shorter alkyl chains 
(lauric acid, C12; octanoic acid, C8) to conjugate with the Helix1 and Helix2, respectively. 
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Again, their assembly behavior was characterized using TEM, Nile Red assays, and CD.
No well-defined nanostructures and emission maximum transitions were observed for 
either Helix1-C8 or C8-Helix2 at the concentration of 100 µM (Figure 2-10), indicating 
that these two conjugates did not self-assemble at and below this concentration. Helix1-
C12 and C12-Helix2 (Figure 2-11 A and B) were observed to associate into filaments of 
12.2 ± 1.4 nm and 9.1 ± 1.6 nm in diameter, respectively. Strong lateral adhesion among 
C12-Helix2 filaments was observed, likely due to the electrostatic attractions among 
lysine/arginine residues and glutamic/aspartic acid residues (Figure 2-11 B). CMC 
measurements suggested both C12 conjugates started to assemble within the micromolar 
concentration range, with the Helix1-C12 showing a slightly higher CMC value (Figure 
2-11 C and D). In the CD studies (Figure 2-11 E and F), both Helix1-C8 and C8-Helix2 
showed similar absorption phenomena to those of the unconjugated, free peptides, for they 
do not possess the ability to aggregate under the studied conditions.242 
 
Figure 2-10. Emission spectra of the reporter dye Nile Red when incubated with (A) 
Helix1-C8, (B) C8-Helix2 for determining the critical micelle concentration (CMC) values. 
All spectra shown here are normalized by the emission maximum. There was no detectable 
peak shift observed even the conjugate concentrations reached 100 µM.  
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Figure 2-11. Characterization of different Peptide conjugates. TEM images of (A) Helix1-
C12 and (B) C12-Helix2 display nanofibers morphology with diameters of 12.9 ± 0.9 nm, 
and 13.9 ± 1.5 nm, respectively. All scale bars: 200 nm. Emission spectra of the reporter 
dye Nile Red when incubated with (C) Helix1-C12 and (D) C12-Helix2 for determining 
the CMC values. Normalized CD spectra of 100 µM (E) Helix1, Helix1-C8, Helix1-C12, and 
Helix1-C16 and (F) Helix2, C8-Helix2, C12-Helix2, and C16-Helix2 in water, pH 7.4.  
Interestingly, β-sheet absorption features appeared in the CD spectrum of Helix1-
C12, whereas α-helix secondary structure was observed in the C12-Helix2 system. Helix2 
peptide may have a relatively higher propensity to assume the helical conformation, which 
might be rooted in their difference in peptide sequence. This observation also suggests that 
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it is possible to preserve the α-helical conformation within their filamentous assemblies 
using the single-chain conjugation strategy. Considering the random coil conformation for 
C8-Helix2 and the free Helix2 peptide, the preservation of α-helical conformation within 
their filamentous assemblies again suggests that this the α-helical stability is not just linked 
to conjugation chemistry, but rooted in the supramolecular assembly process. 
The peptide sequences, CMCs, and secondary structures of all the studied 
molecules in this work are summarized in Table 2-1. Details of molecular structures and 
characterization are shown in Figure 2-12 to Figure 2-27. As we can see, both long single-
chain and double-chain alkylation can effectively promote the formation of supramolecular 
filaments, but the resultant assemblies differ in morphology, CMCs, and secondary 
structures. The length and number of alkyl chains are known to promote the aqueous self-
assembly of the resultant conjugates.244 Jan van Hest and coworkers found that the 
GANPNAAG peptide conjugated with C12 or shorter alkyl chains showed no aggregates 
under their studied conditions, but in the C14 conjugates and C16 or longer conjugates 
fibrous aggregates and tubular structures can be found.197 The studies on self-assembly of 
immuno amphiphiles bearing C8, C12, and C16 conjugated chains corroborate van Hest’s 
findings. The CMCs of the single-chain alkylated amphiphiles decreases as the length of 
alkyl chain increases,198, 245 due to the enhanced hydrophobicity that promotes the 
aggregation potential. Alkyl chain conjugation was previously demonstrated to enhance 
the stability of α-helix secondary structures and bioactivities.187, 189, 198, 246 Mihara and co-
workers found that longer N-terminal alkylated 2α-helix peptide underwent a higher rate 
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of α-to-β transitions, indicating the formation of β-sheets promoted by long alkyl chains.196 
My results showed the recurrence of α-helix conformation in the alkylated Helix1 and 
Helix2 peptides. I also showed that a relatively long alkyl chains could induce the 
formation of β-sheets. To the best of my knowledge, the α-to-β transitions regulated by 
single- and double-alkylation are unprecedented.    
Table 2-1. All the studied IA molecules, their CMC values, and peptide conformation 
measured at 100 µM. 



































Figure 2-12. Peptide sequences and chemical structures of Helix1, Helix2, and Z33. 
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Figure 2-13. Chemical structures of Helix1-C8, Helix1-C12, Helix1-C16, Helix1-2C8, and 
Helix1-2C12. 
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Figure 2-14. Chemical structures of C8-Helix2, C12-Helix2, C16-Helix2, 2C8-Helix2, and 
2C12-Helix2. 
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Figure 2-15. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Z33. The RP-
HPLC spectrum confirms the purity of the product (>99%). The expected mass is 4102.0. 
The peak at 4103.4 corresponds to [M+H]+. 
 
Figure 2-16. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Helix 1. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
1980.9. The peak at 1982.1 corresponds to [M+H]+. 
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Figure 2-17. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Helix 2. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2181.3. The peak at 2182.4 corresponds to [M+H]+. 
 
Figure 2-18. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Helix1-C8. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2235.1. The peak at 2236.3 corresponds to [M+H]+. 
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Figure 2-19. RP-HPLC (A) and MALDI-TOF MS (B) characterization of C8-Helix2. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2265.2. The peak at 2266.3 corresponds to [M+H]+. 
 
Figure 2-20. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Helix1-C12. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2292.2. The peak at 2293.3 corresponds to [M+H]+. 
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Figure 2-21. RP-HPLC (A) and MALDI-TOF MS (B) characterization of C12-Helix2. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2321.2. The peak at 2322.2 corresponds to [M+H]+. 
 
Figure 2-22. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Helix1-C16. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2248.8. The peak at 2350.4 corresponds to [M+H]+. 
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Figure 2-23. RP-HPLC (A) and MALDI-TOF MS (B) characterization of C16-Helix2. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2378.7. The peak at 2380.3 corresponds to [M+H]+. 
 
Figure 2-24. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Helix1-2C8. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2489.3. The peak at 2490.2 corresponds to [M+H]+. 
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Figure 2-25. RP-HPLC (A) and MALDI-TOF MS (B) characterization of 2C8-Helix2. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2520.9. The peak at 2521.7 corresponds to [M+H]+. 
 
Figure 2-26. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Helix1-2C12. 
The RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2603.2. The peak at 2604.1 corresponds to [M+H]+. 
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Figure 2-27. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Helix1-2C12. 
The RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
2603.2. The peak at 2604.1 corresponds to [M+H]+. 
2.5 Conclusion 
In summary, two series of Z33-based immuno-amphiphiles were successfully 
designed and synthesized. I found that the way of peptide alkylation can have a significant 
impact on the self-assembly behavior of the resultant conjugates, leading to variations in 
CMCs, assembled morphology, and most notably the peptide conformation. These results 
clearly demonstrate that although both single-chain and double-chain alkylation can 
promote the formation of supramolecular filaments. For single-chain alkylation, self-
assembled IAs with longer alkyl chains likely induce a tighter packing between adjacent 
molecules, thus promoting the formation of β-sheet assemblies. Importantly, I found short 
double-chain alkylation could effectively preserve the α-helical conformation, although 
increasing the length of double chains may lead to the recurrence of β-sheets. Compared to 
the single-chain alkylation, the double-chain alkylation could likely introduce more steric 
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hindrance and provide more volume for loose packing that favor the presentation of helical 
conformation. Clearly, there are many variation factors related to the exact sequences of 
each conjugated peptides, my studies show important guiding principles in the design of 
supramolecular filaments containing α-helical peptides. Longer single alkyl chains favor 
the formation of β-sheets, while short double-chain alkylation promotes the preservation 
of α-helical secondary structures. I believe that this strategy of tuning the length and 
number of alkyl chains can be further developed and applied in various peptide-based self-
assembling systems to obtain the desired conformation in a simple yet effective way. It has 
been well-known that many systems based on helices can be used as responsive 
biomaterials triggered by various stimuli to act in biomedical, gelation, and bio-sensing 
applications.51 Although the peptide sequences I chose to study here are not directly related 
to drug delivery or tissue engineering, the conclusion derived from my studies, in my 
opinion, can be extended to peptides implicated in tumor targeting and stem cell 
stimulations. This strategy can also be applied in the incorporation of collagen-like triple 
helices into filamentous assemblies for cellular applications and tissue engineering.247-248 
Another perspective practice may rely on the presentation of helical antimicrobial peptides 
as anti-infective agent in filamentous networks for cell culture, biomedical, and immune 
applications.249  
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Bioinspired Supramolecular Engineering of 
Self-Assembling Immunofibers for High 
Affinity Binding of Immunoglobulin Gd 
3.1 Overview 
Many one-dimensional (1D) nanostructures are constructed by self-assembly of 
peptides or peptide conjugates containing a short β-sheet sequence as the core building 
motif essential for the intermolecular hydrogen bonding that promotes directional, 
anisotropic growth of the resultant assemblies. While this molecular engineering strategy 
has led to the successful production of a plethora of bioactive filamentous β-sheet 
assemblies for interfacing with biomolecules and cells, concerns associated with effective 
presentation of α-helical epitopes and their function preservation have yet to be resolved. 
In this context, I report on the direct conjugation of the protein A mimicking peptide Z33, 
a motif containing two α-helices, to linear hydrocarbons to create self-assembling immuno-
amphiphiles (IAs). The results suggest that the resulting amphiphilic peptides can, despite 
lacking the essential β-sheet segment, effectively associate under physiological conditions 
into supramolecular immunofibers (IFs) while preserving their native α-helical 
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conformation. Isothermal titration calorimetry (ITC) measurements confirmed that these 
self-assembling immunofibers can bind to the human immunoglobulin G class 1 (IgG1) 
with high specificity at pH 7.4, but with significantly weakened binding at pH 2.8. I further 
demonstrated the accessibility of Z33 ligand in the immunofibers using transmission 
electron microscopy (TEM) and confocal imaging. I believe these results shed important 
light into the supramolecular engineering of α-helical peptides into filamentous assemblies 
that may possess an important potential for antibody isolation. 
3.2  Introduction 
 Supramolecular 1D nanostructures can be formed either by self-assembly of low 
molecular weight surfactants250 or amphiphilic block copolymers251-252 as a result of 
minimizing system free energy to assume a spontaneous interfacial curvature, or by self-
assembly of synthetic or naturally occurring peptides and their derivatives via directional, 
intermolecular hydrogen bonding.44, 220, 253-257 Given the inherent biodegradability and the 
potential bioactive feature, peptide-based 1D assemblies have been widely explored over 
the past three decades for their potential biomedical applications in regenerative 
medicine,22, 41, 44, 258-259 drug delivery,220, 260-267 immunotherapy,26, 174, 268 and disease 
diagnostics.180, 269-271 In order to effectively modulate the assembly behavior and to enhance 
the bioactive features, a hydrophobic auxiliary segment has been often placed on either the 
N- or C- terminus of the intended peptide sequence. The conjugation strategy has been 
pioneered and developed by a number of research laboratories.31, 186, 220, 254, 272-276 For 
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instance, the Stupp laboratory has molecularly crafted a class of peptide amphiphiles (PAs) 
by conjugating linear hydrocarbons onto a β-sheet-forming sequence that could self-
assemble into supramolecular nanofibers under the physiological conditions.31, 41, 44, 182-185 
To impart the PA assemblies with the desired bioactivities to interface with biology, a 
variety of bioactive epitopes, such as cell adhesion motif RGD, have been incorporated 
into the molecular design.31, 41, 182-183, 186 In one example, Webber et al. investigated 
bioactive PA nanofibers displaying the RGDS epitope on the surface for therapeutic 
delivery of bone-marrow mononuclear cells (BMNCs), implying an enhanced biological 
adhesion.41 In an effort to modulate immunogenicity of peptide assemblies, Collier and 
coworkers covalently linked the self-assembling peptide Q11 to an antigen OVA peptide 
and found that the resultant supramolecular OVA-Q11 nanofibers possess enhanced 
immunogenicity.174 This direct placement of bioactive peptide on either C- or N- terminus 
of a self-assembling peptide motif has become a popular strategy to create bioactive 
materials for a specific biomedical application. In the cases where the epitope has to retain 
an α-helical conformation to be bioactive, adjusting hydrophobic segments277-278 and 
tuning solvent property193 are often adopted to solve the potential spacing incompatibility 
issue of presenting an α-helical motif on β-sheet assemblies.   
High affinity antibody-binding particles and materials are receiving rapidly 
growing interest in the pharmaceutical industry, as driven by the increasing demand of 
monoclonal antibodies for biological therapeutics.1, 279-280 Protein A, a well-known 
antibody-binding ligand, has the capacity of specific binding to the Fc-portion of IgG from 
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most mammalian species, including human.212-213 However, the large size of protein A 
limits its industrial application, and as such a number of synthetic and minimized domains 
of protein A have been designed and studied.214-216 The Z-domain of protein A is the first 
and most famous synthetic domain with 59 amino acid residues and a dissociation constant 
(Kd) of ~10 nM when bound to human IgG1.217-219 To further minimize the Z-domain of 
protein A, a two-helix derivative Z33 was designed without significantly changing the 
binding affinity (Kd = 43 nM).214 While various high affinity ligands have been identified, 
the way to present ligands on a desired substrate is equally essential for ligand-protein 
interactions. In this context, I report on the direct conjugation of the protein A mimicking 
peptide Z33, a motif containing two α-helices, to linear hydrocarbons to create self-
assembling IAs and demonstrate for the first time that the resultant supramolecular 
immunofibers possess high binding affinity to human IgG1. Similar to protein A, the 
chosen Z33 sequence is capable of recognizing various members of the human 
immunoglobulin family. But given that the modern bioprocessing technology has enabled 
the production of one particular type of immunoglobulins, I focus my studies only on the 
specific interactions between Z33 conjugates and human IgG1. A variety of techniques 
were utilized to characterize the self-assembly and binding properties of the self-assembled 
IFs to human IgG1, and I envision the promising prospects of these biomaterials would 




3.3  Experimental Procedures 
3.3.1 Materials and Molecular Synthesis  
All Fmoc amino acids and resins were obtained from Advanced Automated Peptide 
Protein Technologies (Louisville, KY). Fmoc-Lys(Fmoc) were purchased from 
Novabiochem (San Diego, CA). The therapeutic human IgG1 was obtained from Bristol-
Myers Squibb (Devens, MA), and IgG elution buffer was sourced from Thermo Fisher 
Scientific (Rockford, IL). FITC-IgG was purchased from Sigma-Aldrich (St. Louis, MO) 
and human IgG-coated gold nanoparticles were purchased from Nanocs Inc. (New York, 
NY). All other reagents were obtained from VWR (Radnor, PA) and used as received 
without further purification. 
All immuno-amphiphiles were synthesized via direct conjugation of alkyl chains to 
the N-terminus of a peptide sequence. In brief, Z33 peptide was first synthesized on the 
Focus XC automatic peptide synthesizer (AAPPTEC, Louisville, KY) using standard 9-
fluorenylmethoxycarbonyl (Fmoc) solid phase synthesis protocols. Fmoc deprotections 
were performed using a 20% 4-methylpiperidine in DMF solution for 10 minutes, repeated 
once. For the synthesis of 2C8-Z33, a bis Fmoc protected lysine was added to the N-
terminus of Z33. For the synthesis of RB-C12-Z33, Fmoc-Lys-methylthiotetrazole (Kmtt) 
was added to the N-terminus of Z33 for selective deprotection. Rhodamine B was 
conjugated to the side chain of Kmtt after deprotection of the mtt group (TFA/TIS/DCM 
in a ratio of 3:5:92). C12 (or 2C8) alkyl chain was then manually coupled at the N-terminus 
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(after Fmoc removal) of Z33 peptide with lauric acid (or octanoic acid)/HBTU/DIEA at a 
ratio of 4 (or 8): 4: 6 relative to the Z33 peptide, and shook overnight at room temperature. 
In all cases, reactions were tested using the ninhydrin test (Anaspec Inc., Fremont, CA) for 
free amines. Completed IAs were cleaved from the solid support using a mixture of 
TFA/TIS/H2O in a ratio of 92.5:5:2.5 for 2.5 hours. Excess TFA was removed by 
evaporation and ice-cold diethyl ether was added to precipitate the crude product. The 
precipitated IAs were collected by centrifugation and then washed 2 more times with 
diethyl ether and centrifuged to remove the remaining solvent.  
The IAs were purified by preparative RP-HPLC using a Varian Polymeric Column 
(PLRP-S, 100 Å, 10 µm, 150 × 25 mm) at 25 °C on a Varian ProStar Model 325 preparative 
HPLC (Agilent Technologies, Santa Clara, CA) monitored at 220 nm for the absorbance 
of peptide segments. Collected fractions were analyzed by MALDI-ToF (BrukerAutoflex 
III MALDI-ToF instrument, Billerica, MA) and product-containing fractions were then 
lyophilized (FreeZone -105 °C 4.5 L freeze dryer, Labconco, Kansas City, MO) and stored 
at -30°C.  
3.3.2  Self-Assembly of IAs and TEM Imaging  
IAs were pretreated with hexafluoroisopropanol (HFIP) to remove the preformed 
nanostructures during the purification process. After the removal of HFIP via evaporation 
by air, IAs were dissolved in phosphate-buffered saline (PBS) at 1 mM and aged overnight 
at room temperature; 10 µL of 10 fold diluted sample was spotted on a copper grid covered 
with carbon film (Electron Microscopy Sciences, Hatfield, PA), and negatively stained 
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using 2% uranyl acetate for 30 seconds. All samples were dried for at least 3 hours before 
TEM imaging on an FEI Tecnai 12 TWIN electron microscope. 
3.3.3  Circular Dichroism (CD) Spectroscopy 
IAs and Z33 peptide samples were instantly diluted from the 1 mM stock solution 
to 100 µM in PBS prior to the CD experiment conducted on a Jasco J-710 
spectropolarimeter (JASCO, Easton, MD) at 25°C. The samples were loaded into a 1 mm 
path length quartz UV-Vis absorption cell (ThermoFisher Scientific, Pittsburgh, PA) and 
the spectra were collected from 190 nm to 280 nm as the average of three scans. A 
background spectrum of the solvent was acquired and subtracted from the sample spectrum 
and the signal was converted from ellipticity (mdeg) to mean molar ellipticity 
(deg·cm2·dmol−1).  
3.3.4  ITC Experiment 
ITC experiments were performed using a high precision VP-ITC titration 
calorimetric system (Microcal Inc.). The human IgG1 solution was titrated with immuno-
amphiphiles in PBS (pH 7.4) or IgG elution buffer (pH 2.8) at 15°C. The IgG1 
concentration was calculated using the mass extinction coefficient of 1.4 at 280 nm for a 
0.1% (1 mg/mL) IgG solution. The concentration of immuno-amphiphles was determined 
by total nitrogen assay.281 The heat evolved after each injection was obtained from the 
integral of the calorimetric signal. The heat associated with the binding of immuno-
amphiphiles to IgG1 was obtained by subtracting the heat of dilution. Analysis of the data 
was performed using MicroCal Origin package. 
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3.3.5  Confocal Imaging 
The fluorescence of Rhodamine B labelled C12-Z33 (RB-C12-Z33) and FITC-IgG 
was imaged using a confocal laser scanning microscope (CLSM, LSM 510, Zeiss). 1 mM 
RB-C12-Z33 stock solution was prepared in PBS and aged overnight. 100 µM RB-C12-
Z33 and 2 µM FITC-IgG were premixed in PBS and spotted on a microscope slide and 
covered by a coverslip. Red channel and green channel were used to record the 
fluorescence from RB-C12-Z33 and FITC-IgG, respectively. All fluorescence images were 
taken under identical conditions. 
3.4  Results and Discussions 
3.4.1 Molecular Design 
The IgG binding IAs studied here are designed to include the overall hydrophilic 
Z33 peptide sequence (FNMQQQRRFYEALHDPNLNEEQRNAKIKSIRDD) and one or 
two hydrophobic alkyl chains. The Z33 peptide is a two-helix derivative from protein A 
(Figure 3-1 A) that specifically binds to the Fc-portion of human IgG1 with a high binding 
affinity (Kd=43 nM).215, 282-283 Two IAs, C12-Z33 and 2C8-Z33 (Figure 3-1 B), were 
synthesized via direct conjugation of lauric acid (C12) or two octanoic acids (2C8) onto 
the N-terminus of Z33 peptide. The Region 2 (β-sheet forming segment) in typical PA 
structures was not included in the molecular design due to the intention of preserving the 
α-helical conformation of Z33 peptide. Benefited by the high water solubility of Z33 
peptide, Region 3 (charged group) was not included either. As shown in Figure 3-1 C, 
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these designed IAs were expected to self-assemble in aqueous solutions into 
supramolecular IFs of high binding affinity to IgGs. I also synthesized the free Z33 peptide 
as the positive control molecule for comparison with the Z33 containing IFs. Another 
negative control molecule, C12-SZ33, was designed by conjugating C12 onto the N-
terminus of Z33 with a scrambled Z33 sequence. All the molecules were synthesized and 
purified using automated solid-phase peptide synthesis (SPPS) methods and RP-HPLC. 
The purity and expected molecular masses of the synthesized compounds were confirmed 
using analytical HPLC and mass spectrometry, respectively. Details for chemical structures 
and molecular characterization are shown in Figure 3-2 to Figure 3-6. 
 
Figure 3-1. (A) Schematic illustration of the Z33 peptide binding to Fc-portion of human 
IgG1. (B) The sequences of C12-Z33 and 2C8-Z33. Alkyl groups and Z33 are indicated 
with the yellow and blue shaded areas, respectively. (C) Schematic illustration of the self-
assembly of IAs and the binding between IFs and IgG.  
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Figure 3-2. Chemical structures of Z33, C12-Z33, 2C8-Z33, and C12-SZ33. The peptide 
and alkyl chain are shown in blue and yellow, respectively. 
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Figure 3-3. RP-HPLC (A) and MALDI-TOF MS (B) characterization of Z33. The RP-
HPLC spectrum confirms the purity of the product (>99%). The expected mass is 4102.0. 
The peak at 4103.2 corresponds to [M+H]+. 
 
Figure 3-4. RP-HPLC (A) and MALDI-TOF MS (B) characterization of C12-Z33. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
4284.2. The peak at 4285.7 corresponds to [M+H]+. 
 
Figure 3-5. RP-HPLC (A) and MALDI-TOF MS (B) characterization of 2C8-Z33. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
4482.3. The peak at 4483.9 corresponds to [M+H]+. 
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Figure 3-6. RP-HPLC (A) and MALDI-TOF MS (B) characterization of C12-SZ33. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
4284.2. The peak at 4285.6 corresponds to [M+H]+. 
3.4.2 Molecular Assembly and Characterization
The self-assembly of the designed IAs was conducted in a two-step procedure. The 
IAs were first pretreated with HFIP to eliminate any pre-existing nanostructures that may 
affect its solubility and complicate the self-assembly processes. After HFIP removal, PBS 
was added to reach a final concentration of 1 mM. Given the amphiphilic nature of the 
molecular design, it is expected that the alkyl segments are embedded within the core of 
the IFs while the bioactive Z33 sequences are displayed on the surface. After aging 
overnight at room temperature, TEM and CD were utilized to characterize the morphology 
of the resultant supramolecular nanostructures. 
Given the vital role of solution pH in the current IgG purification method, I
evaluated the self-assembly behavior of C12-Z33 at both binding and elution conditions. 
Physiological pH (~7.4) is normally used as the binding condition, while acidic pH (~2.8) 
is to elute antibodies from the protein A affinity column.284-285 As such, PBS (pH 7.4) and 
 
 87 
IgG elution buffer (pH 2.8) were chosen as the aqueous environment to promote the self-
assembly of C12-Z33. The morphologies of C12-Z33 IFs at different pH were studied by 
regular TEM (Figure 3-7 A-D). It was found that the C12-Z33 molecule could self-
assemble into filaments under both conditions. Representative TEM images from a solution 
of 100 µM C12-Z33 revealed that C12-Z33 self-assembled into filamentous structures with 
a diameter of 16.0 ± 1.7 nm, a value that is significantly smaller than the fully extended 
molecular length (~22 nm in the case of β-sheets) but larger than the molecular length if 
all of the amino acids are forming in helical structures (~12 nm). The observed nanofibers 
are several micrometers in length.      
To further understand the molecular packing within the IFs, CD was used to study 
the peptide secondary structure (Figure 3-7 E). Strong negative signals at ~222 nm (n-π*) 
and 208 nm (π-π*) are indicative of α-helical secondary structure of Z33 segment in the 
self-assembled state, as shown in the free Z33 peptide. On the basis of the CD spectra and 
the measured diameter of IFs, it is reasonable to assume that the peptides maintained their 
α-helix secondary structure when forming IFs at both pH 7.4 and pH 2.8. The difference in 
mean molar ellipticity between C12-Z33 and the free Z33 peptide may be a combinative 
result of peptide alkylation and subsequent molecular assembly into IFs. Tirrell and others 
have suggested that lipidation of small molecule peptides could enhance the stability of α-
helix secondary structures of the conjugated peptides.225, 254, 273, 286-287 
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Figure 3-7. Molecular assembly and nanostructure characterization of IAs. TEM 
characterization of C12-Z33 at pH 7.4 (A, B) and 2.8 (C, D). The TEM samples were 
prepared at concentration of 100 µM in PBS (pH 7.4) and IgG elution buffer (pH 2.8), 
respectively. The TEM samples were negatively stained with 2 wt% uranyl acetate aqueous 
solution. (E) Normalized CD spectra of Z33 peptide and C12-Z33 at pH 7.4 and 2.8, 
respectively.  
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3.4.3 Binding Affinity Measurements
 
Figure 3-8. ITC profiles and binding curves for the stepwise injection of 100 µM C12-Z33 
into a solution of 2 µM IgG1 at 15 °C in (A) PBS buffer, pH 7.4, and (C) IgG elution 
buffer, pH 2.8. ITC profiles and binding curves for the stepwise injection of 100 µM (B) 
Z33 and (D) C12-SZ33 into 2 µM IgG1 in PBS at 15 °C, pH 7.4. 
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Table 3-1. Thermodynamic parameters for binding of Z33-based ligands to IgG1 at 15 °C 
in PBS at pH 7.4. Data are reported per ligand/Z33. 
Ligands Kd,Z33 (nM) ΔH° (kcal·mol-1) N (Ligands/IgG) 
Z33 60 -23.1 2.3 
C12-Z33 650 -9.3 3.1 
2C8-Z33 1115 -2.8 9.1 
Table 3-2. Recalculation of the thermodynamic parameters (per IgG1) for binding of Z33-
based ligands to IgG1 at 15 °C in PBS at pH 7.4. Please note Kd, the binding affinity 










Z33 26 -10.0 -53.4 43.4 
C12-Z33 209 -8.8 -28.9 20.1 
2C8-Z33 122 -9.1 -25.9 16.8 
Isothermal titration calorimetry measurement is an effective way to assess the 
binding affinity between proteins and ligands.161, 288-291 Given the preservation of the α-
helical conformation within supramolecular IFs, I expect a high IgG binding ability by 
C12-Z33 IFs. ITC was then used to investigate thermodynamic properties of their binding 
to human IgG1. The heat associated with the binding reaction is recorded during the 
stepwise titrations. The binding thermodynamic parameters including dissociation constant 




In a typical ITC experiment, a solution of 100 µM C12-Z33 in PBS buffer was aged 
overnight and then titrated into a PBS buffer solution of 2 µM IgG1 at 15 °C, pH 7.4. 
Representative thermograms and binding isotherms were shown in Figure 3-8 A and the 
thermodynamic parameters reported per ligand are summarized in Table 3-1. The ITC 
results for the binding of C12-Z33 to IgG1 revealed an enthalpy driven binding event 
characterized by a Kd of 650 nM. To further compare the binding efficiency of C12-Z33, I 
synthesized the Z33 peptide which was shown to bind tightly to IgG1 with a Kd of 43 nM 
measured by surface plasmon resonance.216 The representative thermograms and binding 
isotherms of the free Z33 peptide to IgG1 were shown in Figure 3-8 B. In addition to an 
approximately 100-fold better affinity, the stoichiometry for Z33 was 2.3, whereas the 
apparent stoichiometry for C12-Z33 was 3.1 (Table 3-1), indicating that not all of the C12-
Z33 in IFs were available for binding to the IgG1 molecule.  
While normalization per ligand allows for the determination of the apparent 
stoichiometry of binding, comparison of the thermodynamic parameters should be done 
after normalization per mole of IgG1, as shown in Table 3-2. The binding of Z33 to IgG1 
was characterized by a large favorable enthalpy opposed by a large unfavorable entropy 
change. The thermodynamic signature for the binding of C12-Z33 was similar, although 
the magnitudes of the enthalpy and entropy changes were smaller. C12-Z33 binds with less 
unfavorable entropy than Z33; however, the loss in favorable enthalpy is even larger, which 
results in an overall lower binding affinity. An overall loss in the favorable binding 
enthalpy could be possibly rooted in the disassembly/disruption of the IFs. There is also a 
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possibility that favorable interactions with IgG1 are limited due to steric restrictions on the 
closely packed IFs. Stepwise injection of IgG1 with C12-Z33 was also performed in IgG 
elution buffer (pH 2.8) at 15 °C (Figure 3-8 C), revealing a significantly reduced binding 
affinity suitable for elution from the IFs.  
To exclude the non-specific binding between IFs and IgG1, C12-SZ33 with 
scrambled Z33 peptide sequence was used as negative control. This C12-SZ33 IA shows 
similar self-assembly properties with β-sheet secondary structures characterized with TEM 
and CD (Figure 3-9 A and B). ITC experiment was carried out by injecting 100 µM C12-
SZ33 IAs into 2 µM IgG1 solution at 15 °C in PBS at pH 7.4 to measure their binding 
ability. The thermograms and binding isotherms in Figure 3-8 D show that the scrambled 
C12-SZ33 lacks the ability to bind with IgG1, suggesting that the binding between C12-
Z33 IFs and IgG1 relies on the specific sequence of Z33 peptide.  
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Figure 3-9. TEM images of 100 µM (A) C12-SZ33 and (C) RB-C12-Z33 in PBS, pH 7.4. 
Both molecules self-assembled into nanofibers with diameters of 11.5 ± 1.5 nm and 13.8 
± 1.8 nm respectively. Normalized CD spectra of 100 µM (B) C12-SZ33 and (D) RB-C12-
Z33 nanofibers in PBS at pH 7.4 showed β-sheet and α-helix conformation, respectively. 
3.4.4 The Universality of the Functional Design of Supramolecular IFs 
 To further evaluate the universality of the functional design of supramolecular IFs, 
I synthesized a double chain alkylated IA 2C8-Z33 (Figure 3-10 A-E). Supramolecular 
IFs of a uniform diameter were also observed in TEM imaging (Figure 3-10 A and B), 
with their α-helix secondary structure confirmed by CD (Figure 3-10 C). According to the 
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ITC studies (Figure 3-10 D and E, Table 3-1), binding between 2C8-Z33 and IgG1 
occurred at 15 °C in PBS, pH 7.4, whereas no detectable binding occurred in elution buffer, 
pH 2.8. The apparent stoichiometry for the binding of 2C8-Z33 at pH 7.4 was 9.1, 
indicating a further compromised efficiency of binding. Although 2C8-Z33 binds with a 
less favorable enthalpy of binding than C12-Z33, the contribution from the entropy is less 
unfavorable, which results in slightly improved binding affinity (Table 3-2). These results 
led to the conclusion that these self-assembled IFs maintain favorable binding ability to 
IgG1. There is nevertheless a loss in overall binding affinity observed for the IFs, which is 
of enthalpic origin. The loss in favorable enthalpy can be explained by the loss of 
interactions due to steric restrictions in the IFs and an unfavorable enthalpy contribution 
associated with the disassembly process of supramolecular nanostructures.  
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Figure 3-10. TEM characterization of 2C8-Z33 in (A) PBS at pH 7.4 with a diameter of 
16.8 ± 1.5 nm and (B) IgG elution buffer at pH 2.8 with a diameter of 17.3 ± 1.9 nm. The 
preparation of TEM sample was similar with that of C12-Z33. (C) Normalized CD spectra 
of 100 µM 2C8-Z33 in PBS at pH 7.4 showed α-helix secondary structures. ITC profiles 
for the stepwise injection of 100 µM 2C8-Z33 into a solution of 2 µM IgG1 in (D) PBS 
buffer, pH 7.4 and (E) IgG elution buffer, pH 2.8. 
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3.4.5 The Direct Visualization of IgG Bound to the Surface of IFs 
 
Figure 3-11. TEM images of (A, B) 100 µM C12-Z33 and (C, D) 100 µM C12-SZ33 after 
incubation with IgG-coated Au nanoparticles in PBS, pH 7.4. IgG concentration: 0.33-0.66 
µM.  
The difficulty in identifying the IgG structure in TEM limits the visualization of 
the binding events between immunofibers and IgG directly. To confirm that the IgG is 
present on the surface of the immunofibers, the preformed C12-Z33 and C12-SZ33 
immunofibers were incubated with 10 nm human IgG-coated Au nanoparticles for 2 h 
separately. After a drop of each solution was placed onto a TEM grid, the grid was blotted 
with a filter paper and left to dry naturally. Then, the grid was washed carefully 3 times 
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with PBS buffer, in an effort to remove the unbounded Au nanoparticles before staining 
the sample with uranyl acetate. TEM images of C12-Z33 incubated with IgG-coated Au 
nanoparticles in both dense and sparse (Figure 3-11 A and B) areas confirmed the binding 
of IgG to the surfaces of Z33-presenting nanofibers. In sharp contrast, very few Au 
nanoparticles were observed to attach onto the control nanofibers bearing the scrambled 
Z33 sequence (Figure 3-11 C and D). This study suggests that the co-localization of C12-
Z33 immunofibers and IgG-coated Au nanoparticles is indeed a result of specific binding. 
It should be noted that the density of Au nanoparticles was relatively low on the long 
immunofibers, likely due to the limited accessibility of the tight packing of Z33 immuno-
amphiphiles after their self-assembly into nanofibers. Another possibility is that the IgG-
coated Au nanoparticles could be bound to the C12-Z33 in the monomer state and then 
taken away in the washing steps. The IgG concentration (0.33-0.66 µM) in the IgG-coated 
Au nanoparticles was actually lower than the critical micelle concentration value for C12-
Z33, which is 2-5 µM (Figure 3-12).  
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Figure 3-12. CMC measurement of C12-Z33. Emission spectra of the reporter dye Nile 
Red monitored by a Fluorolog fluorometer (Jobin Yvon, Edison, NJ) after incubated with 
a series of concentrations of C12-Z33. Excitation wavelength was fixed at 560 nm; 
emission spectra were monitored 580−720 nm. The CMC of C12-Z33 is determined by a 
blue-shift of the emission maximum, where the transition indicates the dye partitioning into 
the hydrophobic compartment of assembled nanostructures. All spectra shown here are 
normalized by the emission maximum. The CMC range for C12-Z33: 2-5 µM.  
To better visualize the interactions between C12-Z33 immunofibers and IgG, 
labelling the C12-Z33 with the fluorescent dye (Rhodamine B) allows for direct imaging 
of fluorescent immunofibers and FITC-IgG under a confocal laser scanning microscope. 
Rhodamine B has been extensively used for staining biomaterials. Rhodamine B labelled 
C12-Z33 (RB-C12-Z33) was synthesized by adding an extra Kmtt residue at the N-
terminus of Z33. Rhodamine B and C12 were conjugated to the amine group on the side 
chain and backbone of the newly added lysine separately. The chemical structure and 
molecular characterization of RB-C12-Z33 are shown in Figure 3-13 and Figure 3-14. I
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assume that the fluorescent labelling will not interfere with the binding ability of C12-Z33 
because the dye is located remotely from the binding sequence Z33 and would be 
embedded in the hydrophobic core after self-assembling into the immunofibers. The self-
assembled fibrous morphology in PBS was confirmed using TEM (Figure 3-9 C). 100 µM 
RB-C12-Z33 diluted from a 1 mM stock solution and 2 µM FITC-IgG were premixed in 
PBS. 30 µL solution was spotted on a clean microscope slide right before imaging and 
covered by a coverslip to obtain a thin layer of liquid. Fluorescence images (Figure 3-15
A-C) were then taken by a confocal laser scanning microscope and showed co-localization 
of fluorescence signals from both RB-C12-Z33 (red) and FITC-IgG (green). It was found 
that FITC-IgG formed large bright assemblies that were never observed in the pure FITC-
IgG solution and the solution incubated with scrambled Z33 (C12-SZ33) under the same 
conditions (Figure 3-16). These findings suggest the binding of FITC-IgG to RB-C12-Z33 
or C12-Z33 was specific and triggered the formation of large aggregates, and that the 
observed assemblies are not a result of electrostatic or other types of interactions because 
FITC-IgG was well dispersed in the presence of C12-SZ33. 
 
Figure 3-13. Chemical structures of RB-C12-Z33. The peptide, alkyl chain, and 
Rhodamine B are shown in blue, yellow, and red, respectively. 
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Figure 3-14. RP-HPLC (A) and MALDI-TOF MS (B) characterization of RB-C12-Z33. 
The RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 
4838.5. The peak at 4840.2 corresponds to [M+H]+. 
Figure 3-15. Confocal fluorescence images of 100 µM RB-C12-Z33 incubated with 2 µM 
FITC-IgG in PBS (pH 7.4) show co-localization of the fluorescence signal of Rhodamine 
B with that of the FITC. (A) Image of Rhodamine B fluorescence. (B) Image of FITC 
fluorescence. (C) Merged image of (A) and (B). Scale bar: 20 µm. 
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Figure 3-16. Confocal fluorescence images of (A) 2 µM FITC-IgG, (B) 100 µM RB-C12-
Z33, (C) 2 µM FITC-IgG incubated with 100 µM C12-Z33, and (D) 2 µM FITC-IgG 
incubated with 100 µM C12-SZ33 in PBS, pH 7.4. All fluorescence images were taken 
under identical conditions. Compared to the bright fluorescence of FITC-IgG when 
incubated with RB-C12-Z33, no fluorescent signals were detected or after incubated with 
C12-SZ33, while comparable fluorescence was observed when incubated with C12-Z33. 
This showed that FITC-IgG was dispersed well in the PBS buffer or in the presence of 
C12-SZ33, while the binding to RB-C12-Z33 or C12-Z33 induced the aggregation of 
FITC-IgG and thus the strong fluorescence. Scale bar: 20 µm. 
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3.5  Conclusion  
In conclusion, I demonstrated that incorporating the protein A mimicking peptide 
immuno-amphiphile design via direct alkylation at the N-terminus of the Z33 peptide could 
lead to the formation of supramolecular nanostructures with high binding affinity to target 
antibodies. These Z33 IAs can self-assemble into uniform immunofibers at both 
physiological pH (7.4) and low pH (2.8), displaying an α-helix secondary structure in the 
self-assembled state. The results clearly showed that the immunofibers can bind to human 
IgG1 at physiological pH with a nanomolar Kd and reduce binding ability at low pH, the 
elution condition, as expected. The binding event can be visualized by TEM images and 
fluorescence imaging. Antibody-related products have become the most rapidly growing 
field for therapeutic applications. In the pharmaceutical industry, antibody purification 
mainly relies on affinity chromatography based on immobilization of antibody-binding 
ligands with high selectivity but suffering from the high chromatography media cost and 
limited capture productivity.284-285, 292 Although the binding affinity of IFs to human IgG1 
is slightly compromised relative to that of the unincorporated Z33 peptide, these IFs may 
present a promising system for IgG capturing. However, there are still many challenges 
ahead for the development of an IFs-based binding system. One potential challenge is that 
the capture rate and selectivity must be optimized for use in more complicated conditions 
such as lysed cells. Another challenge is that the separation of the IF-IgG complex from 
other components and the recovery process of IgG from IF-IgG complex needs to be further 
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explored. Despite these challenges, I believe that the Z33 containing immunofibers can 
serve as an effective IgG capturing and possible affinity purification agent for applications 










Supramolecular Copolymers as Reversible 
Affinity Precipitants for Selective Capture 
and Recovery of Monoclonal Antibodiesd 
4.1 Overview 
The separation and purification of therapeutic proteins from their biological 
resources poses a great limitation for industrial manufacturing of biologics in a cost-
effective manner. I report here a supramolecular copolymeric system that can undergo 
multiple levels of reversible assembly processes for efficient capture, one-step 
precipitation and facile recovery of monoclonal antibodies (mAbs). These supramolecular 
copolymers, namely immunofibers (IFs), are formed by co-assembly of a protein A-
mimicking ligand amphiphile with a rationally designed filler molecule. I found that the 
composition of IFs and the molar ratio of ligand to proteins contribute significantly to the 
mAb capture efficiency. Under the optimized conditions, IFs can specifically capture mAbs 
with a precipitation yield greater than 99%, leading to an overall mAb recovery yield of 
>94%. I also demonstrated the feasibility of capturing and recovering two mAbs from 
clarified cell culture harvest. Importantly, the added IFs can be easily removed via 
membrane separation after mAb elution, without introducing new contaminants in the 
process. These results showcase the highly promising potential of supramolecular 




    Supramolecular polymers formed by self-assembly of peptides and peptide 
derivatives have been widely explored for use in regenerative medicine,31-32, 34-35, 46, 293 drug 
delivery,22, 26-27, 181, 294-301 and disease diagnostics.36-37, 302 As molecular building units, 
peptides are particularly attractive for creating supramolecular materials for biomedical 
applications due to their inherent biodegradability and biocompatibility, and most 
importantly, their ability to incorporate a variety of bioactive epitopes for specific 
biological interfacing.39-43 In a typical supramolecular polymeric system, reversible 
transitions can occur at multiple length scales,46 including the intramolecular chain 
adjustment to adopt various conformations,47 the intermolecular interactions to assemble 
into discrete polymeric nanostructures,40, 48-49 and the inter-particle interactions to percolate 
into a 3D network (gelation) or to cause macroscopic phase separation (coacervation or 
precipitation).50-52 The transitions among different assembly states can be induced by 
changes in temperature,303 pH,304 ionic strength,305 concentration,40 or molecular 
interactions.40, 51 While there have been some reports in the literature to exploit the soluble-
insoluble transition of elastin-like polypeptides (ELP) based on their unique thermo-
responsive property,51, 151, 306-308 macroscopic phase separation is generally considered as a 
failure in supramolecular design of a peptide-based system. In this context, I purposely 
took advantage of the inherent reversible transitions in supramolecular systems to develop 
peptide-based supramolecular polymers as effective affinity precipitants for selective 
capture of monoclonal antibodies. 
Monoclonal antibodies (mAbs) have received considerable attention over the past 
three decades for the treatment of human diseases in oncology, hematology, dermatology, 
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rheumatology, etc.1-2 Affinity precipitation has been increasingly explored as a promising 
alternative to purify mAbs and other therapeutic proteins,11, 309 as the conventional protein 
A affinity chromatography method suffers from limited production capacities and high 
media cost.6, 9 A typical protein precipitant features high mAb capture affinity as well as 
reversible soluble-insoluble transitions.13, 162 The precipitation can be triggered either by 
the ligand-mAb interactions or applying external stimuli.15 Although affinity precipitation 
can potentially overcome the chromatography limitations associated with column size and 
ligand immobilization,16 it demands high mAb capture selectivity and also the effective 
clearance of precipitants from the product pool. Despite recent efforts in the development 
of new affinity precipitants,17-21 the challenges in achieving a high capture efficiency and 
effective removal of the added precipitants have yet to be resolved, limiting their potential 
for industrial bioprocessing applications. 
In fact, the facile incorporation of affinity ligands into supramolecular polymers 
and the reversible soluble-insoluble phase transition enable their promising potential for 
the affinity capture, one-step precipitation and recovery of mAbs. The transition between 
monomeric units and their assembled nanostructures provides an effective means for their 
effective removal from the protein product pool through dissociation (not chemical 
degradation). In light of this, I have designed and synthesized self-assembling immuno-
amphiphiles by incorporating Z33, a protein A mimicking peptide that binds to the Fc-
portion of IgG in a pH sensitive manner.214, 310 However, although a high binding affinity 
was probed between the immuno-amphiphile and mAbs, the capture/precipitation 
efficiency of mAbs by its supramolecular form was found to be very modest. I attributed 
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this low capture efficiency to the possible steric hindrance among tightly packed ligands 
that prevents their effective binding to target proteins.  
Co-assembly of two or more peptide building blocks represents an effective 
strategy to craft supramolecular nanostructures with different structural and functional 
properties.311-314 For example, it has been shown that mixing of catanionic drug 
amphiphiles provides a means of forming tubular morphologie.173 To modulate the epitope 
density and achieve enhanced bioactivities, co-assembly of bioactive peptide amphiphiles 
(PAs) with an inert molecule has been developed by the Stupp lab and others.315-318 For 
example, in an effort to modulate cell adhesion to supramolecular artificial extracellular 
matrices, 10 wt.% RGDS-presenting PA co-assembled with a diluent PA showed 
maximum adhesion.315 Inspired by this strategy, I report here the co-assembly of mAb 
binding immuno-amphiphiles with a filler molecule into one class of supramolecular 
copolymers, which is termed immunofibers (IFs), for efficient mAb capture, precipitation, 
and recovery. I believe these results shed important light on the use of supramolecular 
systems for non-chromatographic purification of mAbs and other protein therapeutics.  
4.3 Experimental Procedures 
4.3.1 Materials and Molecular Synthesis 
All Fmoc amino acids and resins were obtained from Advanced Automated Peptide 
Protein Technologies (AAPPTEC, Louisville, KY). The pure mAb1, pure Fc-fusion 
protein, and mAb1 and mAb2 in clarified Chinese hamster ovary (CHO) cell culture 
harvest were obtained from Bristol-Myers Squibb (Devens, MA). The cell culture was 
clarified using depth filtration. IgG (FITC) from human serum was purchased from Sigma-
Aldrich (St. Louis, MO) and was further purified by ProA-HPLC. Unless otherwise 
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specified, all other reagents were obtained from VWR (Radnor, PA) and used as received 
without further purification.  
Filler and ligand molecules were synthesized via direct conjugation of lauric acid 
(C12) to the N-terminus of corresponding peptide sequences. VVEE and VVKKGGZ33 
were synthesized on the Focus XC automatic peptide synthesizer (AAPPTEC, Louisville, 
KY) using standard 9-fluorenyl-methoxycarbonyl (Fmoc) solid phase synthesis protocols. 
Fmoc deprotections were performed using a 20% 4-methylpiperidine in DMF solution for 
15 min, repeating once. C12 alkyl chain was then manually coupled at the N-terminus of 
two peptides after Fmoc deprotection. In all cases, reactions were tested using the ninhydrin 
test (Anaspec Inc., Fremont, CA) for free amines. The crude products were cleaved from 
the solid support using a mixture of trifluoroacetic acid (TFA)/triisopropylsilane 
(TIS)/H2O in a ratio of 92.5:5:2.5 for 2.5 h. Excess TFA was removed by evaporation and 
ice-cold diethyl ether was added to precipitate the crude products, followed by 
centrifugation. The precipitates were then washed two more times with diethyl ether and 
centrifuged to remove the remaining solvent. 
The crude products were purified by preparative RP-HPLC using a Varian 
Polymeric Column (PLRP-S, 100 Å, 10 µm, 150×25 mm) at 25 °C on a Varian ProStar 
Model 325 preparative HPLC (Agilent Technologies, Santa Clara, CA) monitored at 220 
nm for the absorbance of peptide segments. Collected fractions were analyzed by MALDI-
TOF (BrukerAutoflex III MALDI-TOF instrument, Billerica, MA) and product-containing 
fractions were then lyophilized (LabconcoTM FreeZone −105 °C, 4.5 L freeze dryer, 
Kansas City, MO) and stored at −30 °C. 
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4.3.2 CMC Measurement 
The CMCs of the filler and ligand molecules in PBS were determined using Nile 
Red, a lipophilic dye that fluoresces depending on solvent polarity and local environment. 
Nile Red prefers to partition into the hydrophobic domains if there exist any 
supramolecular assemblies. The CMC is determined by a blue-shift of the emission 
maximum, whereas this transition occurs as the incubated molecules exceed their CMC 
values. Nile Red was initially dissolved in acetone (20 µM) and Nile Red solution (10 µL) 
was loaded into several centrifuge tubes. After the solvent evaporated under room 
temperature, filler or ligand solutions (500 µL) in PBS at various concentrations were 
added into the centrifuge tubes containing dry Nile Red and aged overnight. Fluorescent 
spectra of Nile Red were then monitored by a Fluorolog fluorometer (Jobin Yvon, Edison, 
NJ) with fixed excitation wavelength at 560 nm; emission spectra were monitored at 580-
720 nm. 
4.3.3 Self-Assembly, Co-Assembly, and TEM Imaging 
Mixtures of filler and ligand molecules in powder form at molar ratios of 0:1, 5:1, 
25:1, 50:1, and 50:0 were pretreated with hexafluoroisopropanol (HFIP), a good solvent 
for the peptide amphiphiles, to eliminate any pre-existing nanostructures that could be 
possibly formed during the synthesis and purification process. HFIP was then removed by 
evaporation, followed by addition of PBS (20 mM sodium phosphate, 150 mM sodium 
chloride, pH 7.4) to prepare IF stock solutions at a final ligand concentration of 50 µM. 
The stock solutions were aged overnight at room temperature before use. Stock solutions 
(10 µL) were spotted on carbon film coated copper grids with 400 square mesh (Electron 
Microscopy Sciences, Hatfield, PA) and the excess was removed with filter paper to leave 
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a thin film of sample on the grid. After letting the sample dry for 5 min, 2% uranyl acetate 
(10 µL) was added to the sample grid, and the excess was removed after 30 s. All samples 
were dried for at least 3 h before imaging. Bright-field TEM imaging was performed on a 
FEI Tecnai 12 TWIN Transmission Electron Microscope and all TEM images were 
required by a SIS Megaview III wide-angle CCD camera. 
4.3.4 Cryo TEM 
50:1 IFs were prepared in PBS one day before the imaging. Prior to sample 
preparation, lacey carbon film coated copper grids with 300 square mesh (Electron 
Microscopy Sciences, Hatfield, PA) were treated with plasma air to make the carbon film 
hydrophilic. 6 μL sample solution for 50:1 IFs, 50:1 IFs incubated with 5 µM mAb1 for 30 
minutes, and 5 µM mAb1 were dropping onto the grids, separately. A thin film of the 
sample solution was generated using the Vitrobot with a controlled humidity chamber and 
the grid was blotted and plunged into liquid ethane pre-cooled by liquid nitrogen. All 
vitrified samples were transferred to a cryo-holder filled with liquid nitrogen to prevent 
sublimation of vitreous water. Cryo-TEM imaging was performed on the FEI Tecnai 12 
TWIN Transmission Electron Microscope, operating at 80 kV. The images were recorded 
by a 16 bit 2K × 2K FEI Eagle bottom mount camera. 
4.3.5 CD Spectroscopy 
The CD spectra of assembled IFs at filler:ligand molar ratios of 0:1, 5:1, 25:1, 50:1 
were collected on a Jasco J-710 spectropolarimeter (JASCO, Easton, MD) using a 1 mm 
path length quartz UV-vis absorption cell (ThermoFisher Scientific, Pittsburgh, PA) at 25 
°C. A background spectrum of the solvent was acquired and subtracted from the sample 
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spectrum. The collected data was averaged from three scans and normalized with respect 
to the ligand concentration. 
4.3.6 ITC Experiment 
ITC experiments were performed using a high precision VP-ITC titration 
calorimetric system (Microcal Inc.). The 40 µM IF solution was titrated with 100 µM mAb1 
in PBS (pH 7.4) at 25 °C. The heat evolved after each injection was obtained from the 
integral of the calorimetric signal. The heat associated with the binding of IFs to mAb1 
was obtained by subtracting the heat of dilution. Analysis of the data was performed using 
MicroCal Origin package. 
4.3.7 Precipitation of Pure mAb1 and Pure Fc-fusion Protein 
IF stock solutions at desired filler:ligand molar ratios were prepared one day before 
the precipitation experiment. In experimental groups, pure mAb1 and pure Fc-fusion 
protein at certain concentrations were well-mixed and incubated with IF solution (100 µL) 
for 30 minutes. Protein control groups were prepared with pure mAb1 and pure Fc-fusion 
protein at same concentrations in PBS. Peptide control groups were prepared with IF 
solution (100 µL) at desired filler:ligand molar ratios. Ammonium sulfate (abbreviated as 
salt below) in PBS was then added to all experimental groups and control groups to reach 
desired final salt concentrations and precipitate proteins and IFs. After 30 minutes, the 
solution was centrifuged at 15000 rpm for 15 minutes. The supernatant was taken out and 
analyzed by ProA-HPLC (POROS™ A 20 µm Column, Stainless Steel, 2.1 x 30 mm, 0.1 
mL) to determine the protein concentrations and by RP-UPLC (ACQUITY UPLC Peptide 
BEH C18 Column, 300 Å, 1.7 µm, 2.1 x 150 mm) to determine filler and ligand 
concentrations. The precipitated amount of each species was calculated by subtracting the 
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amount in the supernatant from the amount added. The precipitation yield was calculated 
by dividing the precipitated amount by the amount added. 
4.3.8 Precipitation of IgG (FITC) and mCherry 
IgG (FITC) (5 µM), mCherry (5 µM), and the mixture of two proteins were well-
mixed and incubated with 50:1 IFs (100 µL) for 30 minutes. Three protein control groups 
with IgG (FITC) (5 µM), mCherry (5 µM), and the mixture of two proteins were prepared 
in PBS (100 µL). Salt solution in PBS was then added to all experimental groups and 
control groups to reach a final concentration of 0.75 M. After 30 minutes, the solution was 
centrifuged at 15000 rpm for 15 minutes. All samples were imaged by the ChemiDoc MP 
imaging system (Bio-Rad, Hercules, CA). The supernatant was taken out and analyzed by 
a fluorescence plate reader. Green channel was excited at 480 nm and collected at 498-605 
nm. Red channel was excited at 550 nm and collected at 580-720 nm. 
4.3.9 Resuspension of Pure mAb1 
5 µM pure mAb1 were well-mixed and incubated with 50:1 IFs (100 µL) for 30 
minutes. The same procedures were performed to precipitate both mAbs and IFs. Three 
buffers (40 mM sodium acetate at pH 3.7, 40 mM sodium phosphate at pH 7.4, and sodium 
carbonate at pH 10.1) were tested to resuspend the precipitates. Resuspension buffer (1 
mL) was added to the precipitates followed by pipetting up and down. After the solution 
was centrifuged at 15000 rpm for 15 minutes, the supernatant was taken out and analyzed 
by ProA-HPLC and RP-UPLC to determine the protein, filler, and ligand concentrations. 
4.3.10 Capture and Recovery of Pure mAbs and mAbs in Clarified Bulk  
Pure mAb1 (5 µM) or mAbs at clarified bulk state (5 µM) were well-mixed and 
incubated with 50:1 IFs (100 µL) for 30 minutes. Same procedures were performed to 
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precipitate both mAbs and IFs. The precipitates were resuspended in PBS (1 mL, 40 mM 
sodium phosphate, pH 7.4) and transferred to a dialysis tube (Pur-A-Lyzer Maxi, 50 kDa 
cut-off molecular weight, Sigma-Aldrich, St. Louis, MO). The resuspended solution was 
then dialyzed against 40 mM sodium phosphate (1 L) at pH 7.4 for 24 h and 40 mM sodium 
acetate (1 L) at pH 3.7 for 24 h successively. The dialysis buffers were replaced three times 
per 24 h. The protein, filler, and ligand concentrations were determined by ProA-HPLC 
and RP-UPLC. 
4.3.11 Size Elusion Chromatography (SEC) 
The SEC was performed on an Agilent AdvanceBio SEC column (300 Å, 2.7 µm, 
4.6x150 mm) using PBS (pH 7.4) as mobile phase at room temperature. Absorbance at 280 
nm was used to monitor the elution of different components in CB. 
4.4 Results and Discussions 
4.4.1 Design Principles and Molecular Characterization 
The overall purification process is illustrated in Figure 4-1 A. The building units 
of the supramolecular polymers containing mAb-binding peptides are expected to 
spontaneously co-assemble into IFs under physiological conditions and then capture and 
precipitate mAbs in a specific manner. After phase separation and resuspension, mAbs can 
be recovered under elution conditions, while IFs are continuously dissociated into 
monomers and removed via membrane separation. As shown in Figure 4-1 B, the 
supramolecular system contains two self-assembling constituents: a filler molecule and a 
ligand molecule. The filler molecule, C12-VVEE, serves as a diluting agent used to 
modulate the distribution density of the ligand molecule (Figure 4-1 B). The alkyl chain, 
C12, was conjugated to the N-terminus of the respective ligand and filler molecules to 
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provide the necessary driving force (hydrophobic interactions) for assembly under aqueous 
conditions. The ligand molecule, C12-VVKKGGZ33, is the active component specifically 
designed for mAb binding (Figure 4-1 B). Specifically, a monoclonal human IgG1 
antibody (abbreviated as “mAb1”) was continuously used in this work. The sequence 
VVKK was molecularly crafted to match with the hydrophobic segment (VV) of VVEE to 
facilitate the formation of the hydrogen network throughout the resultant IFs, while 
providing cohesive interactions through electrostatic complexation to promote the co-
assembly of the two components and also to avoid possible self-sorting (demixing) that has 
been observed in other co-assembly systems.318-320 A double glycine (GG) segment was 
inserted as a spacer between C12 and Z33 to extend the Z33 ligand further out of the IFs 
surface for better accessibility. The filler and ligand molecules were synthesized using 
automated solid-phase peptide synthesis (SPPS) methods. Chemical structures of filler and 
ligand molecules and their RP-HPLC and MALDI-TOF MS characterization are shown in 




Figure 4-1. The overview of the purification process, design of filler and ligand, and 
molecular characterization. (A) Schematic illustration of the overall mAb purification 
process using co-assembled IFs. (B) Chemical structures and key design components of 
the filler and ligand molecules. Representative transmission electron microscopy (TEM) 
images of self-assembled filamentous structures formed by (C) filler and (D) ligand with a 
diameter of 7.4 ± 0.6 nm and 14.9 ± 1.5 nm, respectively. Filament diameters are 
represented as mean ± SD (n = 30). TEM sample was stained with 2 wt % uranyl acetate 
aqueous solution to improve imaging quality. Scale bars in (C-D) are 100 nm. (E) 
Normalized CD spectra of self-assembled filler, self-assembled ligand, and free Z33 
peptide. (F) ITC profiles and binding curves for the stepwise injection of 100 µM mAb1 




Figure 4-2. Chemical structures of filler (C12-VVEE) and ligand (C12-VVKKGGZ33) 
molecule. The alkyl chain (C12), VVKK/EE, GG, and Z33 are shown in yellow, blue, 
green, and black, respectively. 
 
 
Figure 4-3. RP-HPLC (A) and MALDI-TOF MS (B) characterization of C12-VVEE. The 
RP-HPLC spectrum confirms the purity of the product (>99%). The expected mass is 655.4. 





Figure 4-4. RP-HPLC (A) and MALDI-TOF MS (B) characterization of C12-
VVKKGGZ33. The RP-HPLC spectrum confirms the purity of the product (>99%). The 
expected mass is 4852.6. The peak at 4853.6 corresponds to [M+H]+. 
The filler and ligand molecules can each self-assemble into filamentous structures 
(Figure 4-1 C-D) with diameters of 7.4 ± 0.6 nm and 14.9 ± 1.5 nm, respectively. Unlike 
the self-assembled ligand nanostructures that mainly consist single fibers, twisted or helical 
ribbons were predominantly observed in the filler morphology due to the merging of single 
filler fibers. Circular dichroism (CD) spectra revealed the formation of β-sheet secondary 
structures in the self-assembled fillers, while ligand molecules effectively preserved the α-
helix conformation as evidenced by the two negative peaks at around 208 nm and 222 nm 
that were observed in the original Z33 peptide (Figure 4-1 E).310 Isothermal titration 
calorimetry (ITC) measurement showed the ligand molecule binds to mAb1 with a Kd of 
36.0 ± 2.1 nM for ligand molecules at 25 ℃ (Figure 4-1 F), similar to the reported value 
(26 nM) for free Z33 peptide.214, 310 However, the self-assembled ligand molecules alone 
were unable to precipitate mAbs likely due to the overcrowding of Z33 (Figure 4-5). The 
binding signal obtained using the ITC may have mostly come from the binding between 
mAbs and the monomeric ligand molecules, which could probably shift the self-assembly 
equilibrium to the monomer side. As such, I anticipated that the co-assembly strategy could 
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modulate Z33 ligand density and optimize the protein binding property for mAb 
purification.  
 
Figure 4-5. mAb1 precipitation after incubation with self-assembled ligand molecule. 20 
µM mAb1 was incubated with 50 µM self-assembled ligand molecule and 1 M ammonium 
sulfate. In the control group, 20 µM mAb1 was incubated with 1 M ammonium sulfate. 
Both mAb1 control group and self-assembled ligand group showed negligible mAb 
precipitation. All experiments were performed in triplicate and the data is shown as mean 
± standard deviation. 
 
 
Figure 4-6. CMC measurement of (A) filler and (B) ligand. The CMC ranges are 50-100 
µM and 2-5 µM, respectively. Emission spectra of the reporter dye Nile Red monitored by 
a Fluorolog fluorometer (Jobin Yvon, Edison, NJ) after incubation with a series of 
concentrations of filler or ligand. Excitation wavelength was fixed at 560 nm; emission 



























the emission maximum, where the transition indicates the dye partitioning into the 
hydrophobic compartment of assembled nanostructures. All spectra shown here are 
normalized by the emission maximum.  
For a co-assembled IF system, the filler:ligand ratio was expected to have a great 
impact on the mAb binding, since it determines the Z33 density on IF surfaces. Considering 
the dynamic equilibrium between IFs and monomers, the ligand molecule was determined 
to possess a critical micelle concentration (CMC) in the range of 2-5 µM (Figure 4-6). 
Therefore, a concentration of 50 µM was set for ligand molecules to ensure its majority in 
the assembled state. Three filler:ligand ratios, 5:1, 25:1, and 50:1, were then randomly 
selected and the corresponding IFs were constructed by mixing 50 µM ligands and different 
amount of fillers accordingly. Ratios higher than 50:1 were not tested due to the solubility 
limitation of filler molecules at neutral pH. Filamentous nanostructures were observed 
formed by co-assembled filler and ligand molecules at 5:1, 25:1, and 50:1 molar ratios 
(Figure 4-7 A-C) with a diameter of 14.1 ± 0.8 nm, 8.4 ± 0.9 nm, and 7.5 ± 0.9 nm, 
respectively. At 25:1 and 50:1 molar ratios, a great portion of single fibers were found to 
merge into twisted or helical ribbons due to the increased concentration of the filler 
molecule (Figure 4-1 C). For co-assembled IFs at the three selected filler:ligand ratios, the 
apparent conformation, according to CD measurements, shifted from α-helix to β-sheet 
with increasing filler:ligand molar ratio as a result of increased dominance by the filler 
assemblies (Figure 4-7 D). To prove mAb binding on the IF surface, the TEM image of a 
mixture of 5 µM mAb1 and 50:1 IFs ratios was taken (Figure 4-7 E). Although it is hard 
to differentiate the mAb1 structures from the background, I observed that IFs exhibit more 
blurring borders possibly due to mAb binding. To avoid the noise from staining and drying 
effect and to better visualize the mAb-IF interactions, the mixture of 50:1 IFs and mAb1 
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was then imaged using cryogenic(cryo)-TEM. As shown in Figure 4-7 F, it’s clear to see 
the IFs were spotted with high-density of black dots. In contrast, 50:1 IFs without addition 
of mAb1 showed sharper edges and smoother surfaces (Figure 4-7 G). The black dots were 
identified as the mAb structures as shown in Figure 4-7 H, confirming the binding of 
mAb1 onto IF surfaces. 
 
Figure 4-7. Representative TEM images of supramolecular copolymers formed by filler 
and ligand molecules at (A) 5:1, (B) 25:1, and (C) 50:1 molar ratios with a diameter of 
14.1 ± 0.8 nm, 8.4 ± 0.9 nm, and 7.5 ± 0.9 nm, respectively. Filament diameters are 
represented as mean ± SD (n = 30). (D) CD spectra of co-assembled IFs at different 
spacer:ligand molar ratios. The spectra were normalized by the concentration of the ligand 
molecules, showing a transition of the apparent conformation from α-helix to β-sheet with 
the increase of the spacer:ligand molar ratio. (E) Representative TEM image of 50:1 
IFs+mAb1. Representative cryo-TEM images of (F) 50:1 IFs+mAb1, (G) 50:1 IFs, and 
(H) mAb1 in PBS showed the binding between mAb1 and IFs. All TEM sample was 
stained with 2 wt % uranyl acetate aqueous solution to improve imaging quality. Scale bars 
are 100 nm. 
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4.4.2 Mechanism Studies of Protein Precipitation and Yield Optimization 
To understand the basic principles behind the IF-protein interactions, I carried out 
a series of protein capture experiments by controlling one variable at a time. In addition to 
mAb1 (144 kDa, pI: 8.4), an Fc-fusion protein (78 kDa, pI: 6.5) that has the same Fc 
fragment as mAb1, were used in the following studies. I first investigated the effect of the 
filler:ligand ratio on the protein precipitation efficiency. As described above, 5:1, 25:1, and 
50:1 IFs were constructed and two proteins from 448 µM stock were added into each IF 
solution (100 µL), respectively, to reach a final concentration of 20 µM. 1 M ammonium 
sulfate (abbreviated as “salt” below) was used to promote the soluble-insoluble transition 
of this supramolecular system. After centrifugation, the supernatant was analyzed by ProA-
HPLC to determine the protein concentration and the protein precipitation yield was then 
calculated. In the control group without any IFs (0:0), adding salt was not able to precipitate 
any proteins (Figure 4-8 A). In the other control group with filler only (50:0), very little 
mAb1 and less than 15% of Fc-fusion proteins were precipitated (Figure 4-8 A), 
suggesting there existed little to no non-specific binding between proteins and filler 
molecules as a result of the overall charge of IFs. Importantly, the precipitation yield for 
both mAb1 and Fc-fusion protein increases with increasing filler:ligand ratios (Figure 4-8 
A), which could be interpreted by the enlarged spacing between ligands that facilitates 
effective protein binding (Figure 4-8 B). Moreover, the two proteins are oppositely 
charged at the tested pH (7.4) according to their pIs but both of them can be captured and 
precipitated by the negatively charged IFs. This suggests that it was the specific binding of 
protein to ligand molecules that played the dominant role in the protein precipitation 
instead of the electrostatic-mediated protein enrichment. It is important to note that for all 
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co-assembled groups, over 95% filler and ligand molecules were precipitated 
concomitantly with the target proteins (Figure 4-8 C and D), suggesting that it is the 
binding step, not the precipitation step that determines the overall protein precipitation 
yield. The precipitation of Fc-fusion proteins suggests that this supramolecular system with 
Z33 ligand can be used to capture any proteins of interest with an Fc domain, not limited 
only to mAbs.  
 
Figure 4-8. Key experimental parameters in the selective capture of mAbs and Fc-fusion 
proteins. (A) Precipitation yields of mAb1 and Fc-fusion protein at different molar ratios 
of filler:ligand with fixed ligand concentration. (B) Schematic illustration of the effect of 
ligand density in IFs when the ligand concentration is fixed. Precipitation yields of (C) 
filler and (D) ligand molecule in co-assembled IFs at different molar ratios of filler:ligand 
with fixed ligand concentration. Precipitation yields of mAb1 and Fc-fusion protein at 
different (E) molar ratios of ligand:protein with fixed ligand concentration and (F) molar 
ratios of filler:ligand with fixed filler concentration. As a proof of concept, purified mAb1 
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and Fc-fusion protein were used in (A, C-F). All experiments were performed in triplicate 
and the data is shown as mean ± standard deviation. 
 
Figure 4-9. Precipitation yields of (A) filler and (B) ligand molecule for 50:1 IFs at various 
ligand:protein ratios and 1 M ammonium sulfate conditions. The IFs were incubated with 
mAb1or Fc-fusion protein. All experiments were performed in triplicate and the data is 
shown as mean ± standard deviation. 
To further improve the precipitation yields, I considered whether the ligand:protein 
molar ratio significantly contributes to the precipitation efficiency, as it is the key factor 
that affects the binding equilibrium. At a fixed 50:1 filler:ligand ratio, ligand:protein ratios 
were varied from 10:1 to 10:8 by increasing protein concentration from 5 µM to 40 µM. 
Ligand:protein molar ratios higher than 10:1 were not investigated due to the detection 
limit of the ProA column at low mAb concentrations. As expected, higher precipitation 
yields were obtained at lower protein concentrations (Figure 4-8 E). At the ligand:protein 
ratio of 10:1, both proteins can be precipitated at a yield greater than 99%. This optimized 
10:1 ratio was much higher than the theoretical mAb (or Fc-fusion protein):Z33 ratio (2:1), 
probably resulting from the limited ligand accessibility on IFs due to steric hindrance or 
compromised surface area due to the merging of IFs. A more efficient ligand:protein ratio 
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could be potentially achieved by improving the ligand flexibility on IF surface and 
minimizing IF merging. Again, in these experiments, it was observed that over 95% filler 
and ligand molecules were co-precipitated with the target proteins (Figure 4-9), 
confirming that the protein precipitation yield was limited by the saturation of accessible 
ligands.  
To investigate which of the two ratios is more dominant and to obtain a higher yield 
at higher protein concentrations, I then conducted another series of experiments for 20 µM 
mAb1. Unlike the IF settings in Figure 4-8 A, I fixed the filler concentration at 2.5 mM 
while increasing the ligand concentration up to 500 µM (solubility limit). In this case, a 
decrease in filler:ligand ratio means an increase in ligand:protein ratio. As shown in Figure 
4-8 F, when more ligands were added, the precipitation yield increased but plateaued at 
around 90%. These results suggest that the ligand:protein ratio is critical and outweighs the 
filler:ligand ratio in protein capture. Importantly, the high precipitation yield for the 20 µM 
mAb1 concentration is a very promising result, as this value approaches to the industrial 
titer level.5 Furthermore, the fact that the precipitation yield leveled out after the 250 µM 
ligand concentration suggests that there exists an optimal ligand density, above which steric 
hindrance may come to play. 
To understand the mechanism of the soluble-insoluble transition of the IF-protein 
complexes, the IFs under optimized conditions were further investigated ligand for 50:1 
IFs with 10:1 ligand:protein molar ratio at different salt concentrations. Salt concentration 
higher than 1 M was not tested due to the instability of proteins (Figure 4-10 A). Results 
showed that 30-40% proteins were precipitated under no salt conditions (Figure 4-11 A). 
There is a possibility that these proteins with two binding sites could crosslink ligands from 
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different IFs, promoting the formation of large filament networks that tend to precipitate. 
As more salt was added, the protein precipitation yield increased significantly (Figure 4-11 
A), which could be attributed to the fact that the addition of salt has a more pronounced 
effect on the soluble-insoluble transition of IFs. For all salt groups, over 95% filler and 
ligand molecules were precipitated concomitantly with the target proteins (Figure 4-11 B 
and C). Similar result was seen for the IF control. It is reasonable to assume that salt 
promotes the agglomeration of IFs, leading to more efficient precipitation of proteins that 
are already bound to IFs. However, high salt concentration is known to increase the risks 
of protein instability and the formation of high molecular weight aggregates.321 Moreover, 
the probability of non-specific precipitation of impurities will increase as well. 
Precipitation at an even lower salt concentration or without salt altogether can be 
potentially achieved by further improving the design of IFs to obtain more flexible ligands 
on IFs and improve the IF-protein interactions.  
 
Figure 4-10. Stability of mAb1 (A) and IgG (FITC) (B) at various salt concentrations. 
Proteins were incubated with salt for 30 minutes and centrifuged at 15000 rpm for 15 





Figure 4-11. Precipitation yields of (A) mAb1 and Fc-fusion protein, (B) filler, and (C) 
ligand for 50:1 IFs with 10:1 ligand:protein molar ratio at different salt conditions. All 
experiments were performed in triplicate and the data is shown as mean ± standard 
deviation. 
4.4.3 Selectivity of Co-Assembled IFs 
High selectivity is one of the most important characteristics of a precipitant that 
specifically target proteins while avoiding impurities.146 To investigate the selectivity of 
IFs and also to visualize the protein precipitation process, a green fluorescent antibody, 
IgG (FITC), and a non-specific red fluorescent protein, mCherry (28.8 kDa, pI:6.2), were 
used for the protein precipitation experiment. IgG (FITC), mCherry, and the mixture of 
two proteins were incubated with 50:1 IFs at a 10:1 ligand:protein ratio. Individual proteins 
and protein mixtures were also prepared in PBS as control groups. To trigger the 
precipitation, 0.75 M was added because the IgG (FITC) was unstable in the 1 M salt 
solution (Figure 4-10 B). As shown in Figure 4-12 A, B, and Figure 4-13, after 
centrifugation, no precipitates were observed in the control groups (i-iv), while IgG (FITC) 
was precipitated in the presence of IFs (v). However, red precipitates were barely seen for 
mCherry (vi), revealing that non-specific protein was not precipitated by IFs. In particular, 
color separation appeared at the solid-liquid interface in the (vii) group with the mixture of 
two proteins, allowing for the direct visualization of the favorable selectivity of IFs towards 
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IgG (FITC). The selectivity was further confirmed by the fluorescence spectra of the 
supernatants of all groups (Figure 4-12 C and D). Fluorescence of IgG (FITC) dropped in 
(v) and (vii) compared to the control groups in (ii) and (iv) after incubation with 50:1 IFs, 
while fluorescence of mCherry in (vi) and (vii) remained similar to those of control groups 
(iii) and (iv), further supporting the selective precipitation of IgG (FITC). 
 
Figure 4-12. Selectivity of co-assembled IFs in precipitating immunoglobulin G (IgG). (A) 
Photographs and (B) fluorescence images of i) PBS, ii) IgG (FITC), iii) mCherry, iv) IgG 
(FITC)+mCherry, v) IgG (FITC)+IFs, vi) mCherry+IFs, and vii) IgG 
(FITC)+mCherry+IFs. IgG (FITC) and mCherry were incubated with 50:1 IFs and 0.75 M 
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ammonium sulfate was used to trigger precipitation. Green precipitates were observed in 
v) and vii), indicating the precipitation of IgG (FITC). However, the precipitation of 
mCherry was not observed in vi) and vii), showing high specificity of mAb precipitation 
by IFs. Fluorescence measurements of supernatant in sample i)-vii) on the (C) green and 
(D) red channels. Fluorescence of IgG (FITC) dropped in v) and vii) after incubated with 
50:1 IFs, while fluorescence of mCherry remained similar with control groups. 
 
Figure 4-13. Supplementary bright field and fluorescence images for Figure 4-12: i) PBS; 
ii) IgG (FITC) control; iii) mCherry control; iv) IgG (FITC)+mCherry control; v) IgG 





4.4.4 Protein Recovery 
Given the reversibility of the soluble-insoluble transition and the mAb binding 
process, I proceeded to investigate whether the mAb could be recovered from the 
precipitates. Similar to protein A, the Z33 ligands release the bound target molecules in 
low pH.214, 322 After precipitation, most salts were removed along with the supernatant. To 
redissolve the precipitates, three buffers at pH 3.7, 7.4, and 10.1 were added to the 
precipitates, respectively. I found that both mAb1 and IFs were insoluble at pH 3.7 (Figure 
4-14 A-C), while around 80% and 100% mAb1 resuspension yield were obtained for pH 
7.4 and pH 10.1 buffer, respectively (Figure 4-14 A). Similar resuspension yields were 
obtained for the filler molecules in pH 7.4 and pH 10.1 buffers (Figure 4-14 B). This trend 
in resuspension yield can be attributed to the pH-dependent solubility of filler molecules. 
The glutamic acid residues (pKa 4.15) in the filler molecule are barely ionized in pH 3.7, 
but are negatively charged at neutral or basic pH, leading to a much higher solubility. To 
maintain the stability of mAbs, I decided to use PBS buffer at pH 7.4 instead of pH 10.1 to 
resuspend the precipitates, and then transferred the solution to a dialyzer with a 50 kDa 
cut-off membrane to separate the mAbs (~150 kDa) and IFs (monomeric size <5 kDa). The 
membrane separation was first conducted in PBS at pH 7.4 for 24 h to remove the filler 
molecules, and then conducted in elution buffer at pH 3.7 for 24h to remove the unbound 
ligand molecules. Under the optimized conditions, 100 µL pure mAb1 at 5 µM can be 
precipitated by the 50:1 IFs with a yield of more than 99% and recovered with a final mAb 
recovery yield greater than 94% (Figure 4-14 D). Meanwhile, more than 99% filler and 





Figure 4-14. mAb recovery and purification. Resuspension yields of (A) mAb1, (B) filler, 
and (C) ligand molecules in three resuspension buffers at pH 3.7, pH 7.4, and pH 10.1, 
respectively. The precipitated samples were 50:1 IFs and mAb1 at 10:1 ligand:protein 
molar ratio with 1 M ammonium sulfate. (D) Precipitation and overall yields of mAb1, 
filler, and ligand molecules after the incubation of pure mAb1 with 50:1 IFs and 1 M 
ammonium sulfate. (E) Schematic illustration of the process of purifying mAbs from CB 
using IFs. (F) mAb precipitation yields, overall yields, and percentage retention of filler 
and ligand molecules after the whole purification process for mAb1 CB and mAb2 CB. All 
experiments were performed in triplicate and the data is shown as mean ± standard 
deviation. 
4.4.5 Capture and Recovery of mAbs from Cell Culture Harvest 
To demonstrate the feasibility for potential industrial applications, I explored the 
capture and recovery of 5.8 mg/mL mAb1 and mAb2 (human IgG4, 144 kDa, pI:7.7, a 
commercialized antibody for cancer treatment) from clarified bulk (CB) of cell culture 
harvest using optimized IF system (Figure 4-14 E and F). mAbs were precipitated with a 
yield about 90%. After the entire process, 87% and 89% of mAb1 and mAb2 were fully 
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recovered (Figure 4-14 F), respectively. Meanwhile most filler and ligand molecules were 
removed (Figure 4-14 F) after membrane separation, showing that these materials would 
introduce little to no additional contaminants. Compared to pure mAb1, the lower 
precipitation yields may be attributable to the macromolecular crowding in the CB 
environment.323 The presence of high concentration macromolecular impurities such as 
host cell proteins and DNAs may alter the molecular motions, accessibility, and 
intermolecular interactions for both IFs and the target mAbs, leading to compromised mAb 
binding efficiency.324 To further prove the selectivity of IFs in CB conditions and to 
confirm the purity of the mAb product, the purity level of the mAbs during the purification 
process was tracked with size exclusion chromatography (SEC). The result shows most 
impurities were left in the supernatant, suggesting a promising selectivity of the IFs for 
isolating the target mAbs from impurities (Figure 4-15). A single peak was observed for 
both purified mAb1 and mAb2 with decent peak shape and the elution time remained the 
same, suggesting the high purity and good quality of these mAbs after purification. 
 
Figure 4-15. SEC spectra of the sample solutions for CB, CB supernatant, and product 




  In conclusion, I demonstrated the design and construction of a supramolecular 
copolymer system with multiple reversible transitions for successful capture, precipitation, 
and recovery of mAbs. Z33 affinity ligands were incorporated into the IF design to achieve 
reversible mAb binding. The reversible soluble-insoluble transition of co-assembled IFs 
enables the precipitation and redissolution of mAbs. The reversible assembly of IFs favors 
convenient removal of IFs from the mAb product pool. I found that multiple experimental 
parameters, in particular the filler:ligand molar ratio, ligand:protein molar ratio, and salt 
concentration could all affect the mAb precipitation and recovery yields. Under optimized 
conditions, more than 99% pure mAb1 was precipitated and more than 94% of pure mAb1 
was recovered after resuspension and membrane separation. Meanwhile, little to no IFs 
were found to remain in the mAb product pool. I confirmed that the IF system shows great 
selectivity towards IgG over a control protein, mCherry. Furthermore, I demonstrated the 
capture and recovery of mAbs from cell harvest with promising overall yields and IF 
clearance performance.  
While highly promising, the reported system can benefit from further optimization 
in molecular design to achieve better purification efficiency under low salt concentrations. 
Membrane separation is another unit operation in this work that contributes to the overhead 
of the purification process. However, membrane separation could also be used in the 
precipitation step to separate the precipitates and supernatant, thus combining the two unit 
operations into one. Future work will seek to evaluate process scalability and robustness 
and analyze the overall process cost, time, efficiency, and product quality. After further 
development, I envision that the co-assembled IFs can eventually serve as an economical 
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alternative to the traditional chromatography methods for highly efficient purification of 
mAbs and other proteins of interest. Additionally, the reported system shows a great 
potential for new applications involved with molecular recognition and targeting and may 
be particularly useful for the purification and concentration of therapeutic antibodies in 
convalescent plasma for COVID-19 treatment.  
134 
Manipulation of Epitope Radial Topography 
in High-Affinity Supramolecular Polymers for 
Binding-Triggered Antibody Precipitation 
5.1 Overview 
Supramolecular polymers, formed by self-assembly of monomeric units, represent 
attractive materials for various biomedical applications including drug delivery, 
regenerative medicine, and biosensing. Challenges still remain in the strategy for epitope 
presentation on supramolecular polymers to obtain their optimal bioactivity. Here I report 
on the manipulation of epitope radial topography in supramolecular immunofibers (IFs) 
for the binding-triggered precipitation of monoclonal antibodies. A series of IF building 
blocks are rationally designed by incorporating various oligo ethylene glycol (OEG) or 
polyethylene glycol (PEG) linkers for more efficient presentation of the mAb-binding 
peptide on the IF surface. The results suggest that the mAb-IF interactions could be 
significantly improved via increasing the linker length; however, too long a linker has an 
adverse impact on the function of the resultant supramolecular polymers. Through the 
optimization of several key parameters that impact the mAb precipitation, I demonstrate 
that the desired IF system is able to precipitate mAbs without the use of additional salt and 
promising mAb precipitation and elution yields were obtained, especially when using a 
sequential precipitation strategy. I believe these results shed important light on designing 
supramolecular nanostructures for specific molecular recognition and the IF system could 
be potentially used for purification of mAbs and other proteins of interest. 
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5.2  Introduction 
Supramolecular assembly is a fascinating bottom-up approach to construct 
hierarchical and functional nanostructures.42, 325-329 Among the recently developed 
supramolecular polymers, peptide-based materials are notably appealing because of their 
biocompatibility, biodegradability, and low toxicity.40, 330-336 The presentation of bioactive 
epitopes on a supramolecular substrate enables the active-targeting of the nanostructures 
for efficient molecular/cellular recognition and signaling, as well as the precise delivery 
and accumulation of therapeutics at desired sites.315, 337-338 In light of the steric hindrance 
introduced by anchoring these epitopes on supramolecular polymer surfaces, the epitope 
spatial arrangement plays an important role in regulating their functionality.257, 316, 339 Co-
assembly of bioactive building units with an inert molecule has been shown to effectively 
modulate the epitope density and achieve enhanced bioactivities.316-317 Meanwhile, the use 
of flexible linkers for spacing out the epitope in the radial direction of the resultant 
nanostructures is equally essential to improve the epitope accessibility and their 
interactions with the target biomolecules.45, 339-340  
Affinity precipitation has been increasingly explored as a promising alternative to 
protein A chromatography for the purification of monoclonal antibodies (mAbs) and other 
therapeutic proteins.6, 9, 341 The use of salt to trigger or aid the precipitation of antibodies is 
prevalent during the purification process.342-343 However, high salt concentration is known 
to increase the risks of protein instability and the non-specific precipitation of impurities 
present in the solution.344-345 Effort has been devoted to minimizing the usage of additional 
salt (besides that present in the cell culture media for protein stabilization) by developing 
more advanced protein precipitating systems.346 In the previous effort to construct 
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supramolecular immunofibers (IFs) for the affinity precipitation of mAbs, the functional 
building unit containing Z33, a protein A mimicking peptide that binds to the Fc-portion 
of immunoglobulin G (IgG) from most mammalian species in a pH-specific manner, was 
co-assembled with an inert component to effectively modulate the distribution of Z33 on 
the IF surface.214, 310 However, this system was limited by the high ammonium sulfate 
(abbreviated as “salt” below) concentration necessary to achieve decent mAb precipitation 
yields. 
To overcome the shortcomings of the IF system, I hypothesized that in addition to 
modulating the Z33 distribution by co-assembly, increasing the linker length for Z33 
conjugation would further improve mAb-IF interactions due to the increased Z33 flexibility 
and accessibility. Given the dual Fc-binding sites on mAbs, specifically IgG, and the 
multivalence of IFs, the enhanced multivalent mAb-IF binding could potentially result in 
IF crosslinking into large complexes and consequently facilitate mAb precipitation under 
low salt conditions. OEG (or PEG) linkers have been widely used in bioconjugation, 
benefiting from their water solubility, chain flexibility, and lack of toxicity.347-349 To prove 
this hypothesis, a series of IF systems with various OEG (or PEG) linkers for Z33 
presentation are designed and constructed in the present work. By comparing the mAb 
precipitation performances of different IF systems, I demonstrated the importance of linker 
length for the mAb-IF interaction and precipitation under low salt conditions. Moreover, 
the key parameters that impact the mAb precipitation yield are identified and discussed. I 





5.3  Experimental Procedures 
5.3.1 Materials and Molecular Synthesis 
 All Fmoc amino acids and resins were obtained from Advanced Automated Peptide 
Protein Technologies (Louisville, KY). The pure mAb1, and mAb1 and mAb2 in clarified 
Chinese hamster ovary (CHO) cell culture harvest were obtained from Bristol-Myers 
Squibb (Devens, MA). The cell culture was clarified using depth filtration. The Fmoc-N-
amido-O(P)EGn-acids were purchased from PurePEG (San Diego, CA) and BroadPharm 
(San Diego, CA). Lauric acid (C12) was obtained from MilliporeSigma (St. Louis, MO). 
Unless otherwise specified, all other reagents were obtained from VWR (Radnor, PA) and 
used as received without further purification. 
Filler and ligand molecules were synthesized using the method described 
previously. In brief, C12-VVEE and C12-VVKK[O(P)EG]nGGZ33 (n=4, 8, 12, 16, 36, 45) 
were synthesized on the Liberty Blue automatic microwave peptide synthesizer (CEM 
Corporation, Matthews, NC) using standard 9-fluorenyl-methoxycarbonyl (Fmoc) solid 
phase synthesis protocols. Crude products were cleaved from the solid support using a 
mixture of trifluoroacetic acid (TFA)/ triisopropylsilane (TIS)/H2O in a ratio of 92.5:5:2.5 
for 2.5 h. Excess TFA was removed by evaporation and ice-cold diethyl ether was added 
to precipitate the crude products, followed by centrifugation. The crude products were 
purified by preparative RP-HPLC using a Varian Polymeric Column (PLRP-S, 100 Å, 10 
µm, 150×25 mm) at 25 °C on a Varian ProStar Model 325 preparative HPLC (Agilent 
Technologies, Santa Clara, CA) monitored at 220 nm for the absorbance of peptide 
segments. Collected fractions were analyzed by MALDI-TOF (BrukerAutoflex III 
MALDI-TOF instrument, Billerica, MA) and product-containing fractions were then 
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lyophilized (LabconcoTM FreeZone −105 °C, 4.5 L freeze dryer, Kansas City, MO) and 
stored at −30 °C. 
5.3.2 CMC Measurement 
The CMCs of the ligand molecules in PBS were determined using Nile Red, a 
hydrophobic dye that undergoes changes in both fluorescence intensity and emission 
wavelength (a blue-shift) upon partition into the hydrophobic domains of supramolecular 
assemblies. Nile Red was initially dissolved in acetone at 20 µM and 10 µL aliquots were 
loaded into several centrifuge tubes. After the acetone evaporated under room temperature, 
500 µL fresh ligand solutions in PBS at various concentrations were added into the 
centrifuge tubes containing dry Nile Red and aged overnight for assembly. Fluorescent 
spectra of Nile Red were then monitored by a Fluorolog fluorometer (Jobin Yvon, Edison, 
NJ) with fixed excitation wavelength at 560 nm; emission spectra were monitored at 580-
720 nm. The ratio of the emission intensity at 635 nm (emission maximum of Nile red in a 
hydrophobic environment) to that at 660 nm (emission maximum of Nile red in an aqueous 
environment) was then plotted against the tested concentrations to obtain a transition curve 
and the CMC value was determined by the intersection of the two fitting lines.  
5.3.3 Self-Assembly, Co-Assembly, and TEM Imaging 
For self-assembly, filler or ligand molecules were dissolved in PBS (20 mM sodium 
phosphate, 150 mM sodium chloride, pH 7.4) to reach a final concentration of 2.5 mM or 
400 µM, respectively, and aged for 24 h at room temperature. To construct co-assembled 
IFs, filler and ligand molecules were pretreated with hexafluoroisopropanol (HFIP) to 
eliminate any pre-existing nanostructures that could be possibly formed during the 
synthesis and purification process. After HFIP evaporation, filler and ligand molecules 
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were dissolved in PBS (20 mM sodium phosphate, 150 mM sodium chloride, pH 7.4) to 
reach desired concentrations and aged for 24 h at room temperature. 10 µL stock of each 
sample solution were then spotted on carbon film coated copper grids with 400 square mesh 
(Electron Microscopy Sciences, Hatfield, PA) and the excess was removed with filter paper 
to leave a thin film of sample on the grid. After letting the sample dry for 5 min, 10 µL 2% 
uranyl acetate was added to the sample grid, and the excess was removed after 30 s. All 
samples were dried for at least 3 h before imaging. Bright-field TEM imaging was 
performed on a FEI Tecnai 12 TWIN Transmission Electron Microscope and all TEM 
images were required by a SIS Megaview III wide-angle CCD camera. 
5.3.4 CD Spectroscopy 
The CD spectra of self-assembled ligand molecules were collected on a Jasco J-710 
spectropolarimeter (JASCO, Easton, MD) using a 1 mm path length quartz UV-vis 
absorption cell (ThermoFisher Scientific, Pittsburgh, PA) at 25 °C. A background spectrum 
of the solvent was acquired and subtracted from the sample spectrum. The collected data 
was averaged from three scans and normalized with respect to the ligand concentration. 
5.3.5 ITC Experiment 
ITC experiments were performed using a high precision VP-ITC titration 
calorimetric system (Microcal Inc.). 40 µM ligand solution was titrated with 100 µM mAb1 
in PBS (pH 7.4) at 25 °C. The heat evolved after each injection was obtained from the 
integral of the calorimetric signal. The heat associated with the binding between ligand 
molecule and mAb1 was obtained by subtracting the heat of dilution. Analysis of the data 
was performed using MicroCal Origin package. 
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5.3.6 mAb Precipitation Experiment 
IF stock solutions at desired filler and ligand concentrations were prepared one day 
before the precipitation experiment. Pure mAb1 from a concentrated solution (448 µM, 
64.5 g/L) was then added into 100 µL IF solutions to reach a desired final concentration 
and incubated for 30 min at room temperature. The solution was then centrifuged at 15000 
rpm for 15 minutes. For 1 M salt group, ammonium sulfate was added to the mAb-IF 
mixtures to reach final concentration of 1 M and incubated for another 30 min before 
centrifugation. The supernatant was taken out and analyzed by ProA-HPLC (POROS™ A 
20 µm Column, Stainless Steel, 2.1 x 30 mm, 0.1 mL) to determine mAb concentration. 
The precipitated amount of each species was calculated by subtracting the amount in the 
supernatant from the amount added. The precipitation yield was calculated by dividing the 
precipitated amount by the amount added. 
5.3.7 Sequential Precipitation and mAb Elution 
Three IF stock solutions, IF1(2.5 mM filler, 250 µM O16), IF2 (2.5 mM filler, 750 
µM O16), and IF3 (2.5 mM filler, 200 µM O16), were prepared one day before the 
precipitation experiment. Pure mAb1 from a concentrated solution (448 µM, 64.5 g/L) was 
added into 100 µL IF1 and 100 µL IF2 to reach a desired final concentration of 40 µM and 
80 µM, respectively. After a 4-hour incubation, the samples were then centrifuged at 15000 
rpm for 15 minutes and the supernatant was transferred to 100 µL IF3 for another 4-hour 
incubation and subsequent centrifugation. 200 µL PBS and 400 µL elution buffer (40 mM 
sodium acetate, pH 3.7) were then used to wash and resuspend the precipitates from two 
precipitation steps. The supernatant from each precipitation step, wash step, and elution 
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step were analyzed by ProA-HPLC (POROS™ A 20 µm Column, Stainless Steel, 2.1 x 30 
mm, 0.1 mL) to determine mAb concentration.  
5.4  Results and Discussions  
5.4.1 Molecular Design and Characterization 
 As described in Chapter 4, the co-assembled IF system is formed by filler and 
ligand molecules. The filler molecule, C12-VVEE, is designed to modulate the distribution 
of the ligand molecule in the co-assembled IFs (Figure 5-1 A and Figure 5-2). The Z33 
peptide, which possesses a two-helix motif, is conjugated on the C-terminus of the ligand 
molecule, C12-VVKK[Linker]Z33, for specific mAb capture (Figure 5-1 A and Figure 
5-2). In the previous ligand design (G2), a double glycine (GG) segment was inserted as a 
linker between the IF surface and Z33. To further increase the Z33 flexibility and 
accessibility, a series of ligand molecules, O4, O8, O12, O16, O36, and P2000, with 
various OEG (or PEG) linkers (n=4, 8, 12, 16, 36, 45) were designed and summarized in 
Table 5-1. The calculated length of fully extended linkers and molecular weight of each 
ligand molecule are also listed in Table 5-1. As shown in Figure 5-1 B, with increasing 
OEG (or PEG) length, the Z33 is expected to be extended further away from the IF surface. 
I hypothesized that the incorporation of OEG (or PEG) linkers would further reduce the 
steric hindrance in the radial direction of the IFs and improve mAb-IF interactions for both 
Fc binding sites. The filler and ligand molecules were synthesized using automated solid-
phase peptide synthesis (SPPS) methods. Details of the chemical structures and molecular 




Table 5-1. Summary of ligand molecule design with various linkers. 
Ligand Molecule 
C12-VVKK[Linker]Z33 
Linker Calculated Length 
of Fully Extended 






G2 GG 0.7 4.9 2.0 
O4 OEG4 1.9 5.0 5.1 
O8 OEG8 3.5 5.2 6.0 
O12 OEG12 5.1 5.3 8.5 
O16 OEG16 6.7 5.5 10.5 
O36 OEG36 14.6 6.4 9.1 
P2000 PEG2000 18.2 6.8 8.1 
 
 
Figure 5-1. Molecular design of the IF building units with OEG (or PEG) linkers and the 
formation of IFs for mAb capture. (A) Chemical structures of the filler molecule, C12-
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VVEE, and the ligand molecules, C12-VVKK[Linker]Z33. (B) Schematic illustration of 
the ligand molecule design with various linkers and the effect of linker length on the 
presentation of Z33 peptide on co-assembled IFs. (C) Co-assembly of filler and ligand 
molecules into supramolecular IFs and four possible states of mAbs in an IF solution: 1) 
Two Fc-portions of a mAb bound to two ligands from two different IFs. 2) Two Fc-portions 
of a mAb bound to two adjacent ligands from the same IF. 3) Only one Fc-portion of a 
mAb bound to one ligand on an IF. 4) Free mAbs in the solution bound to zero, one, or two 
monomer ligands that are not assembled in IFs. 
 
Figure 5-2. Chemical structures of filler and ligand molecule. The alkyl chain (C12), 




Figure 5-3. RP-HPLC and MALDI-TOF MS characterization of O4 (A-B), O8 (C-D), and 
O12 (E-F).  
 
Figure 5-4. RP-HPLC and MALDI-TOF MS characterization of O16 (A-B), O36 (C-D), 
and P2000 (E-F).  
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Figure 5-1 C illustrates the spontaneous co-assembly process of filler and ligand 
molecules in aqueous solution, forming filamentous IFs with Z33 displayed on the IF 
surface. Upon the addition of mAbs, there are four possible states of mAbs in the IF 
solution. States 1 and 2 represent two Fc-portions of a mAb bound to two ligands from 
two different IFs or the same IF, respectively. In State 3, only one Fc-portion of a mAb is 
bound to one ligand on an IF. Given the equilibrium between ligand monomers and co-
assembled structures, it’s also possible that in State 4 mAbs are bound to zero, one, or two 
monomer ligands in the solution instead of those assembled in IFs. mAb binding and 
precipitation represent two separate process. The previous results showed that 1 M salt was 
not able to precipitate mAb1 directly, but it served as a strong charge screening agent to 
precipitate almost all IFs and thus precipitate mAbs that are bound to IFs (State 1-3). Under 
no salt conditions, however, binding to IFs may not be sufficient for mAbs to be 
precipitated. I speculate that the key to the precipitation of mAbs under no salt conditions 
lies in the formation of the cross-linked mAb-IF complexes, which is mainly triggered by 
mAbs in State 1. In this regard, increasing the linker length could probably promote the 
mAb binding to the Z33 peptides on different IFs and thus increase the State 1 probability.  
  
5.4.2 Molecular Assembly and Characterization 
To estimate the behavior of the filler and ligand molecules in the co-assembled IFs, 
I first investigated their self-assembly properties in PBS, pH 7.4. With OEG (or PEG) 
linkers, the critical micelle concentrations (CMCs) of ligand molecules are relatively 
higher than the previous G2 ligand, ranging from 5.1 to 10.5 µM (Table 5-1 and Figure 
5-5). The CMC decrease seen in O36 and P2000 may relate to the entanglement of long 
PEG chains. As shown in Chapter 4, the filler molecule is able to self-assemble into 
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filamentous structures with a diameter of 7.4 ± 0.6 nm (Figure 5-6 A), showing β-sheet 
characteristic hydrogen bonding. Representative transmission electron microscopy (TEM) 
images reveal that each of the ligand molecules can self-assemble into filamentous 
structures with diameters of 11.1 ± 0.9 nm (O4), 12.6 ± 1.2 nm (O8), 13.6 ± 1.2 nm (O12), 
14.9 ± 1.3 nm (O16), 18.5 ± 1.8 nm (O36), 19.3 ± 2.0 nm (P2000), respectively (Figure 
5-6 B-G). As expected, the IF diameter increased with the increase of the linker length. To 
gain insight into the molecular packing within the self-assembled ligand molecules, the 
circular dichroism (CD) spectra were collected for each of the newly designed ligand 
molecules. The negative peaks around 208 nm and 222 nm suggest the preservation of α-
helix secondary structures in all the self-assembled ligand molecules (Figure 5-6 H), as 
shown in the original Z33 peptide.310 Isothermal titration calorimetry (ITC) were used to 
determine the binding affinity between a monoclonal human IgG1 (144 kDa, abbreviated 
as “mAb1” below) and ligand molecules O4-O16. The dissociation constant Kd ranges 
between 50 nM and 70 nM, similar to the reported value (26 nM) for free Z33 peptide, 
showing that the conjugation of OEG linkers within ligand molecules would not 




Figure 5-5. CMC measurement of O4-P2000. Normalized emission spectra of the reporter 
dye Nile Red monitored by a Fluorolog fluorometer (Jobin Yvon, Edison, NJ) after 
incubation with a series of concentrations of ligand molecules. Plotting the ratio of intensity 
at 635 nm (emission maximum of Nile red in a hydrophobic environment) to that at 660 
nm (emission maximum of Nile red in an aqueous environment) against the tested 
concentration indicates the transition that occurs when the concentration exceeds the CMC. 
The CMC value for each ligand molecule was then determined by the intersection of the 




Figure 5-6. Characterization of filler and ligand molecules. Representative TEM images 
of self-assembled filler and ligand molecules (A:C12-VVEE, B:O4; C:O8; D:O12; E:O16; 
F:O36; G:P2000) in PBS with a diameter of 7.4 ± 0.6 nm, 11.1 ± 0.9 nm, 12.6 ± 1.2 nm, 
13.6 ± 1.2 nm, 14.9 ± 1.3 nm, 18.5 ± 1.8 nm, 19.3 ± 2.0 nm, respectively. Diameters are 
given as mean ± SD (n = 30). Scale bars: 100 nm. (H) Normalized CD spectra of self-
assembled ligand molecules with different OEG (or PEG) linkers suggest the formation 




Figure 5-7. ITC profiles and binding curves for the stepwise injection of 100 µM mAb1 
into 40 µM (A) O4, (B) O8, (C) O12, (D) O16 at 25 °C in PBS, pH 7.4. 
5.4.3 Impact of Linker Length and Ligand Selection 
To compare the ligand performance, 100 µM ligand molecules were individually 
co-assembled with 2.5 mM filler molecules in 100 µL PBS (pH 7.4). The filler molecule 
at 2.5 mM (solubility limit) was found to give the best mAb precipitation results and was 
consistently used in this work. Pure mAb1 from a stock solution was then added into 
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different IF solutions to reach a final concentration of 20 µM and incubated for 30 min at 
room temperature. To investigate salt effects on the mAb precipitation yield, two parallel 
experiments were performed for each co-assembled IF system: one with 1 M salt and one 
without salt (Figure 5-8 A). After centrifugation, the supernatant was analyzed by ProA-
HPLC to determine the remaining mAb concentration and calculate the mAb precipitation 
yield. With 1 M salt, the mAb precipitation yield showed significant improvement from 
65% to higher than 88% when replacing the GG linker with O(P)EG linkers in the ligand 
design. In particular, greater than 95% mAb precipitation yields were obtained for O4-O36. 
Since there’s no bias against the IF precipitation efficiency under 1 M salt conditions, this 
mAb precipitation yield increase from G2 to the new ligand molecules with OEG (or PEG) 
linkers specifically reflects the significant improvement in the mAb binding efficiency as 
a result of the increased linker length and flexibility. A slight drop in the mAb precipitation 
yield was seen for P2000, likely due to the entanglement of long PEG chains that 
undermines the accessibility of the Z33 peptide for mAb capture.  
Under no salt conditions, the mAb precipitation yields were generally lower than 
salt groups, while an upward trend was observed with an increase of the OEG linker length. 
Unlike the salt group, the mAb precipitation yield under no salt conditions was determined 
by a combination of mAb binding efficiency and the precipitation efficiency of the mAb-
IF complexes. From O4 to O36, there are no obvious differences in the mAb binding 
efficiency as indicated by the salt group data set. The increase in the mAb precipitation 
yield under no salt conditions represents an enhancement in the mAb precipitation 
efficiency, possibly caused by the improved crosslinking between IFs. More importantly, 
the yield difference between 1 M salt and no salt groups was gradually diminished with 
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increasing the linker length, leading to a less than 10% yield discrepancy for O36. This was 
considered very promising for mAb precipitation, in that the improved mAb-IF interactions 
achieved by using OEG or (PEG) linkers could potentially substitute for the salt 
contribution to mAb precipitation. 
 
Figure 5-8. Comparison of mAb precipitation performance of IFs with different ligand 
molecules. mAb precipitation yields for (A) 20 µM and (B) 40 µM mAb1 incubated with 
various co-assembled IFs (2.5 mM filler, 100 µM ligand) under 1 M salt or no salt 
conditions. Precipitated mAb mass from 100 µL samples of (C) 20 µM (0.3 mg) and (D) 
40 µM (0.6 mg) mAb1 incubated with various 100 IFs (2.5 mM filler, 100 µM ligand) 
under 1 M salt or no salt conditions. (E) Photographs of co-assembled IFs (2.5 mM filler, 
100 µM ligand) after mixed with 40 µM mAb for 5 min under 1 M salt or no salt conditions. 




To confirm the above observation and have a preliminary understanding of the mAb 
binding capacity for this IF system, the experiments were repeated with a higher mAb1 
concentration (40 µM). Similar yield trends were observed in Figure 5-8 B, except for a 
slightly upward trend in the 1 M salt group for O4-O36, indicating an improvement in mAb 
binding efficiency with increasing the OEG linker length. Despite the consistent drop in 
the mAb precipitation yield from 20 to 40 µM mAbs, the precipitated mAb mass for a 100 
µL sample (20 µM:0.3 mg; 40 µM:0.6 mg) were actually similar or higher for 40 µM mAbs 
(Figure 5-8 C-D), showing that the Z33 peptide displayed on the IF surfaces were not fully 
saturated by 20 µM mAb1 and could potentially be further utilized if more mAbs were 
added.  
The difference in mAb precipitation yield can also be revealed by the cloudiness of 
the IF solution. IF solutions of O12, O16, O36, and P2000 became cloudy within 5 minutes 
after the mAb addition, which was not seen in the first three IF systems. Figure 5-8 E 
shows the sample vials of O4-O16 IFs after being mixed with 40 µM mAb1 for 5 min under 
1 M salt or no salt conditions. Generally, the cloudiness of the salt groups is relatively 
higher than the no salt groups, suggesting a higher mAb precipitation yield for the salt 
groups. Meanwhile, the cloudiness increases from O4 to O16 in accordance with the yield 
trend shown in Figure 5-8 B. The results here demonstrated that the increase of the linker 
length can simultaneously improve the mAb binding efficiency of the ligand molecules as 
well as the precipitation efficiency of the mAb-IF complex. Although O36 shows the best 
mAb precipitation yields in all conditions, O16 is more desirable in terms of the synthesis 





5.4.4 Optimization of mAb Precipitation under No Salt Conditions 
 
Figure 5-9. Optimization of mAb precipitation yield. The (A) yield and (B) mass of mAb 
precipitation for 100 µL mAb1 at 40 µM (0.6 mg), 80 µM (1.2 mg), and 133 µM (2 mg) 
incubated with IFs at various O16 concentrations. (C) Comparison of mAb precipitation 
yield for 40 µM mAb1 incubated with optimized IFs (2.5 mM filler, 250 µM O16) at 
different salt concentrations. (D) Proposed mechanism of mAb-IF agglomeration as the 
ligand concentration increases for a fixed mAb concentration. mAbs at States 3, State 1, 
and State 2 are dominant at low, medium, and high ligand concentrations, respectively. 
(E) Turbidity of 40 µM mAb with optimized IFs (2.5 mM filler, 250 µM O16) in 2 hours. 
(F) The effect of binding time on the mAb precipitation yield for 40 µM mAb1 incubated 
with optimized IFs (2.5 mM filler, 250 µM O16). All experiments were performed in 




In Chapter 4, the ligand:mAb molar ratio was shown to play the most significant 
role in the mAb precipitation yield. To optimize the mAb precipitation yield under no salt 
conditions and investigate whether the O16 IF system could be efficiently applied to high 
mAb concentrations, mAb1 at three concentrations, 40 µM (6 mg/mL), 80 µM (12 mg/mL), 
133 µM (20 mg/mL), was incubated with IFs formed by 2.5 mM filler molecule and O16 
ligand molecule at various concentrations in 100 µL PBS. Figure 5-9 A and B show the 
plots of mAb precipitation yield and mass versus O16 concentration, respectively, and an 
optimal point was observed at a ligand:mAb molar ratio between 6:1 to 9:1 for all three 
mAb concentrations. These optimal ratios were much higher than the theoretical binding 
ratio (2:1). A better understanding in the precipitation mechanism under no salt conditions 
would inspire a more efficient IF design to improve the ligand utilization rate. At the 
optimal O16 concentration, the mAb precipitation yields for 40 and 80 µM mAb were 
around 85%, while only about 65% mAb was precipitated for 133 µM mAb, showing a 
decrease in the IF performance when scaling up for high mAb concentrations. To better 
understand the salt effect on mAb precipitation yield, parallel experiments were carried out 
for 40 µM mAb with the optimal IFs (2.5 mM filler, 250 µM O16) at different salt 
concentrations (Figure 5-9 C). More than 99% mAb1 was precipitated when 1 M salt was 
present, indicating a complete capture of mAb1 onto IFs. However, only 88% mAb1 was 
precipitated for 0 M salt group, which was attributed to the insufficient IF precipitation that 
may be caused by the limited IF crosslinking. This could be an inherent limitation of the 
IF system under no salt conditions and deserves further exploration in the future. Moreover, 




To understand the trend for mAb precipitation yield observed in Figure 5-9 A-B, I 
propose that States 3, State 1, and State 2 are dominant at low, medium, and high ligand 
concentrations, respectively (Figure 5-9 D). At low ligand concentration, all ligands are 
saturated by the excessive mAbs with little left for the binding of the second Fc site (State 
3). The initial yield increase could be attributed to the increase in dual site mAb binding 
for IF crosslinking (State 1) as the ligand concentration increases. After the optimal 
operating point, further increasing ligand concentration resulted in a yield decline which 
could be caused by a decrease in the crosslinking efficiency. Since chances for mAbs to 
bind to two Z33 from the same IF (State 2) would be much higher with decreased spacing 
of O16 ligands on IFs surfaces.  
To gain insight into the kinetics of the agglomeration, the turbidity of a mixture of 
40 µM mAb1 and the optimized IFs (2.5 mM filler, 250 µM O16) was monitored by the 
absorbance at 350 nm for 24 h. As shown in Figure 5-9 E, the turbidity increases with time 
and plateaus within 30 min, suggesting rapid initial agglomeration. To correlate the 
solution turbidity to the mAb precipitation yield, the supernatant for 30 min, 2 h, and 24 h 
were analyzed (Figure 5-9 F). Consistent with the turbidity study, the mAb-IF binding and 
agglomeration could nearly complete within 30 min to reach a high precipitation yield of 
83%. Although a slight yield increase was seen for 2h (88%) and 24 h (92%), which was 
not revealed by the lower-sensitivity turbidity study, it sacrificed the time efficiency of the 
mAb precipitation process.  
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5.4.5 Sequential Precipitation and mAb Elution 
 
Figure 5-10. Sequential precipitation and mAb purification. (A) Schematic illustration of 
the mAb purification process using IFs. (B) mAb precipitation yield, yield loss at wash 
step, elution yield for 40 µM and 80 µM pure mAb1 after two sequential precipitations 
under no salt conditions. All experiments were performed in triplicate and the data is shown 
as mean ± standard deviation. 
To further improve the mAb precipitation yield, I proposed to conduct two-step 
sequential precipitation to precipitate the remaining mAbs. As depicted in Figure 5-10 A, 
the supernatant from the first precipitation step was added into fresh IF solution. A wash 
step was then carried out using PBS to remove the non-specifically bound impurities in the 
precipitates from the two precipitation steps. To resuspend the precipitated mAbs, elution 
buffer (40 mM sodium acetate, pH 3.7) was added to dissociate the mAb-IF complexes.  
As a proof of concept, the sequential precipitation was carried out with pure mAb1 
at 40 µM and 80 µM. For the first precipitation, 40 µM (6 mg/mL) and 80 µM (12 mg/mL) 
mAb1 were incubated with IFs containing 250 µM and 750 µM O16, respectively, the 
optimized condition indicated by Figure 5-9 A. More than 82% mAb1 was precipitated for 
both groups while 8~20 µM mAb1 remained in the supernatant (Figure 5-10 B). Based on 
another set of O16 concentration optimization in Figure 5-11, IFs containing 200 µM O16 
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was used for the second precipitation step. Eventually, a final precipitation yield of greater 
than 97% and ~88% elution yield were achieved for both mAb concentration with little 
yield loss during the wash step (Figure 5-10 B). To fully recover the eluted mAbs, a 
membrane separation step using a 50 kDa cut-off membrane will be conducted in future 
work to separate the mAb1 (~144 kDa) and dissociated IFs (monomeric size <6 kDa) 
(Figure 5-10 A). With the promising precipitation and elution yield obtained by the two-
step sequential precipitation, future work will focus on the mAb purification process in 
bio-relevant conditions under no salt conditions and the assessment of the purity level and 
quality of the final mAb product. 
 
Figure 5-11. mAb precipitation yields for 100 µL mAb1 at 10 µM and 20 µM after an 
incubation with 100 µL IFs at various O16 concentrations. IFs with 200 µM O16 gave the 
best mAb precipitation yield for both mAb concentrations. 
 


























5.5  Conclusion 
In conclusion, I have designed and constructed a series of supramolecular IF 
systems containing OEG (or PEG) linkers and demonstrated the great impact of epitope 
topography in the radial direction of IFs on the IF bioactivity. The results reveal that 
increasing the linker length to OEG16 can simultaneously improve the mAb binding and 
precipitation efficiency when no additional salt is added. However, too long a linker has 
an adverse impact on the function of the resultant supramolecular polymers. Importantly, 
the mAb precipitation yield under no salt conditions could be efficiently optimized by 
tuning the ligand concentration to reach desired mAb binding states. The mAb-IF binding 
and agglomeration is a quick process that could nearly complete within 30 min. Further 
increasing binding time can improve the mAb precipitation yield, but only to a small extent. 
Moreover, I demonstrated the promising precipitation and elution yield of mAbs using the 
sequential precipitation strategy. I believe that the strategy of engineering linkers for better 
epitope presentation will shed important light on the design of supramolecular polymers 
for specific molecular recognition and targeted drug delivery. I also envision that after 
further optimizing the operational process, the supramolecular IF system can potentially 
serve as an efficient alternative for the purification of mAbs and other proteins of interest. 
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Conclusions and Future Work 
6.1 Conclusions 
 Supramolecular polymers represent an important class of polymeric materials 
formed by self-assembly of molecular building units through non-covalent interactions for 
their use in various biomedical applications. This dissertation aims to develop a peptide-
based supramolecular polymer system, namely immunofibers (IFs), for efficient capture 
and purification of monoclonal antibodies, which could potentially serve as an alternative 
to the conventional protein A-based affinity chromatography.  
In Chapter 2, I discovered that the alkylation strategy, including the the number and 
length of the alkyl chains, plays an important role in preserving the α-helical conformation 
of the mAb-binding peptides within its supramolecular filamentous assemblies. With the 
knowledge gained in Chapter 2, I successfully incorporated a high affinity mAb-binding 
peptide, Z33, into self-assembling immuno-amphiphile (IA) in Chapter 3 via the direct 
conjugation of the Z33 peptide to one or two short linear hydrocarbons. I demonstrated that 
the resulting IA can effectively associate under physiological conditions into 
supramolecular IFs while preserving the native α-helical conformation and mAb binding 
affinity of the Z33 peptide.  
To reduce the steric hindrance among tightly packed ligands with the self-
assembled IFs and promote mAb precipitation, I developed a co-assembled IF system in 
Chapter 4 formed by a mAb-binding ligand molecule, containing Z33, and a rationally 
designed filler molecule to modulate the distribution of the Z33 peptide on IF surfaces. I 
found that the composition of IFs and the molar ratio of ligand to proteins contribute 
significantly to the mAb capture efficiency. With the help of ammonium sulfate, these co-
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assembled IFs can specifically capture mAbs with a precipitation yield greater than 99%, 
leading to an overall mAb recovery yield of >94%. I also demonstrated the feasibility of 
capturing and recovering two mAbs from clarified cell culture harvest. In Chapter 5, I 
designed and developed a more advanced IF system containing various OEG (or PEG) 
linkers to optimize the radial arrangement of the Z33 peptide on the IF surfaces. My results 
reveal that the mAb-IF interactions were significantly improved as the linker length is 
increased; however, too long a linker has an adverse impact on the function of the resultant 
IFs. I demonstrated that this IF system is able to form large complexes upon mAb binding 
and precipitate mAbs with a promising mAb precipitation and elution yield when no 
additional salt is added. The use of a sequential precipitation strategy can increase the 
precipitation yield to greater than 97%. Through rational molecular design and continuous 
optimization, the resultant IF system exhibits promising performance in mAb capture and 
precipitation, with great potential for mAb purification from cell culture harvest without 
the help of additional salt. 
6.2  Future Work 
While the peptide-based supramolecular immunofiber system has been successfully 
established in this dissertation for efficient capture and purification of monoclonal 
antibodies, further efforts are needed to improve current constructs and optimize the 
purification process in bio-relevant conditions. First, current IF system requires 6~9 Z33 
to precipitate one mAb molecule, which was much higher than the theoretical ratio (2:1). 
A better understanding in the mAb binding and precipitation mechanism, such as the 
required linker length for mAb to crosslink different IFs and the ideal ligand spacing on 
IFs to prevent a mAb molecule from binding to adjacent ligands on the same IF, would 
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inspire a more efficient IF design to improve the ligand utilization rate. Next, a more 
thorough mAb purification process needs to be set up in bio-relevant conditions with the 
correlations among yield, purity, and mAb functionality established. Future work will seek 
to evaluate process scalability and robustness and analyze the overall process cost, time, 
efficiency, and product quality. Currently the building units of the IF system are produced 
by solid phase peptide synthesis and only for single use in the purification process. The 
development of a large-scale IF production process using microorganisms or mammalian 
cells as well as a process for IF recycling will help in reducing material costs. Furthermore, 
this IF system could be conveniently applied to the capture and purification of other 
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